DNA POLYMERASE OF GAMMA HERPES VIRUSES ASSOCIATED WITH KAPOSI'S SARCOMA AND RETROPERITONEAL FIBROMATOSIS

Abstract: This invention provides isolated polynucleotides encoding DNA polymerases of three members of a subfamily of gamma herpes viruses. Two were obtained from macaque monkeys affected with retroperitoneal fibromatosis, the other from human AIDS patients affected with Kaposi's sarcoma. A 454-base pair fragment encoding a region near the active site of the DNA polymerase is 69-83 % identical amongst the three viruses, but only 54-68 % identical with other known gamma herpes sequences and < 55 % identical with alpha and beta herpes sequences. Also provided are ploynucleotides encoding DNA polymerase from related viruses in the RFHV/KSHV subfamily. Polynucleotides prepared according to the sequence data can be used as reagents to detect and characterize related sequences. Such reagents may be used to detect members of the RFHV/KSHV subfamily, including but not limited to RFHV, RFHV2, and KSHV. Corresponding polypeptides and peptide fragments may be obtained by expressing the polynucleotide or by chemical synthesis. They may be used for detecting specific antibody potentially present in the serum of infected subjects. They may also be used for designing or screening pharmaceutical compounds that limit viral replication by inhibiting DNA polymerase activity.

Description: DNA POLYMERASE OF GAMMA HERPES VIRUSES ASSOCIATED WITH KAPOSI'S SARCOMA AND RETROPERITONEAL FIBROMATOSIS CROSS-REFERENCE TO RELATED APPLICATIONS This application is a continuation-in-part of U.S. provisional patent application Serial No. 60/001,148, filed July 14, 1995, and pending U.S. patent application Serial No. [pending, attorney docket 29938- 20001.00], filed July 11, 1996, which are hereby incoφorated herein by reference in their entirety. STATEMENT OF RIGHTS TO INVENTIONS MADE UNDER FEDERALLY SPONSORED RESEARCH This invention was made in part during work supported by a grant from the National Institutes of Health (RR00166-34). The Government has certain rights in the invention. TECHNICAL FIELD The present invention relates generally to the field of virology, particularly viruses of the heφes family. More specifically, it relates to the identification and characterization of DNA polymerase in a virus subfamily, members of which are associated with fibroproliferative and neoplastic conditions in primates, including humans. BACKGROUND ART Kaposi's Sarcoma is a disfiguring and potentially fatal form of hemorrhagic sarcoma. It is characterized by multiple vascular tumors that appear on the skin as darkly colored plaques or nodules. At the histological level, it is characterized by proliferation of relatively uniform spindle-shaped cells, foiming fascicles and vascular slits. There is often evidence of plasma cells, T cells and monocytes in the inflammatory infiltrate. Death may ultimately ensue due to bleeding from gastrointestinal lesions or from an associated lymphoma. (See generally Martin et al., Finesmith et al.) Once a relatively obscure disease, it has leapt to public attention due to its association with AIDS. As many as 20% of certain AIDS-affected populations acquire Kaposi's during the course of the disease. Kaposi's Sarcoma occurs in other conditions associated with immunodeficiency, including kidney dialysis and therapeutic immunosuppression. However, the epidemiology of the disease has suggested that immunodeficiency is not the only causative factor. In particular, the high degree of association of Kaposi's with certain sexual practices suggests the involvement of an etiologic agent which is not the human immunodeficiency virus (Berel et al.). A heφes-virus-like DNA sequence has been identified in tissue samples from Kaposi's lesions obtained from AIDS patients (Chang et al., confirmed by Ambroziuk et al.). The sequence was obtained by representational difference analysis (Lisitsyn et al.), in which DNA from affected and unaffected tissue were amplified using unrelated priming oligonucleotides, and then hybridized together to highlight differences between the cells. The sequence was partly identical to known sequences of the Epstein Ban- Virus and heφesvirus saimiri. It coded for capsid and tegument proteins, two stmctural components. In a survey of tissues from various sources, the sequence was found in 95% of Kaposi's sarcoma lesions, regardless of the patients' HIV status (Moore et al.). 21% of uninvolved tissue from the same patients was positive, while 5% of samples from a control population was positive. There was approximately 0.5% sequence variation between samples. The sequence was also detected at a higher copy number in body cavity lymphoma, a lymphomatous effusion with a B-cell genotype occuπing uniquely in AIDS patients (Cesarman et al.). Other AIDS-associated lymphomas were negative. The heφes vims family comprises a number of multi-enveloped viruses about 100 nm in size, and capable of infecting vertebrates. (For general reviews, see, e.g., Emery et al., Fields et al.). The double-stranded DNA genome is unusually large - from about 88 to about 229 kilobases in length. It may produce over 50 different transcripts at various stages in the life cycle of the vims. In one of the stages, a number of nucleotide and polynucleotide processing enzymes are produced that are required for viral replication, including DNA polymerase, DNAse, dUTPase, ribonucleotide reductase, uracil-DNA glycosylase, and thymidine kinase. These functional proteins tend to be relatively well conserved between species, compared with external viral components (Karlin et al.). The heφes vims family has been divided into several subfamilies. Assignments to each of the categories were originally based on the basis of biologic properties, and are being refined as genomic sequence data emerges. The alpha subfamily comprises vimses that have a broad host range, a short replicative cycle, and an affinity for the sensory ganglia. They include the human simplex vims and the Varicella-zoster vims. The beta subfamily comprises vimses that have a restricted host range, and include Cytomegalovirus and human Heφes Vims 6. The gamma subfamily comprises vimses that are generally lymphotrophic. The DNA is marked by a segment of about 110 kilobases with a low GC content, flanked by multiple tandem repeats of high GC content. The subfamily includes Epstein Barr Vims (EBV), heφes vims saimiri, equine Heφes Vims 2 and 5, and bovine Heφes Vims 4. Heφes vimses are associated with conditions that have a complex clinical course. A feature of many heφes vimses is the ability to go into a latent state within the host for an extended period of time. Vimses of the alpha subfamily maintain latent forms in the sensory and autonomic ganglia, whereas those of the gamma subfamily maintain latent forms, for example, in cells of the lymphocyte lineage. Latency is associated with the transcription of certain viral genes, and may persist for decades until conditions are optimal for the vims to resume active replication. Such conditions may include an immunodeficiency. In addition, some heφes vimses of the gamma subfamily have the ability to genetically transform the cells they infect. For example, EBV is associated with B cell lymphomas, oral hairy leukoplakia, lymphoid interstitial pneumonitis, and nasopharyngeal carcinoma. A number of other conditions occur in humans and other vertebrates that involve fibroproliferation and the generation of pre-neoplastic cells. Examples occuπing in humans are retroperitoneal fibrosis, nodular fibromatosis, pseudosarcomatous fibromatosis, and sclerosing mesenteritis. Another condition known as Enzootic Retroperitoneal Fibromatosis (RF) has been observed in a colony of macaque monkeys at the University of Washington Regional Primate Research Center (Giddens et al.). Late stages of the disease are characterized by proliferating fibrous tissue around the mesentery and the dorsal part of the peritoneal cavity, with extension into the inguinal canal, through the diaphragm, and into the abdominal wall. Once clinically apparent, the disease is invariably fatal within 1-2 months. The condition has been associated with simian immunodeficiency (SAIDS) due to a type D simian retrovims, SRV-2 (Tsai et al.). However, other colonies do not show the same frequency of RF amongst monkeys affected with SAIDS, and the frequency of RF at Washington has been declining in recent years. The study of such conditions in non-human primates is important not only as a model for human conditions, but also because one primate species may act as a reservoir of vimses that affect another species. For example, the heφes vims saimiri appears to cause no disease in its natural host, the squirrel monkey (Saimiri sciureus), but it causes polyclonal T-cell lymphomas and acute leukemias in other primates, particularly owl monkeys. There is a need to develop reagents and methods for use in the detection and treatment of heφes vims infections. For example, there is a need to develop reagents and methods which can be used in the diagnosis and assessment of Kaposi's sarcoma, and similar conditions. Being able to detect the etiologic agent in a new patient may assist in differential diagnosis; being able to assess the level of the agent in an ongoing condition may assist in clinical management. The tegument encoding polynucleotide of Chang et al. may have limited applicability in this regard. It is desirable to obtain a marker capable of distinguishing active from latent infection. It is also desirable to obtain a marker that is immunogenic, and can be used to assess immunological exposure to the agent as manifest in the antibody response. Second, there is a need to develop reagents and methods which can be used in the development of new pharmaceuticals for Kaposi's sarcoma, and similar conditions. The current treatment for Kaposi's is radiation in combination with traditional chemotherapy, such as vincristine (Northfelt, Mitsuyasu). While lesions respond to these modalities, the response is temporary, and the downward clinical course generally resumes. Even experimental therapies, such as treatment with cytokines, are directed at the symptoms of the disease rather than the cause. Dmg screening and rational dmg design based upon the etiologic agent can be directed towards the long-felt need for a clinical regimen with long-term efficacy. Third, there is a need to develop reagents and methods which can be used to identify viral agents that may be associated with other fibroproliferative conditions. The representational difference analysis technique used by Chang et al. is arduously complex, and probably not appropriate as a general screening test. More desirable are a set of primers or probes to be used as reagents in more routine assays for surveying a variety of tissue samples suspected of containing a related etiologic agent. Preferably, the reagents are sufficiently cross-reactive to identify previously undescribed viral compounds, but sufficiently specific to avoid identifying unwanted vimses or endogenous components ofthe host. DISCLOSURE OF THE INVENTION It is an objective of this invention to provide isolated polynucleotides, polypeptides, and antibodies derived from or reactive with the products of novel DNA polymerase genes. The genes are present in heφes vimses associated with fibroproliferative conditions and neoplasms, especially those that occur in humans and non-human primates. Another objective of this invention is to provide polynucleotide primers and probes for detecting and characterizing DNA polymerase genes in any member of the heφes vims family, especially the gamma heφes subfamily. Another object of this invention is to provide materials and methods based on these polynucleotides, polypeptides, and antibodies for use in the diagnosis and treatment of gamma heφes vims infection in primates, particularly humans. Embodiments of the invention include the following: • An isolated polynucleotide with a region encoding a DNA polymerase of a heφes vims, the polynucleotide comprising a sequence (preferably 475 nucleotides long) that is at least 69% identical to nucleotides 27 to 501 of a sequence selected from the group consisting of SEQ. ID NO:1 and SEQ. ID NO:3. • An isolated polynucleotide comprising a fragment of at least 18, more preferably at least about 35, still more preferably at least about 50 consecutive nucleotides of the DNA polymerase encoding region of the polynucleotide of the previous embodiment, wherein the sequence of said fragment is not contained in SEQ. ID NOS:110 or 111. Preferred examples are isolated polynucleotides comprising a fragment of at least 18 consecutive nucleotides contained in SEQ. ID NOS:1, 3, 116, or 118. • An isolated polynucleotide with a region encoding a DNA polymerase of a heφes vims, the polynucleotide comprising a sequence of 26 nucleotides at least 80% identical to oligonucleotide LSGGA (SEQJD NO:107). • An isolated polynucleotide with a region encoding a DNA polymerase of a heφes vims, the polynucleotide comprising a sequence of 29 nucleotides at least 69% identical to oligonucleotide CTDPA (SEQJD NO:108). • An isolated polynucleotide with a region encoding a DNA polymerase of a heφes vims, the polynucleotide comprising a sequence of 32 nucleotides at least 80% identical to oligonucleotide KMLEA (SEQ. ID NO:22). • An isolated polynucleotide with a region encoding a DNA polymerase of a heφes vims, the polynucleotide comprising a sequence of 29 nucleotides at least 69% identical to oligonucleotide GISPA (SEQJD NO:109). • An isolated polynucleotide comprising a fragment of at least 18, more preferably at least about 35, more preferably at least about 50 consecutive nucleotides of the DNA polymerase encoding region of the polynucleotide of the previous embodiments, wherein the sequence of said fragment is not contained in SEQ. ID NOS:110 or 111. • The polynucleotide of any of the previous embodiments, wherein said heφes vims is capable of infecting primates. Preferred examples are RFHV, KSHV, and RFHV2. • An isolated polynucleotide comprising a linear sequence of at least 18 nucleotides identical to a linear sequence between nucleotides 27 to 501 inclusive of SEQ. ID NO:1, or between nucleotides 27 to 501 inclusive of SEQ. ID NO:3, or between nucleotides 36 to 2499 inclusive of SEQ. ID NO:116, or between nucleotides 1 to 454 inclusive of SEQ. ID NO: 118, but not to a linear sequence within either SEQ. ID NO:110 or SEQ. ID NO:111. The isolated polynucleotide preferably comprises a linear sequence essentially identical to nucleotides 27 to 501 of SEQ. ID NO:1 , or to nucleotides 27 to 501 of SEQ. ID NO:3, or to nucleotides 36 to 2499 of SEQ. ID NO:116, or to nucleotides 1 to 454 of SEQ. ID NO:118. • An isolated polypeptide encoded by any of the polynucleotides embodied in this invention. • An isolated polypeptide, comprising a linear sequence of at least 11, preferably 12, and more preferably 15 amino acids essentially identical to a sequence between amino acids 10 to 167 inclusive of SEQ. ID NO:2 or between amino acids 10 to 167 inclusive of SEQ. ID NO:4 or between amino acids 13 to 833 inclusive of SEQ. ID NO:117, or in any of SEQ. ID NOS:119-123, but which is not contained in SEQ. ID NOS:112 or in SEQ. ID NO:113. • A fusion polypeptide comprising the amino acid sequence of an isolated peptide of the previous embodiment, joined to a second amino acid sequence. • The isolated polypeptide of the previous embodiment, which has nucleic acid binding activity, nucleotide binding activity, or DNA polymerase activity. • An isolated polypeptide, comprising a linear sequence of amino acids identical to a sequence selected from the group consisting of SEQ. ID NOS:80, 82, 84, 86, 88, and 90 to 103. • An isolated polynucleotide encoding a polypeptide embodied in this invention. • A non-naturally occurring polynucleotide encoding a polypeptide embodied in this invention. • A polynucleotide encoding a fusion polypeptide, comprising the polynucleotide embodied in this invention joined directly to a second polynucleotide encoding a polypeptide. • A recombinant cloning vector comprising a polynucleotide sequence encoding a polypeptide of at least 11, preferably at least 12, more preferably at least 15 consecutive amino acids between amino acids 10-167 inclusive of SEQ. ID NO:2, or between amino acids 10-167 inclusive of SEQ. ID NO:4, or between amino acids 13-833 inclusive of SEQ. ID NO:117, or in any of SEQ. ID NOS:119-123, but not contained in SEQ. ID NO:112 or SEQ. ID NO:113. • A recombinant expression vector comprising a polynucleotide sequence encoding a polypeptide of at least 1, preferably at least 12, more preferably at least 15 consecutive amino acids between amino acids 10-167 inclusive of SEQ. ID NO:2, or between amino acids 10-167 inclusive of SEQ. ID NO:4, or between amino acids 13-833 inclusive of SEQ. ID NO:117, or in any of SEQ. ID NOS:119-123, but not contained in SEQ. ID NO:112 or SEQ. ID NO:113, operatively linked to a control polynucleotide sequence. • A recombinant cloning vector comprising a linear sequence of at least 18 nucleotides identical to a linear sequence within SEQ. ID NOS:1 , 3, 116, or 118, but not in SEQ. ID NOS:110 or 111. • A host cell genetically altered by any of the polynucleotides, cloning vectors, or expression vectors of this invention. • A monoclonal or isolated polyclonal antibody specific for a DNA polymerase encoded in said encoding region of a polynucleotide of this invention. • A monoclonal or isolated polyclonal antibody specific for a peptide of this invention. • An oligonucleotide essentially identical to an oligonucleotide selected from the group consisting of SEQ. ID NOS:5 to 16, 21, 22, 104-109, and 124-152. • A method of obtaining an amplified copy of a polynucleotide encoding a DNA polymerase, comprising the steps of contacting the polynucleotide with an oligonucleotide of this invention, which may be a Type 1 , Type 2, or Type 3 oligonucleotide, and elongating oligonucleotide that has formed a duplex with the polynucleotide. Preferably, the amplification reaction is a polymerase chain reaction (PCR). The PCR preferably comprises repeated cycles of annealing and elongating, and the annealing is conducted at a temperature of at least 60°C. • The PCR is preferably conducted in a buffer containing 10-30 mM (NH 4 ) 2 S0 4 and 1-10 mM MgCI 2 ., such as WB4 buffer. • A method of obtaining an amplified copy of a polynucleotide encoding a DNA polymerase, wherein the polynucleotide which is amplified is first obtained from a biological sample taken from an individual affected with a disease featuring fibroblast proliferation and collagen deposition. • A method of obtaining an amplified copy of a polynucleotide encoding a DNA polymerase, wherein the polynucleotide which is amplified is first obtained from a biological sample taken from an individual affected with a malignancy of the lymphocyte lineage. Also included is a method wherein the polynucleotide which is amplified is first obtained from a biological sample taken from an individual affected with a condition selected from the group consisting of retroperitoneal fibrosis, nodular fibromatosis, pseudosarcomatous fibromatosis, fibrosarcoma, sclerosing mesenteritis, acute respiratory disease syndrome, idiopathic pulmonary fibrosis, diffuse proliferative glomerulonephritis, glioma, glioblastomas, gliosis, leukemia and lymphoma. • A method of detecting viral DNA or RNA in a sample of primate origin, comprising the steps of: contacting the DNA or RNA in the sample with a probe comprising the polynucleotide of this invention. under conditions that would permit the probe to form a stable duplex with a polynucleotide having the sequence shown in SEQ. ID NOJ and with a polynucleotide having the sequence shown in SEQ. ID NO:3, but not with a polynucleotide having a sequence of any of SEQ. ID NOS:24 to 29; and detecting the presence of said stable duplex formed in step a), if any. The conditions referred to are a single set of reaction parameters, such as incubation time, temperature, solute concentrations, and washing steps, that fulfills all the criteria listed. Under these conditions, the polynucleotide would be capable of forming a stable duplex if contacted with a polynucleotide having SEQ. ID NOJ It would also be capable of forming a stable duplex if contacted with a polynucleotide having SEQ. ID NO:3. It would not be capable of forming a stable duplex if contacted with a polynucleotide having a sequence of any of SEQ ID NO:24 to SEQ. ID NO:29. The reaction conditions may optionally be tested by contacting with the polynucleotides consisting only of the sequences indicated, or by contacting with polynucleotides with the sequences indicated linked to additional nucleotides, so long as formation of a stable duplex under the test conditions relies on the sequence indicated. Also included are similar methods using other polynucleotides of this invention. This includes conducting an amplification reaction on the DNA or RNA of the sample prior to being contacted with the probe. The amplification reaction may be conducted using an oligonucleotide primer of this invention. • A method of detecting viral DNA or RNA in a sample of primate origin, comprising the steps of: contacting the DNA or RNA in the sample with an oligonucleotide probe comprising a sequence shown in SEQ. ID NOS: 21 , 22, 107, 108, or 109, under conditions that would permit the probe to form a . stable duplex with a polynucleotide having the sequence shown in SEQ. ID NO:1, and with a polynucleotide having the sequence shown in SEQ. ID NO:3, but not with a polynucleotide having a sequence of any of SEQ. ID NOS:24 to 29; and detecting the presence of said stable duplex formed, if any. • A method of detecting viral DNA or RNA in a sample, comprising the steps of: contacting the DNA or RNA in the sample with an oligonucleotide probe comprising a sequence shown in SEQ. ID NOS:22, 107, 108 or 109 under conditions that would permit the probe to form a stable duplex with a polynucleotide having the sequence shown in SEQ. ID NO:1, and with a polynucleotide having the sequence shown in SEQ. ID NO:3, but not with a polynucleotide having a sequence of any of SEQ. ID NOS:23 to 29; and detecting the presence of said stable duplex formed f any. • A method of detecting viral DNA or RNA in a sample, comprising the steps of: conducting an amplification reaction on a polynucleotide in the sample using the oligonucleotide of this invention as a primer in the reaction; and detecting the presence of amplified copies of the polynucleotide, if any. • An isolated polynucleotide capable of forming a stable duplex with an oligonucleotide comprising a sequence selected from the group consisting of SEQ. ID NO: 107, SEQ. ID NO: 108, and their respective complementary sequences, under conditions wherein the oligonucleotide is capable of forming a stable duplex with a polynucleotide having the sequence shown in SEQ. ID NO:1 , and with a polynucleotide having the sequence shown in SEQ. ID NO:3, but not with a polynucleotide having a sequence of any of SEQ. ID NOS:23 to 29.An isolated polypeptide comprising a linear sequence of at least 11 amino acids, preferably at least 12 amino acids, more preferably at least 15 amino acids encoded within the polynucleotide of the preceding embodiment. • A method for detecting infection of an individual by a heφes vims, comprising detecting viral DNA or RNA in a biological sample obtained from the individual, wherein the detecting of viral DNA or RNA is by the method of embodied in this invention. Also included is a method for detecting infection of an individual by a heφes vims, comprising detecting viral DNA or RNA in a biological sample obtained from the individual, wherein the detecting of viral DNA or RNA is by the method of: a) contacting the DNA or RNA in the sample with a probe comprising the polynucleotide of this invention under conditions that would permit the probe to form a stable duplex with a polynucleotide having at least one sequence selected from the group consisting of SEQ. ID NOS:1, 3, 116, or 118, but not with polynucleotides having a sequence of any of SEQ. ID NOS:24 to 29; and b) detecting the presence of said stable duplex fonned in step a), if any. Also included is a method for detecting infection of an individual by a heφes vims, comprising detecting viral DNA or RNA in a biological sample obtained from the individual, wherein the detecting of viral DNA or RNA is by the method of: a) contacting the DNA or RNA in the sample with a probe comprising the polynucleotide of this invention under conditions that would permit the probe to form a stable duplex with a polynucleotide having a sequence shown in SEQ. ID NO:116, but not with polynucleotides having a sequence of any of SEQ. ID NOS:24 to 29; and b) detecting the presence of said stable duplex formed in step a), if any. • A diagnostic kit for detecting a heφes vims polynucleotide in a biological sample, comprising a reagent in suitable packaging, wherein the reagent comprises a polynucleotide of this invention • A diagnostic kit for detecting a heφes vims polynucleotide in a biological sample, comprising a reagent in suitable packaging, wherein the reagent comprises the oligonucleotide of this invention. • A method of detecting infection of an individual by a heφes vims, comprising the steps of: contacting antibody from a sample obtained from the individual with the polypeptide of this invention under conditions that permit the formation of a stable antigen-antibody complex; and detecting said stable complexes formed , if any. • A diagnostic kit for detecting an anti-heφesvims antibody present in a biological sample, comprising a reagent in suitable packaging, wherein the reagent comprises a polypeptide of this invention. • A method of detecting infection of an individual by a heφes vims, comprising the steps of: contacting antibody from a sample obtained from the individual with a polypeptide of this invention under conditions that permit the formation of a stable antigen-antibody complex; and detecting said stable complexes formed, if any. • A diagnostic kit for detecting an anti-heφesvims antibody present in a biological sample, comprising a reagent in suitable packaging, wherein the reagent comprises a polypeptide of this invention. • A method of detecting infection of an individual by a heφes vims, comprising the steps of: contacting a polypeptide from a sample obtained from the individual with the antibody of this invention under conditions that permit the formation of a stable antigen-antibody complex; and detecting said stable complexes formed, if any. • A diagnostic kit for detecting a heφes vims polypeptide present in a biological sample, comprising a reagent in suitable packaging, wherein the reagent comprises an antibody of this invention. • A composition for use in the treatment of heφes vims infection, comprising a polynucleotide, polypeptide, or antibody of this invention. • A method of determining whether a phaimaceutical candidate is useful for treating gamma heφes infection, comprising the steps of: contacting a peptide of this invention with the pharmaceutical candidate; and determining whether a biochemical function of the polypeptide is altered by the pharmaceutical candidate. The biochemical function of the polypeptide determined may be the binding ofthe polypeptide to a nucleic acid., or DNA polymerase activity. • A method of determining whether a pharmaceutical candidate is useful for treating gamma heφes infection, comprising the steps of: genetically altering a cell using a polynucleotide of this invention, and determining the effect of the phaimaceutical candidate on the cell in comparison with a cell not genetically altered with the polynucleotide. • A method of obtaining a compound for use in treating an individual infected with heφes vims, comprising the steps of: creating a compound capable of binding a region of the polypeptide of this invention involved in interacting with a nucleic acid; and determining whether the compound interferes with a biochemical function of the polypeptide. BRIEF DESCRIPTION OF THE DRAWINGS Figure 1 is a listing of polynucleotide sequences amplified from a DNA polymerase encoding region of RFHV and KSHV, along with the encoded polypeptides. The 475-base fragment of each polynucleotide between primers DFASA and GDTD1B is underlined. Also shown in lower-case letters are oligonucleotides useful as amplification primers aligned with corresponding regions of the DNA polymerase gene. DFASA, VYGA and GDTD1B are oligonucleotides with consensus and degenerate segments that can be used to amplify any heφes vims DNA polymerase gene. LSGGA, CTDPA, PCLNA, KMLEA and GISPA are oligonucleotides specific for the RFHV/KSHV subfamily of heφes vimses. VASGA, ILPCA, PIEAB and PEARB are RFHV-specific primers. SGILA, CLNIA, IEASB and EARFB are KSHV-specific primers. Oligonucleotides that initiate amplification in the direction of the coding sequence (with designations ending in "A") are listed 5'→3'. Oligonucleotides that initiate amplification in the direction opposite to that ofthe coding sequence (with designations ending in "B") are listed 3'→5', to show alignment with the corresponding sequences in the RFHV and KSHV polynucleotide. Figure 2 is a listing of the previously known polypeptide sequences of other heφes vims DNA polymerases, showing regions that are relatively conserved between species. Figure 3 is a listing of previously known polynucleotide sequences of heφes vimses near conserved REGION 2, showing the alignment of oligonucleotides DFASA and DFQSA with the sequences from which they were designed. Figure 4 is a listing of previously known polynucleotide sequences of heφes vimses near conserved REGION 3, showing the alignment of oligonucleotides VYGA, VYGCA and VYGSQA with the sequences from which they were designed. Figure 5 is a listing of previously known polynucleotide sequences of heφes vimses near conserved REGION 1, showing the alignment of oligonucleotides GDTD1B and GDTDSQB with the sequences from which they were designed. Figure 6 is a listing comparing the polynucleotide sequences of DNA polymerase of the gamma heφes vims subfamily. The fragment shown is the 475 base pairs between the hybridizing site of DFASA and GDTDIB. Figure 7 is a listing comparing polypeptide sequences of DNA polymerase for the same vimses over the same fragment as Figure 6. This figure also shows examples of possible antibody binding regions, including those which are specific for RFHV, KSHV, or the RFHV/KSHV subfamily. Figure 8 is a comparison of the polypeptide sequence for the fragment encoded between DFASA and GDTD1 B across a broader range of heφes vimses. Sequences are shown for heφes vimses of the alpha, beta, and gamma subfamilies, and for endogenous mammalian DNA polymerase. Figure 9 is a relationship map of DNA polymerases, based on polypeptide sequences shown in Figure 8. Figure 10 is a listing of the DNA polymerase genes for members of the gamma heφes vims subfamily over the same region as Figure 6. This Figure shows the alignment of oligonucleotides LSGGA, CTDPA, PCLNA, KMLEA and GISPA aligned with the sequences from which they were designed. These oligonucleotides are specific for DNA polymerase from the RFHV/KSHV vims subfamily. Figure 11 is a Hopp-Woods antigenicity plot for the polypeptide fragment of RFHV encoded between VYGA and GDTD1B. Indicated below are spans of hydrophobic and antigenic residues in the sequence. Figure 12 is a Hopp-Woods antigenicity plot for the polypeptide fragment of KSHV encoded between DFASA and GDTD1 B. Indicated below are spans of hydrophobic and antigenic residues in the sequence. Figure 13 is a listing of about 2511 nucleotides of the DNA polymerase encoding sequence of KSHV, estimated to be about 3000 nucleotides long, along with the amino acid translation. Additional sequence data is provided in the 5' and 3' direction from the PCR segment shown in Figure 1. Figure 14 is a listing comparing a portion of the KSHV DNA polymerase amino acid sequence with that of other heφes vimses. Asterisks (*) and bullets (•) indicate conserved residues or conservative substitutions. Arrows (t) indicate residues that are conserved amongst other heφes vimses, but different in the KSHV sequence. Figure 15 is a listing showing known variants of the KSHV DNA polymerase amino acid sequence. Figure 16 is a listing of polynucleotide sequences amplified from a DNA polymerase encoding region of RFHVMm (designated here as RFMm), RFHVMm is a third member of the RFHV/KSHV heφes vims subfamily identified according to the criteria of this invention. Shown for comparison are DNA polymerase encoding regions of RFHV (designated RFMn) and KSHV. Figure 17 is a listing comparing amino acid sequences encoded in a DNA polymerase encoding region of RFHVMm with corresponding sequences of RFHVMn, KSHV, and three other heφes vimses. Figure 18 is a statistical phylogeneic analysis of the amino acid alignments in Figure 17. The numbers shown are bootstrap values out of 100 repetitions. Figure 19 is a map showing approximate hybridization positions of Type 1, Type 2, and Type 3 oligonucleotide probes in the DNA polymerase nucleotide sequences of members of the RFHV/KSHV subfamily. Figure 20 is a representative screen for the prevalence of RFHVMn and RFHVMm heφesvirus sequences in M. nemestrina monkeys (lanes A-D, I, and J), and M. mulatta monkeys (lanes G and H) in a nested amplification assay using vims-specific oligonucleotide primers. BEST MODE FOR CARRYING OUT THE INVENTION We have discovered and characterized polynucleotides encoding DNA polymerase from RFHV, RFHV2, and KSHV, which are exemplary members of the RFHV/KSHV subfamily of heφes vimses. The polynucleotides obtained, related polynucleotides, and corresponding polypeptides and antibodies are useful in the diagnosis, clinical monitoring, and treatment of heφes vims infections and related conditions. Sources for the polynucleotides from RFHV and KSHV were affected tissue samples taken from Macaque nemestrina monkeys with retroperitoneal fibromatosis ("RF") and from humans with Kaposi's sarcoma ("KS"), respectively. We predicted that these conditions were associated with vimses distinct from those responsible for any contemporaneous immunodeficiency. We did not know in advance that the RF and KS associated vimses would be related. We decided to test the premise that vimses associated with both conditions are members of the heφes vims family. Accordingly, we designed oligonucleotides for use in an amplification reaction to obtain polynucleotides encoding a DNA polymerase from a broad spectmm of heφes vimses. Comparing amino acid sequences of heφes vimses that have been previously described, three conserved regions were identified. The corresponding known polynucleotide sequences were used to constmct oligonucleotides comprising a degenerate segment and a consensus segment. These oligonucleotides served as primers in amplification reactions that yielded fragments of the DNA polymerase encoding segment from each of the two tissue sources. The sequences of the polynucleotide fragments obtained from the final step of the amplification reactions are shown in Figure 1 (SEQ. ID NO:1 and SEQ. ID NO:3, respectively). Both sequences are novel, although they contain regions that are highly homologous to regions of DNA polymerase sequences from other heφes vimses. The vims infecting the M. nemestrina monkeys was designated "Retroperitoneal Fibromatosis Heφes Vims" ("RFHV"). The vims infecting the human patients was designated "Kaposi's Sarcoma Heφes Vims" ("KSHV"). The polynucleotide sequences shown include segments at each end corresponding to the hybridizing regions of the DFASA and GDTD1 B primers used in the amplification. The 475 base pair fragment between the primers represents an amplified portion of the DNA polymerase gene for RFHV and KSHV. Since the primers were designed to amplify a broad spectmm of DNA polymerases, we were suφrised to find that these two DNA polymerase sequences are apparently more closely related to each other (71% identity at the nucleotide level) than to any other known heφes vims DNA polymerase. The next most closely related polynucleotide sequences are from equine heφes vims 2 (eHV2), saimiri heφes vims 1 (sHV1), and Epstein Barr vims (EBV). We therefore predict that both RFHV and KSHV are members of the heφes gamma subfamily. RFHV and KSHV share with other gamma heφes an association with abnormal cellular or fibrotic growth, and an association with immune abnormalities, including immunosuppression and B cell dysplasias. However, RFHV and KSHV DNA polymerase sequences differ from sHV1 and EBV in the frequency of CpG dinucleotides. RFHV and KSHV DNA polymerase nucleotide sequences and oligonucleotides based upon them define the RFHV/KSHV subfamily as described below. The DNA polymerase sequence of a third member of the subfamily infecting M. mulatta monkeys, RFHV2, is also provided. The degree of conservation between DNA polymerases means that the polynucleotides and polypeptides embodied in this invention are reliable markers amongst different strains of RFHV and KSHV. Because it is a sequestered antigen, DNA polymerase is not under the same degree of immunological pressure to form escape mutants. Furthermore, the sequences are constrained by the critical role that these regions play in the catalytic activity of the DNA polymerase. Thus, the polynucleotides, polypeptides, and antibodies embodied in this invention are useful in such applications as the detection of viral infection in an individual, due to RFHV, KSHV, or other heφes vimses that are of the same subfamily. Embodiments of the invention are also useful in the characterization of heφes vims DNA polymerase, and the design of pharmaceutical therapies. Because the DNA polymerase plays a critical role in viral replication, it is an appropriate target for pharmacological intervention. Particularly sensitive regions of the molecule are those involved in substrate recognition, template binding, catalysis, and association with regulatory subunits. Polynucleotides of the RFHV/KSHV subfamily, related oligonucleotide probes and primers, related polypeptides and antigens, related specific antibodies, the preparation and use of these compounds, and related methods and products are described in further detail in the sections that follow. Abbreviations The following abbreviations are used herein to refer to species of heφes vimses, and polynucleotides and genes derived therefrom that encode DNA polymerase: TABLE 1: Abbreviations for Herpes Virus Strains Designation Virus Provisional Subfamily Assignment RFHV simian Retroperitoneal Fibromatosis- gamma-HeφesVirus associated HeφesVims KSHV human Kaposi's Sarcoma-associated HeφesVims eHV2 equine HeφesVims 2 SHV1 saimiri monkey HeφesVims 1 hEBV human Epstein-Barr Vims hCMV human CytoMegaloVirus beta-HeφesVirus mCMV murine CytoMegaloVirus gpCMV guinea pig CytoMegaloVirus hHV6 human HeφesVims 6 hVZV human Varicella-Zoster Vims alpha-HeφesVirus hHSVI human Heφes Simplex Vims 1 hHSV2 human Heφes Simplex Vims 2 eHV1 equine HeφesVims 1 iHV1 ictalurid catfish HeφesVims hPOLd human endogenous DNA polymerase eukaryotic delta DNA polymerase bPOLd bovine endogenous DNA polymerase Definitions "RFHV and "KSHV are vimses of the heφes family detected in tissue samples of infected macaque nemestrina monkeys and humans, respectively. Cells infected with these vimses contain polynucleotides encoding the respective DNA polymerases as described herein. "RFHV is synonymous with the terms "RFHV1", "RFHVMn", and "RFMn". A third member of the RFHV/KSHV subfamily is a vims identified in a M. mulatta monkey. The vims is referred to herein as "RFHV2". "RFHV2" is synonymous with the terms "RFHVMm" and "RFMm". The "RFHV/KSHV subfamily" is a term used herein to refer to a collection of heφes vimses capable of infecting vertebrate species. The subfamily consists of members that have sequences that are more closely related to the corresponding sequences of RFHV or KSHV than either of these vimses are to any other vims listed in Table 1. The sequence comparison may be made at either the polynucleotide or the polypeptide level, and may be across intact genes or proteins, or across fragments thereof. As used herein, the subfamily refers to heφes vimses that contain a portion of a DNA-polymerase-encoding polynucleotide that is more closely identical to the corresponding region of RFHV or KSHV than either of these vimses are to the vimses in Table 1. Preferably, the polynucleotide encoding the polymerase comprises a segment that is at least 69% identical to that of RFHV (SEQ. ID NO:1) or KSHV (SEQ. ID NO:3) between residues 27 and 501; or at least 80% identical to the oligonucleotide LSGGA; or at least 69% identical to the oligonucleotide CTDPA; or at least 80% identical to the oligonucleotide KMLEA; or at least 69% identical to the oligonucleotide GISPA. As used herein, a "DNA polymerase" is a protein or a protein analog, that under appropriate conditions is capable of catalyzing the assembly of a DNA polynucleotide with a sequence that is complementary to a polynucleotide used as a template. A DNA polymerase may also have other catalytic activities, such as 3'-5' exonuclease activity; any of the activities may predominate. A DNA polymerase may require association with additional proteins or co-factors in order to exercise its catalytic function. "DNA polymerase activity" refers to the catalytic activity directed at DNA polynucleotide assembly. A "DNA polymerase reaction" is any step in a reaction mechanism on the pathway to polymerization of nucleotides, including association with substrates, cofactors, and regulatory subunits, the formation of intermediates, and the formation of reaction products. The term "DNA polymerase gene" includes any gene that encodes a polypeptide capable of a DNA polymerase reaction. It also includes any gene that is believed to be derived from an ancestral gene that encoded a DNA polymerase, because of homology with other DNA polymerase genes or its location relative to neighboring genes; such a gene may encode a non-functional DNA polymerase analog, a DNA polymerase fragment or mutant, or it may be untranscribed or untranslated. A "regulatory subunit" for a first polypeptide that has DNA polymerase activity is a second polypeptide that regulates DNA polymerase activity of the first polypeptide when associated with it. UL42 is an example of a regulatory subunit. "UL42" or "UL42 subunit" is an accessory protein that is encoded in the genome of some heφes vimses. It is capable of associating with the DNA polymerase of the vims. Under certain conditions, it enhances the DNA polymerase activity of a polypeptide encoded by a DNA polymerase gene, and may be required for the vims to replicate. As used herein, the definition is a functional one, and does not depend on the stmcture or genomic location of the corresponding gene. Thus, a UL42 subunit of RFHV or KSHV may have a sequence that is not essentially identical to the UL42 subunit of other vimses. The terms "polynucleotide" and "oligonucleotide" are used interchangeably, and refer to a polymeric form of nucleotides of any length, either deoxyribonucleotides or ribonucleotides, or analogs thereof. Polynucleotides may have any three-dimensional stmcture, and may perform any function, known or unknown. The following are non-limiting examples of polynucleotides: a gene or gene fragment, exons, introns, messenger RNA (mRNA), transfer RNA, ribosomal RNA, ribozymes, cDNA, recombinant polynucleotides, branched polynucleotides, plasmids, vectors, isolated DNA of any sequence, isolated RNA of any sequence, nucleic acid probes, and primers. A polynucleotide may comprise modified nucleotides, such as methylated nucleotides and nucleotide analogs. If present, modifications to the nucleotide stmcture may be imparted before or after assembly of the polymer. The sequence of nucleotides may be intermpted by non-nucleotide components. A polynucleotide may be further modified after polymerization, such as by conjugation with a labeling component. The term polynucleotide, as used herein, refers interchangeably to double- and single-stranded molecules. Unless otherwise specified or required, any embodiment of the invention described herein that is a polynucleotide encompasses both the double-stranded form and each of two complementary single-stranded forms known or predicted to make up the double-stranded form. In the context of polynucleotides, a "linear sequence" or a "sequence" is an order of nucleotides in a polynucleotide in a 5' to 3' direction in which residues that neighbor each other in the sequence are contiguous in the primary stmcture of the polynucleotide. A "partial sequence" is a linear sequence of part of a polynucleotide which is known to comprise additional residues in one or both directions. "Hybridization" refers to a reaction in which one or more polynucleotides react to form a complex that is stabilized via hydrogen bonding between the bases of the nucleotide residues. The hydrogen bonding may occur by Watson-Crick base pairing, Hoogsteen binding, or in any other sequence-specific manner. The complex may comprise two strands forming a duplex stmcture, three or more strands forming a multi-stranded complex, a single self-hybridizing strand, or any combination of these. A hybridization reaction may constitute a step in a more extensive process, such as the initiation of a PCR, or the enzymatic cleavage of a polynucleotide by a ribozyme. Hybridization reactions can be performed under conditions of different "stringency". Conditions that increase the stringency of a hybridization reaction are widely known and published in the art: see, for example, Sambrook Fritsch & Maniatis. Examples of relevant conditions include (in order of increasing stringency): incubation temperatures of 25°C, 37°C, 50°C, and 68"C; buffer concentrations of 10 x SSC, 6 x SSC, 1 x SSC, 0.1 x SSC (where SSC is 0.15 M NaCl and 15 mM citrate buffer) and their equivalent using other buffer systems; formamide concentrations of 0%, 25%, 50%, and 75%; incubation times from 5 min to 24 h; and washes of increasing duration, increasing frequency, or decreasing buffer concentrations. "T m " is the temperature in degrees Centigrade at which 50% of a polynucleotide duplex made of complementary strands hydrogen bonded in an antiparallel direction by Watson-Crick base paring dissociates into single strands under the conditions of the experiment. T m may be predicted according to standard formula; for example: T m = 81.5 + 16.6 log [Na + ] + 0.41 (%G/C) - 0.61 (%F) - 600/L where Na + is the cation concentration (usually sodium ion) in mol/L; (%G/C) is the number of G and C residues as a percentage of total residues in the duplex; (%F) is the percent formamide in solution (wt/vol); and L is the number of nucleotides in each strand of the duplex. A "stable duplex" of polynucleotides, or a "stable complex" formed between any two or more components in a biochemical reaction, refers to a duplex or complex that is sufficiently long-lasting to persist between the formation of the duplex or complex, and its subsequent detection. The duplex or complex must be able to withstand whatever conditions exist or are introduced between the moment of formation and the moment of detection, these conditions being a function of the assay or reaction which is being performed. Intervening conditions which may optionally be present and which may dislodge a duplex or complex include washing, heating, adding additional solutes or solvents to the reaction mixture (such as denaturants), and competing with additional reacting species. Stable duplexes or complexes may be irreversible or reversible, but must meet the other requirements of this definition. Thus, a transient complex may form in a reaction mixture, but it does not constitute a stable complex if it dissociates spontaneously or as a result of a newly imposed condition or manipulation introduced before detection. When stable duplexes form in an antiparallel configuration between two single-stranded polynucleotides, particulariy under conditions of high stringency, the strands are essentially "complementary". A double-stranded polynucleotide can be "comple-mentary" to another polynucleotide, if a stable duplex can form between one of the strands of the first polynucleotide and the second. A complementary sequence predicted from the sequence of a single stranded polynucleotide is the optimum sequence of standard nucleotides expected to form hydrogen bonding with the single-stranded polynucleotide according to generally accepted base-pairing mles. A "sense" strand and an "antisense" strand when used in the same context refer to single-stranded polynucleotides which are complementary to each other. They may be opposing strands of a double-stranded polynucleotide, or one strand may be predicted from the other according to generally accepted base-pairing mles. Unless otherwise specified or implied, the assignment of one or the other strand as "sense" or "antisense" is arbitrary. A linear sequence of nucleotides is "identical" to another linear sequence, if the order of nucleotides in each sequence is the same, and occurs without substitution, deletion, or material substitution. It is understood that purine and pyrimidine nitrogenous bases with similar stmctures can be functionally equivalent in terms of Watson-Crick base-pairing; and the inter-substitution of like nitrogenous bases, particularly uracil and thymine, or the modification of nitrogenous bases, such as by methylation, does not constitute a material substitution. An RNA and a DNA polynucleotide have identical sequences when the sequence for the RNA reflects the order of nitrogenous bases in the polyribonucleotide, the sequence for the DNA reflects the order of nitrogenous bases in the polydeoxyribonucleotide, and the two sequences satisfy the other requirements of this definition. Where at least one of the sequences is a degenerate oligonucleotide comprising an ambiguous residue, the two sequences are identical if at least one of the alternative forms of the degenerate oligonucleotide is identical to the sequence with which it is being compared. For example, AYAAA is identical to ATAAA, if AYAAA is a mixture of ATAAA and ACAAA. When comparison is made between polynucleotides, it is implicitly understood that complementary strands are easily generated, and the sense or antisense strand is selected or predicted that maximizes the degree of identity between the polynucleotides being compared. For example, where one or both of the polynucleotides being compared is double-stranded, the sequences are identical if one strand of the first polynucleotide is identical with one strand of the second polynucleotide. Similarly, when a polynucleotide probe is described as identical to its target, it is understood that it is the complementary strand of the target that participates in the hybridization reaction between the probe and the target. A linear sequence of nucleotides is "essentially identical" to another linear sequence, if both sequences are capable of hybridizing to form duplexes with the same complementary polynucleotide. Sequences that hybridize under conditions of greater stringency are more preferred. It is understood that hybridization reactions can accommodate insertions, deletions, and substitutions in the nucleotide sequence. Thus, linear sequences of nucleotides can be essentially identical even if some of the nucleotide residues do not precisely correspond or align. Sequences that correspond or align more closely to the invention disclosed herein are comparably more preferred. Generally, a polynucleotide region of about 25 residues is essentially identical to another region, if the sequences are at least about 80% identical; more preferably, they are at least about 90% identical; more preferably, they are at least about 95% identical; still more preferably, the sequences are 100% identical. A polynucleotide region of 40 residues or more will be essentially identical to another region, after alignment of homologous portions if the sequences are at least about 75% identical; more preferably, they are at least about 80% identical; more preferably, they are at least about 85% identical; even more preferably, they are at least about 90% identical; still more preferably, the sequences are 100% identical. In determining whether polynucleotide sequences are essentially identical, a sequence that preserves the functionality of the polynucleotide with which it is being compared is particularly preferred. Functionality can be determined by different parameters. For example, if the polynucleotide is to be used in reactions that involve hybridizing with another polynucleotide, then preferred sequences are those which hybridize to the same target under similar conditions. In general, the T m of a DNA duplex decreases by about 1°C for every 1% decrease in sequence identity for duplexes of 200 or more residues; or by about 5°C for duplexes of less than 40 residues, depending on the position of the mismatched residues (see, e.g., Meinkoth et al.). Essentially identical sequences of about 100 residues will generally form a stable duplex with each other's respective complementary sequence at about 20°C less than T m ; preferably, they will form a stable duplex at about 15°C less; more preferably, they will form a stable duplex at about 10°C less; even more preferably, they will form a stable duplex at about 5°C less; still more preferably, they will form a stable duplex at about T m . In another example, if the polypeptide encoded by the polynucleotide is an important part of its functionality, then preferred sequences are those which encode identical or essentially identical polypeptides. Thus, nucleotide differences which cause a conservative amino acid substitution are preferred over those which cause a non-conservative substitution, nucleotide differences which do not alter the amino acid sequence are more preferred, while identical nucleotides are even more preferred. Insertions or deletions in the polynucleotide that result in insertions or deletions in the polypeptide are preferred over those that result in the down-stream coding region being rendered out of phase; polynucleotide sequences comprising no insertions or deletions are even more preferred. The relative importance of hybridization properties and the encoded polypeptide sequence of a polynucleotide depends on the application ofthe invention. A polynucleotide has the same "characteristics" of another polynucleotide if both are capable of forming a stable duplex with a particular third polynucleotide under similar conditions of maximal stringency. Preferably, in addition to similar hybridization properties, the polynucleotides also encode essentially identical polypeptides. "Conserved" residues of a polynucleotide sequence are those residues which occur unaltered in the same position of two or more related sequences being compared. Residues that are relatively conserved are those that are conserved amongst more related sequences than residues appearing elsewhere in the sequences. "Related" polynucleotides are polynucleotides that share a significant proportion of identical residues. As used herein, a "degenerate" oligonucleotide sequence is a designed sequence derived from at least two related originating polynucleotide sequences as follows: the residues that are conserved in the originating sequences are preserved in the degenerate sequence, while residues that are not conserved in the originating sequences may be provided as several alternatives in the degenerate sequence. For example, the degenerate sequence AYASA may be designed from originating sequences ATACA and ACAGA, where Y is C or T and S is C or G. Y and S are examples of "ambiguous" residues. A degenerate segment is a segment of a polynucleotide containing a degenerate sequence. It is understood that a synthetic oligonucleotide comprising a degenerate sequence is actually a mixture of closely related oligonucleotides sharing an identical sequence, except at the ambiguous positions. Such an oligonucleotide is usually synthesized as a mixture of all possible combinations of nucleotides at the ambiguous positions. Each of the oligonucleotides in the mixture is referred to as an "alternative form". The number of forms in the mixture is equal to n π ^ i=l where kj is the number of alternative nucleotides allowed at each position. As used herein, a "consensus" oligonucleotide sequence is a designed sequence derived from at least two related originating polynucleotide sequences as follows: the residues that are conserved in all originating sequences are preserved in the consensus sequence; while at positions where residues are not conserved, one alternative is chosen from amongst the originating sequences. In general, the nucleotide chosen is the one which occurs in the greatest frequency in the originating sequences. For example, the consensus sequence AAAAA may be designed from originating sequences CAAAA, AAGAA, and AAAAT. A consensus segment is a segment of a polynucleotide containing a consensus sequence. A polynucleotide "fragment" or "insert" as used herein generally represents a sub-region of the full-length form, but the entire full-length polynucleotide may also be included. Different polynucleotides "correspond" to each other if one is ultimately derived from another. For example, messenger RNA corresponds to the gene from which it is transcribed. cDNA corresponds to the RNA from which it has been produced, such as by a reverse transcription reaction, or by chemical synthesis of a DNA based upon knowledge of the RNA sequence. cDNA also corresponds to the gene that encodes the RNA. Polynucleotides also "correspond" to each other if they serve a similar function, such as encoding a related polypeptide, in different species, strains or variants that are being compared. A "probe" when used in the context of polynucleotide manipulation refers to an oligonucleotide which is provided as a reagent to detect a target potentially present in a sample of interest by hybridizing with the target. Usually, a probe will comprise a label or a means by which a label can be attached, either before or subsequent to the hybridization reaction. Suitable labels include, but are not limited to radioisotopes, fluorochromes, chemiluminescent compounds, dyes, and proteins, including enzymes. A "primer" is an oligonucleotide, generally with a free 3' -OH group, that binds to a target potentially present in a sample of interest by hybridizing with the target, and thereafter promotes polymerization of a polynucleotide complementary to the target. Processes of producing replicate copies of the same polynucleotide, such as PCR or gene cloning, are collectively referred to herein as "amplification" or "replication". For example, single or double- stranded DNA may be replicated to form another DNA with the same sequence. RNA may be replicated, for example, by an RNA-directed RNA polymerase, or by reverse-transcribing the DNA and then performing a PCR. In the latter case, the amplified copy of the RNA is a DNA with the identical sequence. A "polymerase chain reaction" ("PCR") is a reaction in which replicate copies are made of a target polynucleotide using one or more primers, and a catalyst of polymerization, such as a reverse transcriptase or a DNA polymerase, and particulariy a thermally stable polymerase enzyme. Generally, a PCR involves reiteratively forming three steps: "annealing", in which the temperature is adjusted such that oligonucleotide primers are permitted to form a duplex with the polynucleotide to be amplified; "elongating", in which the temperature is adjusted such that oligonucleotides that have formed a duplex are elongated with a DNA polymerase, using the polynucleotide to which they've formed the duplex as a template; and "melting", in which the temperature is adjusted such that the polynucleotide and elongated oligonucleotides dissociate. The cycle is then repeated until the desired amount of amplified polynucleotide is obtained. Methods for PCR are taught in U.S. Patent Nos. 4,683,195 (Mullis) and 4,683,202 (Mullis et al.). Elements within a gene include but are not limited to promoter regions, enhancer regions, repressor binding regions, transcription initiation sites, ribosome binding sites, translation initiation sites, protein encoding regions, introns and exons, and termination sites for transcription and translation. A "control element" or "control sequence" is a nucleotide sequence involved in an interaction of molecules that contributes to the functional regulation of a polynucleotide, including replication, duplication, transcription, splicing, translation, or degradation of the polynucleotide. The regulation may affect the frequency, speed, or specificity of the process, and may be enhancing or inhibitory in nature. Control elements are known in the art. For example, a "promoter" is an example of a control element. A promoter is a DNA region capable under certain conditions of binding RNA polymerase and initiating transcription of a coding region located downstream (in the 3' direction) from the promoter. "Operatively linked" refers to a juxtaposition of genetic elements, wherein the elements are in a relationship permitting them to operate in the expected manner. For instance, a promoter is operatively linked to a coding region if the promoter helps initiate transcription of the coding sequence. There may be intervening residues between the promoter and coding region so long as this functional relationship is maintained. The terms "polypeptide", "peptide" and "protein" are used interchangeably herein to refer to polymers of amino acids of any length. The polymer may be linear or branched, it may comprise modified amino acids, and it may be intermpted by non-amino acids. The terms also encompass an amino acid polymer that has been modified; for example, disulfide bond formation, glycosylation, lipidation, acetylation, phosphorylation, or any other manipulation, such as conjugation with a labeling component. In the context of polypeptides, a "linear sequence" or a "sequence" is an order of amino acids in a polypeptide in an N-terminal to C-terminal direction in which residues that neighbor each other in the sequence are contiguous in the primary stmcture of the polypeptide. A "partial sequence" is a linear sequence of part of a polypeptide which is known to comprise additional residues in one or both directions. A linear sequence of amino acids is "essentially identical" to another sequence if the two sequences have a substantial degree of sequence identity. It is understood that the folding and the biochemical function of proteins can accommodate insertions, deletions, and substitutions in the amino acid sequence. Thus, linear sequences of amino acids can be essentially identical even if some of the residues do not precisely correspond or align. Sequences that correspond or align more closely to the invention disclosed herein are more preferred. It is also understood that some amino acid substitutions are more easily tolerated. For example, substitution of an amino acid with hydrophobic side chains, aromatic side chains, polar side chains, side chains with a positive or negative charge, or side chains comprising two or fewer carbon atoms, by another amino acid with a side chain of like properties can occur without disturbing the essential identity of the two sequences. Methods for determining homologous regions and scoring the degree of homology are well known in the art; see for example Altschul et al. and Henikoff et al. Well-tolerated sequence differences are referred to as "conservative substitutions". Thus, sequences with conservative substitutions are preferred over those with other substitutions in the same positions; sequences with identical residues at the same positions are still more preferred. Generally, a polypeptide region of about 25 residues is essentially identical to another region if the sequences are at least about 80% identical; more preferably, they are at least about 85% identical; more preferably, they are at least about 90% identical; more preferably, they are at least about 95% identical; still more preferably, the sequences are 100% identical. A polypeptide region of 40 residues or more will be essentially identical to another region, after alignment of homologous portions, if the sequences are at least about 70% identical; more preferably, they are at least about 70% identical, and comprise at least another 10% which are either identical or are conservative substitutions; more preferably, they are at least about 80% identical; more preferably, they are at least about 80% identical, and comprise at least another 10% which are either identical or are conservative substitutions; more preferably, they are at least about 90% identical; still more preferably, the sequences are 100% identical. In determining whether polypeptide sequences are essentially identical, a sequence that preserves the functionality ofthe polypeptide with which it is being compared is particularly preferred. Functionality may be established by different parameters, such as enzymatic activity, the binding rate or affinity in a substrate-enzyme or receptor-ligand interaction, the binding affinity with an antibody, and X ^ ray crystallographic structure. A polypeptide has the same "characteristics" of another polypeptide if it displays the same biochemical function, such as enzyme activity, ligand binding, or antibody reactivity. Preferred characteristics of a polypeptide related to a DNA polymerase or a DNA polymerase fragment are DNA polymerase activity, DNA template binding, and the binding of deoxyribonucleotide triphosphates. Also preferred is a polypeptide that displays the same biochemical function as the polypeptide with which it is being compared, and in addition, is believed to have a similar three-dimensional conformation, as predicted by computer modeling or determined by such techniques as X-ray crystallography. The "biochemical function" or "biological activity" of a polypeptide includes any feature of the polypeptide detectable by suitable experimental investigation. "Altered" biochemical function can refer to a change in the primary, secondary, tertiary, or quaternary stmcture of the polypeptide; detectable, for example, by molecular weight determination, circular dichroism, antibody binding, difference spectroscopy, or nuclear magnetic resonance. It can also refer to a change in reactivity, such as the ability to catalyze a certain reaction, or the ability to bind a cofactor, substrate, inhibitor, dmg, hapten, or other polypeptide. A substance may be said to "interfere" with the biochemical function of a polypeptide if it alters the biochemical function of the polypeptide in any of these ways. A "fusion polypeptide" is a polypeptide comprising regions in a different position in the sequence than occurs in nature. The regions may normally exist in separate proteins and are brought together in the fusion polypeptide; or they may normally exist in the same protein but are placed in a new arrangement in the fusion polypeptide. A fusion polypeptide may be created, for example, by chemical synthesis, or by creating and translating a polynucleotide in which the peptide regions are encoded in the desired relationship. An "antibody" (interchangeably used in plural form) is an immunoglobulin molecule capable of specific binding to a target, such as a polypeptide, through at least one antigen recognition site, located in the variable region of the immunoglobulin molecule. As used herein, the term encompasses not only intact antibodies, but also fragments thereof, mutants thereof, fusion proteins, humanized antibodies, and any other modified configuration of the immunoglobulin molecule that comprises an antigen recognition site of the required specificity. "Immunological recognition" or "immunological reactivity" refers to the specific binding of a target through at least one antigen recognition site in an immunoglobulin or a related molecule, such as a B cell receptor or a T cell receptor. The term "antigen" refers to the target molecule that is specifically bound by an antibody through its antigen recognition site. The antigen may, but need not be chemically related to the immunogen that stimulated production of the antibody. The antigen may be polyvalent, or it may be a monovalent hapten. Examples of kinds of antigens that can be recognized by antibodies include polypeptides, polynucleotides, other antibody molecules, oligosaccharides, complex lipids, dmgs, and chemicals. An "immunogen" is an antigen capable of stimulating production of an antibody when injected into a suitable host, usually a mammal. Compounds may be rendered immunogenic by many techniques known in the art, including crosslinking or conjugating with a carrier to increase valency, mixing with a mitogen to increase the immune response, and combining with an adjuvant to enhance presentation. A "vaccine" is a pharmaceutical preparation for human or animal use, which is administered with the intention of conferring the recipient with a degree of specific immunological reactivity against a particular target, or group of targets. The immunological reactivity may be antibodies or cells (particularly B cells, plasma cells, T helper cells, and cytotoxic T lymphocytes, and their precursors) that are immunologically reactive against the target, or any combination thereof. Possible targets include foreign or pathological compounds, such as an exogenous protein, a pathogenic virus, or an antigen expressed by a cancer cell. The immunological reactivity may be desired for experimental puφoses, for the treatment of a particular condition, for the elimination of a particular substance, or for prophylaxis against a particular condition or substance. A "passive vaccine" is a vaccine that does not require participation of the recipient's immune response to exert its effect. Usually, it is comprised of antibody molecules reactive against the target. The antibodies may be obtained from a donor subject and sufficiently purified for administration to the recipient, or they may be produced in vitro, for example, from a culture of hybridoma cells, or by genetically engineering a polynucleotide encoding an antibody molecule. An "active vaccine" is a vaccine administered with the intention of eliciting a specific immune response within the recipient, that in turn has the desired immunological reactivity against the target. An active vaccine comprises a suitable immunogen. The immune response that is desired may be either humoral or cellular, systemic or secretory, or any combination of these. A "reagent" polynucleotide, polypeptide, or antibody, is a substance provided for a reaction, the substance having some known and desirable parameters for the reaction. A reaction mixture may also contain a "target", such as a polynucleotide, antibody, or polypeptide that the reagent is capable of reacting with. For example, in some types of diagnostic tests, the amount of the target in a sample is determined by adding a reagent, allowing the reagent and target to react, and measuring the amount of reaction product. In the context of clinical management, a "target" may also be a cell, collection of cells, tissue, or organ that is the object of an administered substance, such as a pharmaceutical compound. An "isolated" polynucleotide, polypeptide, protein, antibody, or other substance refers to a preparation of the substance devoid of at least some of the other components that may also be present where the substance or a similar substance naturally occurs or is initially obtained from. Thus, for example, an isolated substance may be prepared by using a purification technique to enrich it from a source mixture. Enrichment can be measured on an absolute basis, such as weight per volume of solution, or it can be measured in relation to a second, potentially interfering substance present in the source mixture. Increasing enrichments of the embodiments of this invention are increasingly more preferred. Thus, for example, a 2-fold enrichment is preferred, 10-fold enrichment is more preferred, 100-fold enrichment is more preferred, 1000-fold enrichment is even more preferred. A substance can also be provided in an isolated state by a process of artificial assembly, such as by chemical synthesis or recombinant expression. A polynucleotide used in a reaction, such as a probe used in a hybridization reaction, a primer used in a PCR, or a polynucleotide present in a pharmaceutical preparation, is referred to as "specific" or "selective" if it hybridizes or reacts with the intended target more frequently, more rapidly, or with greater duration than it does with alternative substances. Similarly, a polypeptide is referred to as "specific" or "selective" if it binds an intended target, such as a ligand, hapten, substrate, antibody, or other polypeptide more frequently, more rapidly, or with greater duration than it does to alternative substances. An antibody is referred to as "specific" or "selective" if it binds via at least one antigen recognition site to the intended target more frequently, more rapidly, or with greater duration than it does to alternative substances. A polynucleotide, polypeptide, or antibody is said to "selectively inhibit" or "selectively interfere with" a reaction if it inhibits or interferes with the reaction between particular substrates to a greater degree or for a greater duration than it does with the reaction between alternative substrates. A "pharmaceutical candidate" or "dmg candidate" is a compound believed to have therapeutic potential, that is to be tested for efficacy. The "screening" of a pharmaceutical candidate refers to conducting an assay that is capable of evaluating the efficacy and/or specificity of the candidate. In this context, "efficacy" refers to the ability of the candidate to affect the cell or organism it is administered to in a beneficial way: for example, the limitation of the pathology due to an invasive vims. The "effector component" of a pharmaceutical preparation is a component which modifies target cells by altering their function in a desirable way when administered to a subject bearing the cells. Some advanced pharmaceutical preparations also have a "targeting component", such as an antibody, which helps deliver the effector component more efficaciously to the target site. Depending on the desired action, the effector component may have any one of a number of modes of action. For example, it may restore or enhance a normal function of a cell, it may eliminate or suppress an abnormal function of a cell, or it may alter a cell's phenotype. Alternatively, it may kill or render dormant a cell with pathological features, such as a virally infected cell. Examples of effector components are provided in a later section. A "cell line" or "cell culture" denotes higher eukaryotic cells grown or maintained in vitro. It is understood that the descendants of a cell may not be completely identical (either morphologically, genotypically, or phenotypically) to the parent cell. A "host cell" is a cell which has been transformed, or is capable of being transformed, by administration of an exogenous polynucleotide. A "host cell" includes progeny of the original transformant. "Genetic alteration" refers to a process wherein a genetic element is introduced into a cell other than by natural cell division. The element may be heterologous to the cell, or it may be an additional copy or improved version of an element already present in the cell. Genetic alteration may be effected, for example, by transfecting a cell with a recombinant plasmid or other polynucleotide through any process known in the art, such as electroporation, calcium phosphate precipitation, contacting with a polynucleotide-Iiposome complex, or by transduction or infection with a DNA or RNA vims or viral vector. The alteration is preferably but not necessarily inheritable by progeny of the altered cell. An "individual" refers to vertebrates, particularly members of a mammalian species, and includes but is not limited to domestic animals, sports animals, and primates, including humans. The term "primate" as used herein refers to any member of the highest order of mammalian species. This includes (but is not limited to) prosimians, such as lemurs and lorises; tarsioids, such as tarsiers; new-world monkeys, such as squirrel monkeys (Saimiri sciureus) and tamarins; old-world monkeys such as macaques (including Macaca nemestπna, Macaca fascicularis, and Macaca fuscata); hylobatids, such as gibbons and siamangs; pongids, such as orangutans, gorillas, and chimpanzees; and hominids, including humans. The "pathology" caused by a herpes virus infection is anything that compromises the well-being or normal physiology of the host. This may involve (but is not limited to) destructive invasion of the vims into previously uninfected cells, replication of the virus at the expense of the normal metabolism of the cell, generation of toxins or other unnatural molecules by the vims, irregular growth of cells or intercellular stmctures (including fibrosis), irregular or suppressed biological activity of infected cells, malignant transformation, interference with the normal function of neighboring cells, aggravation or suppression of an inflammatory or immunological response, and increased susceptibility to other pathogenic organisms and conditions. "Treatment" of an individual or a cell is any type of intervention in an attempt to alter the natural course of the individual or cell. For example, treatment of an individual may be undertaken to decrease or limit the pathology caused by a herpes vims infecting the individual. Treatment includes (but is not limited to) administration of a composition, such as a pharmaceutical composition, and may be performed either prophylactically, or therapeutically, subsequent to the initiation of a pathologic event or contact with an etiologic agent. It is understood that a clinical or biological "sample" encompasses a variety of sample types obtained from a subject and useful in an in vitro procedure, such as a diagnostic test. The definition encompasses solid tissue samples obtained as a surgical removal, a pathology specimen, or a biopsy specimen, tissue cultures or cells derived therefrom and the progeny thereof, and sections or smears prepared from any of these sources. Non-limiting examples are samples obtained from infected sites, fibrotic sites, unaffected sites, and tumors. The definition also encompasses blood, spinal fluid, and other liquid samples of biologic origin, and may refer to either the cells or cell fragments suspended therein, or to the liquid medium and its solutes. The definition also includes samples that have been solubilized or enriched for certain components, such as DNA, RNA, protein, or antibody. Oligonucleotide primers and probes described herein have been named as follows: The first part of the designation is the single amino acid code for a portion of the conserved region of the DNA polymerase they are based upon, usually 4 residues long. This is followed with the letter A or B, indicating respectively that the oligonucleotide is complementary to the sense or anti-sense strand of the DNA polymerase encoding region. Secondary consensus oligonucleotides used for sequencing have the letters SQ at the end of the designation. General techniques The practice of the present invention will employ, unless otherwise indicated, conventional techniques of molecular biology, microbiology, recombinant DNA, and immunology, which are within the skill of the art. Such techniques are explained fully in the literature. See, for example, "Molecular Cloning: A Laboratory Manual", Second Edition (Sambrook, Fritsch & Maniatis, 1989), "Oligonucleotide Synthesis" (M.J. Gait, ed., 1984), "Animal Cell Culture" (R.I. Freshney, ed., 1987); the series "Methods in Enzymology" (Academic Press, Inc.); "Handbook of Experimental Immunology" (D.M. Weir & C.C. Blackwell, eds.), "Gene Transfer Vectors for Mammalian Cells" (J.M. Miller & M.P. Calos, eds., 1987), "Current Protocols in Molecular Biology" (F.M. Ausubel et al., eds., 1987); and "Current Protocols in Immunology" (J.E. Coligan et al., eds., 1991). All patents, patent applications, articles and publications mentioned herein, both supra and infra, are hereby incoφorated herein by reference. Polynucleotides encoding DNA polymerase of the herpes virus RFHV/KSHV subfamily This invention embodies isolated polynucleotide segments derived from DNA polymerase genes present in heφes vimses, preferably that encode a fragment of a polypeptide that is capable of a DNA polymerase reaction. Polynucleotides provided are from the RFHV/KSHV subfamily of heφes vimses. Preferred polynucleotides are those encoding a fragment of a DNA polymerase from either RFHV or KSHV. Prefe ed fragments are those that have been amplified and isolated from the DNA polymerase gene, as described in the Examples below. Exemplary fragments are shown in Figure 1, and designated SEQ. ID NO:1 and SEQ. ID NO:3, respectively. Especially preferred are polynucleotides comprising the sequence between residues 27 and 501 of the RFHV sequence (SEQ. ID NO:1), and the sequence between residues 27 and 329 ofthe KSHV sequence (SEQ. ID NO:3). The polynucleotide segments of RFHV and KSHV between residues 27 and 501 (the 475 base pair fragment underlined in Figure 1) are 71% identical. Shared residues are indicated in Figure 1 by "*". The largest number of consecutive bases shared between RFHV and KSHV within this segment is 17. The 475 base pair fragments of RFHV and KSHV are more identical to each other than either of them are to the corresponding segment of any of the previously sequenced heφes vimses of Table 1. The next most closely related sequence is the DNA polymerase from the eHV2 vims, which is about 68% identical in this region to either RFHV or KSHV. Contained within this region is a first 20 base pair subfragment (SEQ. ID NO: 110) and a second 20 base pair subfragment (SEQ. ID NO:111) which is shared identically between eHV2 and RFHV. The 475 base pair region is less than about 65% identical between either RFHV or KSHV and the other known DNA polymerase sequences from heφes vimses capable of infecting primates, including sHV1 and EBV. The longest subfragment shared identically between RFHV or KSHV, and sHV1, is about 14 bases in length. The longest subfragment shared identically between RFHV or KSHV, and EBV, is about 15 bases in length. It is predicted that polynucleotide sequences are more likely to be conserved between heφes vims DNA polymerase encoding regions than with other polynucleotides. Therefore, other than the two subfragments shared with eHV2, it is believed that any subfragment of the RFHV or KSHV sequence of 18 base pairs or longer will be unique to the RFHV/KSHV subfamily, or to particular heφes vims species and variants within the subfamily. This invention embodies subfragments contained in the DNA polymerase gene of the RFHV/KSHV subfamily, preferably contained in the region corresponding to the 475 base pair fragment between residues 27-501, as shown in Figure 1. Preferably, the sub-fragments are at least about 16 residues in length; more preferably they are at least 18 residues in length; more preferably they are at least 20 nucleotides in length; more preferably they are at least about 25 nucleotides in length; more preferably they are at least about 35 nucleotides in length; still more preferably they are at least about 50 nucleotides in length; yet more preferably they are at least about 75 nucleotides in length, and even more preferably they are 100 nucleotides in length or more. Also embodied in this invention are polynucleotides comprising the entire open reading frame of each respective heφes vims DNA polymerase. To predict the role encoded peptide fragments play in the biological function of the DNA polymerase, comparisons may be made with other DNA polymerases. Conserved regions in the amino acid sequence of DNA polymerase from various heφes vimses are shown in Figure 2. The areas labeled Exol, Exoll, and Exolll have been shown to be important binding sites for metal ligands at the 3'-5' exonuclease active site (Derbyshire et al., Bernard et al. (1989), Simon et al., Soengas et al.). The area designated as REGION 1 has been shown to be important in polymerization activity, and functions both as a dmg binding site and polymerization substrate (deoxyribonucleotide triphosphate) binding site (Dorsky et al. (1988, 1990), Bernard et al. (1990)). A mutation of the amino acid G to A in this region of heφes simplex (HSV) 1 DNA polymerase inhibits polymerase activity in vims-infected cells. A mutation of F to C, Y or M yield different sensitivities to dmgs such as nucleoside and pyrophosphate analogs, and aphidicolin. REGION 2 and REGION 3 of the HSV1 DNA polymerase appear to be involved in dmg and substrate recognition (Gibbs et al. (1988a, 1988b), Basco et al. (1993)). REGION 3 is involved in binding to the DNA template (Basco et al. (1992)). REGION 7 may be important in polymerization activity (Basco et al. (1993)). In some heφes vimses such as HSV1, amino acids near the C-terminal are involved in binding to a regulatory subunit known as UL42, encoded elsewhere in the heφes genome, and essential for DNA polymerase activity associated with replication of the vims (Dignard et al., Stow). The RFHV and KSHV polynucleotides shown in Figure 1 are near regions of the polynucleotide that encode functionally important parts of the DNA polymerase. Specifically, the oligonucleotides DFASA, VYGA, and GDTD1B map respectively to REGION 2, REGION 3, and REGION 1. The fragment between DFASA and GDTD1B obtained for KSHV encompasses the entire REGION 4 and REGION 3 sequences, and overlaps with the REGION 2 and REGION 1 sequences. The RFHV/KSHV subfamily consists of members that have sequences that are more closely identical to the corresponding sequences of RFHV or KSHV, than RFHV or KSHV are to any other vims listed in Table 1. Preferred members of the family may be identified on the basis of the sequence of the DNA polymerase gene in the region corresponding to that of Figure 1. Table 2 provides the degree of sequence identities in this region: TABLE 2: Sequence identities Between DNA Polymerase of Select Heφes Viruses and RFHV and KSHV Viral DNA SEQ. Identity to RFHV fragment identity to KSHV fragment Poly¬ ID NO: merase <SEQJD O:1) (SEQ. ID NO:3) Sequence Bases Bases Bases Bases Bases Bases 27-501 27-329 330-501 27-501 29-329 320-501 RFHV 1 (100%) (100%) (100%) 71% 72% 70% KSHV 3 71% 72% 70% (100%) (100%) (100%) eHV2 23 68% 68% 67% 68% 71% 63% sHV1 24 59% 60% 59% 62% 65% 58% EBV 25 64% 66% 58% 62% 62% 57% hCMV 26 53% 54% < 50% 49% 49% < 50% hHV6 27 46% 52% < 50% 48% 50% < 50% hVZV 28 45% 46% < 50% 48% 47% < 50% hHSVI 29 53% 58% < 50% 53% 53% < 50% The percentage of sequence identity is calculated by first aligning the encoded amino acid sequence, determining the corresponding alignment of the encoding polynucleotide, and then counting the number of residues shared between the sequences being compared at each aligned position. No penalty is imposed for the presence of insertions or deletions, but insertions or deletions are permitted only where required to accommodate an obviously increased number of amino acid residues in one of the sequences being aligned. Offsetting insertions just to improve sequence alignment are not permitted at either the polypeptide or polynucleotide level. Thus, any insertions in the polynucleotide sequence will have a length which is a multiple of 3. The percentage is given in terms of residues in the test sequence that are identical to residues in the comparison or reference sequence. The degree of identity between vimses in Table 2 has been calculated for segments of the RFHV and KSHV sequence numbered as shown in Figure 1. Preferred DNA polymerase-encoding polynucleotide sequences of this invention are those derived from the RFHV/KSHV herpes vims subfamily. They include those sequences that are at least 69% identical with the RFHV or KSHV sequence between bases 27 and 501 as shown in Figure 1; more preferably, the sequences are at least 70% identical; more preferably, the sequences are at least about 72% identical; more preferably, the sequences are at least about 75% identical; more preferably, the sequences are at least about 80% identical; more preferably, the sequences are at least about 85% identical; more preferably, the sequences are at least about 90% identical; even more preferably, the sequences are over 95% identical. Also preferred are sequences that are at least 69% identical to the RFHV sequence between bases 27 and 329; more preferably, they are 70% identical; more preferably, they are at least 72% identical; more preferably, they are at least 75% identical; more preferably, they are at least 80% identical; more preferably, the sequences are at least 90% identical; even more preferably, the sequences are at least 95% identical. Also preferred are sequences that are at least 72% identical to the KSHV sequence between bases 27 and 329; more preferably, they are at least 75% identical; more preferably, they are at least 80% identical; more preferably, they are at least 90% identical; even more preferably, they are 95% identical or more. Other preferred DNA polymerase-encoding polynucleotide sequences may be identified by the percent identity with RFHV/KSHV subfamily-specific oligonucleotides, described in more detail in a further section. The percent identity of RFHV and KSHV DNA polymerase with example oligonucleotides is shown in Table 3: TABLE 3: Sequence identities Between DNA Polymerase of Select Herpes Viruses and RFHV/KSHV Subfamily Specific Oligonucleotides Viral DNA identity to identity to identity to Identity to identity to Poly¬ LSGGA CTDPA PCLNA KMLEA GISPA SEQJD merase Sequence NO: (SEQ. ID (SEQ. ID (SEQ. ID (SEQ. ID (SEQ. ID NO:107) NO:108) NO:21) NO:22) NO:109) RFHV 1 92% 86% 93% 94% 100% KSHV 3 96% 86% 93% 88% 90% eHV2 23 77% 55% 93% 72% 66% SHV1 24 65% 62% 76% 78% 66% EBV 25 65% 66% 73% 78% 66% hCMV 26 < 50% < 50% 54% 53% 48% hHV6 27 < 50% < 50% < 50% 47% 38% hVZV 28 54% < 50% < 50% < 50% 38% hHSVI 29 50% < 50% 50% 58% 52% The percent identity shown in Table 3 was calculated for the corresponding residues of the viral sequences, aligned as shown in Figure 6. Preferred DNA polymerase sequences are those which over the corresponding region are at least about 80% identical to LSGGA; more preferably they are at least about 83% identical; more preferably they are at least about 86% identical; more preferably they are at least about 90% identical; even more preferably, they are at least 95% identical. Other preferred DNA polymerase sequences are those which over the corresponding region are at least about 69% identical to CTDPA; more preferably they are at least about 72% identical; more preferably they are at least about 75% identical; more preferably they are at least about 80% identical; more preferably they are at least about 85% identical; even more preferably, they are at least about 95% identical. Other preferred DNA polymerase sequences are those which over the corresponding region are at least about 95% identical to PCLNA. Other preferred DNA polymerase sequences are those which over the corresponding region are at least about 80% identical to KMLEA; more preferably they are at least about 83% identical; more preferably they are at least about 86% identical; more preferably they are at least about 90% identical; even more preferably, they are at least 95% identical or more. Other preferred DNA polymerase sequences are those which over the corresponding region are at least about 69% identical to GISPA; more preferably they are at least about 72% identical; more preferably they are at least about 75% identical; more preferably they are at least about 80% identical; more preferably they are at least about 85% identical; even more preferably, they are at least about 95% identical. DNA polymerase encoding sequences from members of the RFHV/KSHV subfamily identified by any of the aforementioned sequence comparisons, using either RFHV or KSHV sequences, or the subfamily-specific oligonucleotides, are equally preferred. Especially preferred are DNA polymerase encoding sequences of RFHV and KSHV. Also embodied in this invention are fragments of DNA polymerase encoding sequences of the subfamily, and longer polynucleotides comprising such polynucleotide fragments. The polynucleotide sequences described in this section provide a basis for obtaining the synthetic oligonucleotides, proteins and antibodies outlined in the sections that follow. These compounds may be prepared by standard techniques known to a practitioner of ordinary skill in the art, and may be used for a number of investigative, diagnostic, and therapeutic puφoses, as described below. Preparation of polynucleotides Polynucleotides and oligonucleotides of this invention may be prepared by any suitable method known in the art. For example, oligonucleotide primers can be used in a PCR amplification of DNA obtained from heφes vims infected tissue, as in Example 3 and Example 5, described below. Alternatively, oligonucleotides can be used to identify suitable bacterial clones of a DNA library, as described below in Example 10. Polynucleotides may also be prepared directly from the sequence provided herein by chemical synthesis. Several methods of synthesis are known in the art, including the triester method and the phosphite method. In a preferred method, polynucleotides are prepared by solid-phase synthesis using mononucleoside phosphoramidite coupling units. See, for example Horise et al., Beaucage et al., Kumar et al., and U.S. Patent No. 4,415,732. A typical solid-phase synthesis involves reiterating four steps: deprotection, coupling, capping, and oxidation. This results in the stepwise synthesis of an oligonucleotide in the 3' to 5' direction. In the first step, the growing oligonucleotide, which is attached at the 3'-end via a (-0-) group to a solid support, is deprotected at the 5' end. For example, the 5' end may be protected by a -ODMT group, formed by reacting with 4,4'-dimethoxytrityl chloride (DMT-CI) in pyridine. This group is stable under basic conditions, but is easily removed under acid conditions, for example, in the presence of dichloroacetic acid (DCA) or trichloroacetic acid (TCA). Deprotection provides a 5' -OH reactive group. In the second step, the oligonucleotide is reacted with the desired nucleotide monomer, which itself has first been converted to a 5'-protected, 3'-phosphoramidite. The 5' -OH of the monomer may be protected, for example, in the form of a -ODMT group, and the 3'-OH group may be converted to a phosphoramidite, such as -OP(OR')NR 2 ; where R is the isopropyl group -CH(CH 3 ) 2 ; and R' is, for example, -H (yielding a phosphoramidite diester), or -CH 3 , -CH 2 CH 3 , or the beta-cyanoethyl group -CH 2 CH 2 CN (yielding a phosphoramidite triester). The 3'-phosphoramidite group of the monomer reacts with the 5' -OH group of the growing oligonucleotide to yield the phosphite linkage 5'-OP(OR')0-3'. (yielding a phosphoramidite triester). The 3'-phosphoramidite group of the monomer reacts with the 5' -OH group of the growing oligonucleotide to yield the phosphite linkage 5'-OP(OR')0-3'. In the third step, oligonucleotides that have not coupled with the monomer are withdrawn from further synthesis to prevent the formation of incomplete polymers. This is achieved by capping the remaining 5' - OH groups, for example, in the form of acetates (-OC(0)CH 3l ) by reaction with acetic anhydride (CH 3 C(0)- 0-C(0)CH 3 ). In the fourth step, the newly formed phosphite group (i.e., 5'-OP(OR')0-3') is oxidized to a phosphate group (i.e., 5'-OP(=0)(OR')0-3'); for example, by reaction with aqueous iodine and pyridine. The four-step process may then be reiterated, since the oligonucleotide obtained at the end of the process is 5'-protected and is ready for use in step one. When the desired full-length oligonucleotide has been obtained, it may be cleaved from the solid support, for example, by treatment with alkali and heat. This step may also serve to convert phosphate triesters (i.e., when R' is not -H) to the phosphate diesters (-OP(=0) 2 0-), and to deprotect base-labile protected amino groups ofthe nucleotide bases. Polynucleotides prepared by any of these methods can be replicated to provide a larger supply by any standard technique, such as PCR amplification or gene cloning. Cloning and expression vectors comprising a DNA polymerase encoding polynucleotide Cloning vectors and expression vectors are provided in this invention that comprise a sequence encoding a heφes vims DNA polymerase or variant or fragment thereof. Suitable cloning vectors may be constmcted according to standard techniques, or may be selected from the large number of cloning vectors available in the art. While the cloning vector selected may vary according to the host cell intended to be used, useful cloning vectors will generally have the ability to self-replicate, may possess a single target for a particular restriction endonuclease, and may carry genes for a marker that can be used in selecting transfected clones. Suitable examples include plasmids and bacterial vimses; e.g., pUC18, mp18, mp19, pBR322, pMB9, ColE1, pCR1, RP4, phage DNAs, and shuttle vectors like pSA3 and pAT28. Expression vectors generally are replicable polynucleotide constructs that encode a polypeptide operatively linked to suitable transcriptional and translational controlling elements. Examples of transcriptional controlling elements are promoters, enhancers, transcription initiation sites, and transcription termination sites. Examples of translational controlling elements are ribosome binding sites, translation initiation sites, and stop codons. Protein processing elements may also be included: for example, regions that encode leader or signal peptides and protease cleavage sites required for translocation of the polypeptide across the membrane or secretion from the cell. The elements employed would be functional in the host cell used for expression. The controlling elements may be derived from the same DNA polymerase gene used in the vector, or they may be heterologous (i.e., derived from other genes and/or other organisms). Polynucleotides may be inserted into host cells by any means known in the art. Suitable host cells include bacterial cells such as E. coli, mycobacteria, other procaryotic microorganisms and eukaryotic cells (including fungal cells, insect cells, plant cells, and animal cells). The cells are transformed by inserting the exogenous polynucleotide by direct uptake, endocytosis, transfection, f-mating, or electroporation. Subsequently, the exogenous polynucleotide may be maintained within the cell as a non-integrated vector, such as a plasmid, or may alternatively be integrated into the host cell genome. Cloning vectors may be used to obtain replicate copies of the polynucleotides they contain, or as a means of storing the polynucleotides in a depository for future recovery. Expression vectors and host cells may be used to obtain polypeptides transcribed by the polynucleotides they contain. They may also be used in assays where it is desirable to have intact cells capable of synthesizing the polypeptide, such as in a dmg screening assay. Synthetic oligonucleotides for herpes virus DNA polymerase useful as hybridization probes and amplification primers Oligonucleotides designed from sequences of heφes vims DNA polymerase, as embodied in this invention, can be used as probes to identify related sequences, or as primers in an amplification reaction such as a PCR. Different oligonucleotides with different properties are described in the sections that follow. Oligonucleotides designated as Type 1 are designed to hybridize with polynucleotides encoding any heφes vims DNA polymerase, and may be used to detect previously known species of heφes vims. They may also be used to detect and characterize new species of heφes vims. Oligonucleotides designated as Type 2 are designed to hybridize with DNA polymerase encoding polynucleotides of the RFHV/KSHV subfamily, including members not yet identified, but not with polynucleotides of other heφes vimses. Oligonucleotides designated as Type 3 are designed to hybridize specifically with polynucleotides encoding DNA polymerase only from RFHV, or altematively from KSHV. Preferred examples of Type 1 oligonucleotides are listed in Table 4. These oligonucleotides have a specificity for DNA polymerase encoding polynucleotides of a broad range of heφes vimses. TABLE 4: Type 1 Oligonucleotides used for Detecting, Amplifying, or Characterizing Herpes Virus Polynucleotides encoding DNA Polymerase Desig¬ Sequence Length No. of Target: Orien¬ SEQ nation (5Jo3'> forms tation ID: DFASA GTGTTCGACTTYGCNAGYYTNT 26 256 Heφes DNA 5'→3' 5 AYCC polymerase DFQSA GTGTTCGACTTYCARAGYYTNT 26 128 Heφes DNA 5'→3' 6 AYCC polymerase, especially the beta subfamily VYGA ACGTGCAACGCGGTGTAYGGN 29 256 Heφes DNA 5'→3' 7 KTNACNGG polymerase VYGCA ACGTGCAACGCGGTGTACGGS 29 8 Heφes DNA 5'→3' 8 GTSACSGG polymerase (GC-rich) VYGSQA ACGTGCAACGCGGTGTA 17 1 Heφes DNA 5'→3' 9 polymerase GDTD1B CGGCATGCGACAAACACGGAG 35 64 Heφes DNA 3'→5' 11 TCNGTRTCNCCRTA polymerase GDTDSQB CGGCATGCGACAAACACGGA 20 1 Heφes DNA 3'→5' 12 polymerase The orientation indicated is relative to the encoding region of the polynucleotide. Oligomers with a 5'-→3' orientation will hybridize to the strand antisense to the coding strand and initiate amplification in the direction of the coding sequence. Oligomers with a 3'→5' orientation will hybridize to the coding strand and initiate amplification in the direction opposite to the coding sequence. These oligonucleotides have been designed with several properties in mind: 1) sensitivity for target DNA even when present in the source material at very low copy numbers; 2) sufficient specificity to avoid hybridizing with unwanted sequences; for example, endogenous DNA polymerase sequences present in the host; 3) sufficient cross-reactivity so that differences between an unknown target and the sequence used to design it do not prevent the oligonucleotide from forming a stable duplex with the target. For some applications, a particularly effective design is oligonucleotides that have a degenerate segment at the 3' end, designed from a region of at least 2 known polynucleotides believed to be somewhat conserved with the polynucleotide target. The various permutations of the ambiguous residues help ensure that at least one of the alternative forms of the oligonucleotide will be able to hybridize with the target. Adjacent to the degenerate segment at the 5' end of the oligonucleotide is a consensus segment which strengthens any duplex which may form and permits hybridization or amplification reactions to be done at higher temperatures. The degenerate segment is located at the 3' end of the molecule to increase the likelihood of a close match between the oligonucleotide and the target at the site where elongation begins during a polymerase chain reaction. The ambiguous residues in the degenerate part of the sequences are indicated according to the following code: TABLE 5: Single Letter Codes for Ambiguous Positions Code Represents R A or G (purine) Y C orT (pyrimidine) W A orT S C or G M A or C K G orT B C or G orT (not A) D A or G orT (not C) H A or C orT (not G) V A or C or G (notT) N A or C or G or T The Type 1 oligonucleotides shown in Table 4 are generally useful for hybridizing with DNA polymerase encoding polynucleotide segments. This may be conducted to detect the presence of the polynucleotide, or to prime an amplification reaction so that the polynucleotide can be characterized further. Suitable targets include polynucleotides encoding a region of a DNA polymerase from a wide spectmm of heφes vimses, including those in the alpha, beta, and gamma herpes vimses, those infecting any vertebrate animal, including humans and non-human primates, whether or not the polymerase or the virus has been previously known or described. Non-limiting examples include polynucleotides encoding DNA polymerase from any of the herpes vimses listed in Table 1. We have used these oligonucleotides to obtain segments of the DNA polymerase from RFHV, KSHV, EBV, HSV1 , HHV6 and HHW - a group that includes representatives from the alpha, beta, and gamma subfamilies. The oligonucleotides may be used, inter alia, to prime a reaction to amplify a region of the target polynucleotide in the 3' direction from the site where the oligonucleotide hybridizes. DFASA, DFQSA, VYGA, VYGCA and GDTD1B are oligonucleotides with a consensus segment adjoining a degenerate segment, and are useful for that puφose, and also may be used when the sequence of the target DNA is unknown. Selection between oligonucleotides DFASA and DFQSA depends on the sequence of the target polynucleotide. DFQSA promotes amplification of HHV6-like sequences somewhat better than other sequences; DFASA promotes amplification of both HHV6- and non-HHV6-like sequences. VYGA has a broad cross-reactivity and is especially useful as a primer for a second amplification reaction preformed using polynucleotides first amplified by another primer, such as DFASA. VYGCA is a GC- rich analog of VYGA, producing less complex amplification mixtures and allowing hybridization reactions to occur at higher temperatures. VYGSQA and GDTDSQB are specific non-degenerate oligonucleotides which can be used, inter alia, to sequence amplification products made with VYGA or GDTD1B, respectively; or for more specific amplification of a target polynucleotide after a preliminary amplification with a degenerate primer. A preferred source of DNA for use as a target for the oligonucleotides of Table 4 is any biological sample (including solid tissue and tissue cultures), particularly of vertebrate animal origin, known or suspected to harbor a heφes vims. DNA is extracted from the source by any method known in the art, including extraction with organic solvents or precipitation at high salt concentration. A preferred method of amplification is a polymerase chain reaction: see generally U.S. Patent No. 4,683,195 (Mullis) and U.S. 4,683,202 (Mullis et al.); see U.S. 5,176,995 (Sninsky et al.) for application to viral polynucleotides. An amplification reaction may be conducted by combining the target polynucleotide to be amplified with short oligonucleotides capable of hybridizing with the target and acting as a primer for the polymerization reaction. Also added are substrate mononucleotides and a heat-stable DNA-dependent DNA polymerase, such as Taq. The conditions used for amplification reactions are generally known in the art, and can be optimized empirically using sources of known vimses, such RFHV, KSHV, EBV or HSV1. Conditions can be altered, for example, by changing the time and temperature of the amplification cycle, particularly the hybridization phase; changing the molarity of the oligonucleotide primers; changing the buffer concentration; and changing the number of amplification cycles. Fine-tuning the amplification conditions is a routine matter for a practitioner of ordinary skill in the art. In one method, a single primer of this invention is used in the amplification, optionally using a second primer, such as a random primer, to initiate replication downstream from the first primer and in the opposite direction. In a preferred method, at least two of the primers of this invention are used in the same reaction to initiate replication in opposite directions. The use of at least two specific primers enhances the specificity of the amplification reaction, and defines the size of the fragment for comparison between samples. For example, amplification may be performed using primers DFASA and GDTD1B. More preferred is the use of all three primers in a nested fashion to enhance the amplification. Nesting is accomplished by performing a first amplification using primers that encompass an intermediate fragment comprising a binding site for a third primer. This is followed by a second amplification using the third primer, thereby providing a final fragment that is a subfragment of the intermediate fragment. Particularly preferred is a first amplification using primer DFASA and primer GDTD1B, followed by a second amplification using primer VYGA and primer GDTD1B. When performed on a polynucleotide from a DNA polymerase gene of RFHV or KSHV, the size of the fragment is about 236 bases. The amplified polynucleotides can be characterized at any stage during the amplification reaction, for example, by size determination. Preferably, this is performed by running the polynucleotide on a gel of about 1-2% agarose. If present in sufficient quantity, the polynucleotide in the gel can be stained with ethidium bromide and detected under ultraviolet light. Alternatively, the polynucleotide can be labeled with a radioisotope such as 32 P or 35 S before loading on a gel of about 6% polyacrylamide, and the gel can subsequently be used to produce an autoradiogram. A preferred method of labeling the amplified polynucleotide is to end-label an oligonucleotide primer such as VYGA or VYGSQA with 32 P using a polynucleotide kinase and gamma-[ 32 P]-ATP, and continuing amplification for about 5-15 cycles. If desired, size separation may also be used as a step in the preparation of the amplified polynucleotide. This is particularly useful when the amplification mixture is found to contain artifact polynucleotides of different size, such as may have arisen through cross-reactivity with undesired targets. A separating gel, such as described in the preceding paragraph, is dried onto a paper backing and used to produce an autoradiogram. Positions of the gel corresponding to the desired bands on the autoradiogram are cut out and extracted by standard techniques. The extracted polynucleotide can then be characterized directly, cloned, or used for a further round of amplification. Unwanted polynucleotides in the mixture from an amplification reaction can also be proportionally reduced by shifting to more specific oligonucleotide primers. For example, an initial 3-5 cycles of amplification can be conducted using primers VYGA and GDTD1B at 1/5 to 1/25 the normal amount. Then a molar excess (for example, 50 pmol) of GDTDSQB and/or VYGSQA are added, and the amplification is continued for an additional 30-35 cycles. This reduces the complexity of the oligonucleotides present in the amplification mixture, and enables the reaction temperatures to be increased to reduce amplification of unwanted polynucleotides. Preferred examples of Type 2 oligonucleotides are listed in Table 6: TABLE 6: Type 2 Oligonucleotides Specific for Polynucleotides Encoding DNA Polymerase from Viruses ofthe RFHV/KSHV Subfamily Desig¬ Sequence Length No. Of Target: Orien¬ SEQ nation (5' to 3') forms tation ID: LSGGA TACGAAACCTTTGACCTNAGY 26 32 DNA polymerase 5'→3' 107 GGNGG ofthe RFHV/KSHV subfamily CTDPA CGCAAGAACCTGGCCTCNTG 29 64 5'→3' 108 YACNGAYCC PCLNA GTCGCCTCTGGCATCCTNCC 29 128 5'→3' 21 NTGYCTNAA KMLEA CAGGGCCGGAAGATGCTGG 32 32 5'→3' 22 ARACRTCNCARGC GISPA TCTCAGGCGTTCGTAGARGG 29 96 5'→3' 109 NATHTCNCC LSGGA, CTDPA, PCLNA, KMLEA and GISPA are all oligonucleotides with a consensus segment at the 5' end joined directly to a degenerate segment at the 3' end. They are capable of forming stable duplexes with a polynucleotide encoding DNA polymerase from either RFHV, KSHV, or from other viruses of the RFHV/KSHV subfamily. They can be used for any purpose in which such specificity is desired, such as the detection or amplification of polynucleotides from the RFHV/KSHV subfamily. In one application, these Type 2 oligonucleotides are used individually or in combination as amplification primers. In one example of this application, the oligonucleotides are used directly on DNA obtained from a tissue sample to obtain a DNA polymerase segment derived from RFHV, KSHV, or closely related viruses, but not more distantly related vimses such as EBV, CMV or HSV. In another example, the DNA from a tissue sample is first amplified with a less specific set of probes, such as DFASA or VYGA, in combination with GDTD1 B. One of the oligonucleotides of Table 6 is then used in a second round of amplification, thereby providing a sensitive nested amplification assay which is specific for RFHV, KSHV, and other members of the RFHV/KSHV subfamily. In another application, Type 2 oligonucleotides, or oligonucleotides comprising these sequences or fragments thereof, are used as probes in a detection assay. For example, they can be provided with a suitable label such as 32 P, and then used in a hybridization assay with a suitable target, such as DNA amplified using DFASA and/or VYGA, along with GDTD1B. Preferred examples of Type 3 oligonucleotides are shown in Table 7: TABLE 7: Type 3 Oligonucleotides Specific for Polynucleotides Encoding DNA Polymerase from RFHV or KSHV Desig¬ Sequence Length No. off Target: Orien¬ SEQ nation (5' to 3') forms tation ID: VASGA CGTCGCTTCCGGCATCCTAC 21 RFHV DNA 5'→3' 13 C polymerase ILPCA GGCATCCTACCGTGCCTGAA 21 5'→3' 14 C PIEAB CCGGAGACGCCTCGATCGGT 21 3'→5' 15 C PEARB AACCTGGCTTCCGGAGACGC 21 3'→5' 16 C SGILA GCGTTGCCTCTGGCATACTG 20 KSHV DNA 5'→3' 17 polymerase CLNIA CTGCCTTGCCTAAACATAGC 21 5'→3' 18 G IEASB GGTGAGACGTCTATTGGCCT 20 3'→5' 19 EARFB AATCGGGCGTCGGGTGAGAC 21 3'→5' 20 G These are non-degenerate oligonucleotides designed to be specific for DNA polymerase encoding polynucleotides of particular herpes vimses; namely RFHV or KSHV. The particular sequence chosen is from a segment of the encoding region that is more different from that of the other virus than neighboring segments. VASGA, ILPCA, PIEAB, and PEARB are specific non-degenerate oligonucleotides for the RFHV DNA polymerase, and can be used in hybridization reactions conducted at high stringency. For example, they can be used alone or in combination as primers for amplifying a target polynucleotide encoding RFHV DNA polymerase. Preferably, the amplification is done using the oligonucleotides in a nested fashion: e.g., a first amplification is conducted using VASGA and PEARB as primers; then a second amplification is conducted using ILPCA and PIEAB as primers. Similarly, SGILA, CLNIA, IEASB, and EARFB are specific non-degenerate oligonucleotides for the KSHV DNA polymerase, and can be used in a similar fashion, including as primers for an amplification reaction. Preferably, the amplification is done using the oligonucleotides in a nested fashion: e.g., a first amplification is conducted using SGILA and EARFB as primers; then a second amplification is conducted using CLNIA and IEASB as primers. This provides an extremely sensitive amplification assay that is specific for KSHV DNA polymerase. Practitioners skilled in the art will immediately recognize that oligonucleotides of Types 1 , 2, and 3 (in particular, those shown in Tables 4, 6, and 7) can be used in combination with each other in a PCR to amplify different sections of a DNA polymerase encoding polynucleotide. The specificity of the amplification reaction generally is determined by the primer with the least amount of cross reactivity. The size and location of the amplified fragment is determined by the primers used in the final round of amplification. For example, LSSGA used in combination with GDTD1B will amplify about 361 bases of DNA polymerase encoding polynucleotide from a virus of the RFHV/KSHV subfamily. Similarly, VYGA used in combination with PEARB will amplify about 444 bases of DNA polymerase encoding polynucleotide from RFHV. Suitable combinations of oligonucleotides may be used as amplification primers in a nested fashion. Use of synthetic oligonucleotides to characterize polynucleotide targets As described in the previous section, the oligonucleotides embodied in this invention, can be used as primers for amplification of polynucleotides encoding a heφes vims DNA polymerase, particulariy in a polymerase chain reaction. The conditions for conducting the PCR depend on the nature of the oligonucleotide being used. In particular, when using oligonucleotides comprising a degenerate segment, or a consensus segment that is only partly identical to the corresponding segment of the target, and when the target polynucleotide comprises an unknown sequence, the selection of conditions may be important to the success of the amplification. Optimizing conditions for a new primer or new polynucleotide target are routine for a practitioner of ordinary skill. What follows is a guide to assist in that objective. First, the temperature of the annealing step of the PCR is optimized to increase the amount of target polynucleotide being amplified above the amount of unrelated polynucleotide amplified. Ideally, the temperature permits the primers to hybridize with the target sequence but not with other sequences. For primers comprising a consensus segment, the temperature of the annealing step is generally at least about 55°C; preferably it is at least about 60°C. Primers which are vims-specific are more selective, and may be effective over a broader temperature range; between 50°C and 65°C. Second, the buffer conditions are optimized. We have found that buffers supplied with commercial preparations of Taq polymerase are sometimes difficult to use, in part because of a critical dependence on the concentration of magnesium ion. PCRs performed using the oligonucleotides of this invention generally are more easily performed using a buffer such as that suggested by M. Wigler (Lisitsyn et al.). Preferably, the final PCR reaction mixture contains (NH 4 ) 2 S0 instead of KCI as the principal ion source. Preferably, the concentration of (NH 4 ) 2 S0 4 in the final reaction mixture is about 5-50 mM, more preferably about 10-30 mM, even more preferably 16 mM. The buffering component is preferably Tris, preferably at a final concentration of about 67 mM and a pH of about 8.8. Under these conditions, the MgCI 2 concentration is less critical. Preferably the final concentration is about 1-10 mM, more preferably it is about 3-6 mM, optimally it is about 4 mM. The reaction mixture may also contain about 10 mM β- mercaptoethanol and 0.05-1 mg/mL bovine semm albumin. An especially preferred buffer is WB4 buffer (67 mM Tris buffer pH 8.8, 4 mM MgCI 2 , 16 mM (NH 4 ) 2 S0 4 , 10 mM β-mercaptoethanol and 0.1 mg/mL albumin. Preferred conditions for performing the reaction are provided below in Example 3. Amplification reactions using any the oligonucleotides of this invention as primers yield polynucleotide fragments encoding a portion of a DNA polymerase. These fragments can be characterized by a number of techniques known to a practitioner of ordinary skill in the art. Some non-limiting methods for characterizing a fragment are as follows: In one method, a fragment may be sequenced according to any method of sequence determination known in the art, including the Maxam & Gilbert method, or the Sanger & Nicholson method. Alternatively, the fragment may be submitted to any of the commercial organizations that provide a polynucleotide sequencing service. The fragment may optionally be cloned and/or amplified before sequencing. The nucleotide sequence can be used to predict the amino acid sequence encoded by the fragment. Sequence data can be used for comparison with other sequenced DNA polymerases, either at the polynucleotide level or the amino acid level, to identify the species of heφes vims present in the original source material. Sequence data can also be used in modeling algorithms to predict antigenic regions or three-dimensional stmcture. In a second method of characterizing, the size of the fragment can be determined by any suitable method, such as mnning on a polyacrylamide or agarose gel, or centrifuging through an appropriate density gradient. For example, for RFHV and KSHV, the fragment between VYGA and GDTD1 B is about 172 bases. Hence, the length of the entire amplified fragment including primer binding regions is about 236 bases. The corresponding EBV fragment contains an additional 9 base pairs. The EBV fragment can therefore be distinguished from that of RFHV or KSHV, for example, by mnning amplified polynucleotide fragments from each in neighboring lanes of a separating gel, or by mnning the EBV fragment beside suitable molecular weight standards. Polynucleotide fragments identical in size to that of RFHV and KSHV may be derived from a variant strain of one of these vimses, or a closely related species. Fragments substantially different in size are more likely to be derived from a different heφes vims. in a third method of characterizing, a fragment can be tested by attempting to hybridize it with an oligonucleotide probe. In a preferred example, a fragment is tested for relatedness to the DNA polymerase encoding region of RFHV or KSHV. The test is conducted using a probe comprising a sequence of a DNA polymerase encoding region, or its genetic complement. Suitable probes are polynucleotides comprising sequences from RFHV or KSHV, a mixture of such polynucleotides, or a polynucleotide comprising a degenerate sequence derived from RFHV and KSHV, such as the oligonucleotides listed in Table 6. The length and nature of the probe and the hybridization conditions are selected depending on the objectives of the test. If the objective is to detect only polynucleotides from RFHV or KSHV, including minor variants, then hybridization is performed under conditions of high stringency. A sequence from the respective RFHV or KSHV DNA polymerase is used. Longer length sequences improve the specificity of the test and can be used under conditions of higher stringency. Preferably, the probe will comprise a DNA polymerase sequence of at least about 30 nucleotides; more preferably, the sequence will be at least about 50 nucleotides; even more preferably, the sequence will be at least about 75 nucleotides in length. If the objective is to detect polynucleotides that are related to RFHV or KSHV, such as in a screening test or a test to recmit previously undescribed vimses of the RFHV/KSHV subfamily, then different conditions are chosen. Sequences from RFHV or KSHV may be used, but a mixture of the two or a degenerate probe is generally preferred. The length of the sequence and the conditions of the hybridization reaction are selected to provide sufficient specificity to exclude unwanted sequences, but otherwise provide a maximum degree of cross-reactivity amongst potential targets. Suitable conditions can be predicted using the formulas given earlier, by calculating the T m and then calculating the corresponding temperature for the maximum degree of mismatch to be tolerated. The suitability of the conditions can be tested empirically by testing the cross-reactivity of the probes with samples containing known target polynucleotides encoding heφes DNA polymerases. The minimum degree of complementarity required for a stable duplex to form under the conditions of the assay will determine what DNA polymerase sequences will hybridize with the probe. Consider, for example, a target obtained from a human or non-human primate, amplified to produce a fragment corresponding to bases 330-501 of Figure 1 , and then probed with the corresponding fragment of the RFHV polynucleotide. According to the data in Table 2, if the hybridization reaction is performed under conditions that require only about 50% identity for a stable duplex to form, the probe may hybridize with targets from any of the sequenced gamma heφes DNA polymerase genes, including EBV and sHV1. If the reaction is performed under conditions that require at least about 62% identity between probe and target, preferably at least about 65% identity, more preferably at least about 68% identity, and even more preferably at least about 70% identity for a stable duplex to form, the assay will detect a target polynucleotide from RFHV, KSHV, or from a related heφes vims DNA polymerase that has not yet been sequenced. Polynucleotides encoding DNA polymerase from EBV or sHV1 are not expected to form a stable duplex under these conditions. A polynucleotide encoding DNA polymerase from eHV2 is not expected to be present in the DNA tested, because eHV2 is not believed to be capable of infecting primates. It is possible to combine characterization by size and characterization by hybridization. For example, the amplified polynucleotide may be separated on a gel of acrylamide or agarose, blotted to a membrane of suitable material, such as nitrocellulose, and then hybridized with a probe with a suitable label, such as 32 P. The presence of the label after washing reflects the presence of hybridizable material in the sample, while the migration distance compared with appropriate molecular weight standards reflects the size of the material. A fragment sequence hybridizing with one of the aforementioned probes under conditions of high stringency but having an unexpected size would indicate a DNA polymerase sequence with a high degree of identity to the probe, but distinct from RFHV or KSHV. Use of polynucleotides and oligonucleotides to detect herpes virus infection Polynucleotides encoding heφes vims DNA polymerase, and synthetic oligonucleotides based thereupon, as embodied in this invention, are useful in the diagnosis of clinical conditions associated with heφes vims infection. For example, the presence of detectable heφes DNA polymerase in a clinical sample may suggest that the respective heφes vims participated as an etiologic agent in the development of the condition. The presence of polymerase in a particular tissue, but not in surrounding tissue, may be useful in the localization of an infected lesion. Differentiating between gamma heφes vims and other heφes vimses in clinical samples, or differentiating between RFHV, KSHV, and EBV, may be useful in predicting the clinical course of an infection or selecting a dmg suitable for treatment. In addition, since DNA polymerase is actively involved in the replication of the heφes vims, it may be preferred over other markers for certain applications. DNA polymerase is not expressed in the latent state of Varicella-Zoster heφes, but is expressed in the replicative state (Meier et al.). Thus, an assay for DNA polymerase may help determine whether an individual infected with gamma heφes is currently in an active phase of the disease. The capacity of a strain of HSV1 to move from the eye to the brain is related to DNA polymerase activity (Yeung et al.). Thus, an assay for DNA polymerase may help predict the aggressiveness or invasiveness of a gamma heφes infection. The procedures for conducting diagnostic tests are extensively known in the art, and are routine for a practitioner of ordinary skill. Generally, to perform a diagnostic method of this invention, one of the compositions of this invention is provided as a reagent to detect a target in a clinical sample with which it reacts. For example, a polynucleotide of this invention may be used as a reagent to detect a DNA or RNA target, such as might be present in a cell infected with a heφes vims. A polypeptide of this invention may be used as a reagent to detect a target with which it is capable of foiming a specific complex, such as an antibody molecule or (if the polypeptide is a receptor) the corresponding ligand. An antibody of this invention may be used as a reagent to detect a target it specifically recognizes, such as a polypeptide expressed by virally infected cells. The target is supplied by obtaining a suitable tissue sample from an individual for whom the diagnostic parameter is to be measured. Relevant test samples are those obtained from individuals suspected of harboring a heφes vims. Many types of samples are suitable for this puφose, including those that are obtained near the suspected site of infection or pathology by biopsy or surgical dissection, in vitro cultures of cells derived therefrom, solubilized extracts, blood, and blood components. If desired, the target may be partially purified from the sample or amplified before the assay is conducted. The reaction is performed by contacting the reagent with the sample under conditions that will allow a complex to form between the reagent and the target. The reaction may be performed in solution, or on a solid tissue sample, for example, using histology sections. The fonnation of the complex is detected by a number of techniques known in the art. For example, the reagent may be supplied with a label and unreacted reagent may be removed from the complex; the amount of remaining label thereby indicating the amount of complex formed. Further details and alternatives for complex detection are provided in the descriptions that follow. To determine whether the amount of complex formed is representative of heφes infected or uninfected cells, the assay result is preferably compared with a similar assay conducted on a control sample. It is generally preferable to use a control sample which is from an uninfected source, and otherwise similar in composition to the clinical sample being tested. However, any control sample may be suitable provided the relative amount of target in the control is known or can be used for comparative puφoses. It is often preferable to conduct the assay on the test sample and the control sample simultaneously. However, if the amount of complex formed is quantifiable and sufficiently consistent, it is acceptable to assay the test sample and control sample on different days or in different laboratories. Accordingly, polynucleotides encoding DNA polymerase of the RFHV/KSHV subfamily, and the synthetic oligonucleotides embodied in this invention, can be used to detect gamma heφes vims polynucleotide that may be present in a biological sample. General methods for using polynucleotides in specific diagnostic assays are well known in the art: see, e.g., Patent Application JP 5309000 (latron). An assay employing a polynucleotide reagent may be rendered specific, for example: 1) by performing a hybridization reaction with a specific probe; 2) by performing an amplification with a specific primer, or 3) by a combination ofthe two. To perform an assay that is specific due to hybridization with a specific probe, a polynucleotide is chosen with the required degree of complementarity for the intended target. Preferred probes include polynucleotides of at least about 16 nucleotides in length encoding a portion of the DNA polymerase of RFHV, KSHV, or a member of the RFHV/KSHV subfamily. Increasingly preferred are probes comprising at least about 18, 20, 25, 30, 50, or 100 nucleotides of the DNA polymerase encoding region. Also preferred are degenerate probes capable of foiming stable duplexes with polynucleotides of the RFHV/KSHV subfamily, but not with that of other heφes vimses. The probe is generally provided with a label. Some of the labels often used in this type of assay include radioisotopes such as 32 P and ^P, chemiluminescent or fluorescent reagents such as fluorescein, and enzymes such as alkaline phosphatase that are capable of producing a colored solute or precipitant. The label may be intrinsic to the reagent, it may be attached by direct chemical linkage, or it may be connected through a series of intermediate reactive molecules, such as a biotin-avidin complex, or a series of inter-reactive polynucleotides. The label may be added to the reagent before hybridization with the target polynucleotide, or afterwards. To improve the sensitivity of the assay, it is often desirable to increase the signal ensuing from hybridization. This can be accomplished by using a combination of serially hybridizing polynucleotides or branched polynucleotides in such a way that multiple label components become incoφorated into each complex. See U.S. Patent No. 5,124,246 (Urdea et al.). If desired, the target polynucleotide may be extracted from the sample, and may also be partially purified. To measure viral particles, the preparation is preferably enriched for DNA; to measure active transcription of DNA polymerase, the preparation is preferably enriched for RNA. Generally, it is anticipated that the level of polynucleotide of a heφes vims will be low in clinical samples: there may be just a few copies of DNA encoding the polymerase per cell where the vims is latent, or up to several hundred copies of DNA per cell where the vims is replicating. The level of mRNA will be higher in cells where the polymerase is actively expressed than those where the polymerase gene is inactive. It may therefore be desirable to enhance the level of target in the sample by amplifying the DNA or RNA. A suitable method of amplification is a PCR, which is preferably conducted using one or more of the oligonucleotide primers embodied in this invention. RNA may be amplified by making a cDNA copy using a reverse transcriptase, and then conducting a PCR using the aforementioned primers. The target polynucleotide can be optionally subjected to any combination of additional treatments, including digestion with restriction endonucleases, size separation, for example by electrophoresis in agarose or polyacrylamide, and affixation to a reaction matrix, such as a blotting material. Hybridization is allowed to occur by mixing the reagent polynucleotide with a sample suspected of containing a target polynucleotide under appropriate reaction conditions. This may be followed by washing or separation to remove unreacted reagent. Generally, both the target polynucleotide and the reagent must be at least partly equilibrated into the single-stranded form in order for complementary sequences to hybridize efficiently. Thus, it may be useful (particularly in tests for DNA) to prepare the sample by standard denaturation techniques known in the art. The level of stringency chosen for the hybridization conditions depends on the objective of the test. If it is desired that the test be specific for RFHV or KSHV, then a probe comprising a segment of the respective DNA polymerase is used, and the reaction is conducted under conditions of high stringency. For example, a preferred set of conditions for use with a preferred probe of 50 nucleotides or more is 6 x SSC at 37°C in 50% formamide, followed by a wash at low ionic strength. This will generally require the target to be at least about 90% identical with the polynucleotide probe for a stable duplex to form. The specificity of the reaction for RFHV or KSHV can also be increased by increasing the length of the probe used. Thus, longer probes are particularly preferred for this application ofthe invention. Alternatively, if it is desired that the test be able to detect gamma heφes vimses related to RFHV or KSHV, then a lower stringency is used. Suitable probes include fragments from the RFHV or KSHV DNA polymerase, a mixture thereof, or degenerate oligonucleotides such as those listed in Table 6. Appropriate hybridization conditions are determined to permit hybridization of the probe only to DNA polymerase sequences that have the desired degree of identity with the probe. The stringency required depends on the length of the polynucleotide probe, and the degree of identity between the probe and the desired target sequence. Consider, for example, a probe consisting of the KSHV polynucleotide fragment between the hybridization sites of DFASA and GDTD1B. Conditions requiring a minimum identity of 55% would result in a stable duplex formed with a corresponding polynucleotide of KSHV, RFHV, and EBV; conditions requiring a minimum identity of 68% would result in a stable duplex forming with a polynucleotide from KSHV, RFHV, or a related polynucleotide, but not EBV; conditions requiring a minimum identity of 80% would result in a stable duplex forming with a polynucleotide from KSHV, but not RFHV or EBV (see Table 2). Conditions can be estimated beforehand using the formula given earlier. Preferably, the exact conditions are confirmed by testing the probe with separate samples known to contain polynucleotides, both those desired to be detected and those desired to go undetected in the assay. Such samples may be provided either by synthesizing the polynucleotides from published sequences, or by extracting and amplifying DNA from tissues believed to be infected with the respective heφes vims. Determining hybridization conditions is a matter of routine adjustment for a practitioner of ordinary skill, and does not require undue experimentation. Since eHV2, sHV1 and EBV are more closely identical to RFHV or KSHV than members of the alpha and beta subfamilies, conditions that exclude polynucleotides of those vimses will generally also exclude the other heφes vimses listed in Table 1. In addition, if it is believed that certain vimses will not be present in the sample to be tested in the ultimate determination (such as eHV2 in a human tissue sample), then the corresponding target sequences may optionally be omitted when working out the conditions of the assay. Thus, conditions can be determined that would permit an oligonucleotide probe such as LSGGA, CTDPA, KMLEA or GISPA to form a stable duplex both with polypeptides comprising SEQ. ID NO:1 and SEQ. ID NO:3, but not a sequence selected from the group consisting of SEQ. ID NO:23 to SEQ. ID NO:29. Conditions can also be determined that would permit an oligonucleotide probe such as PCLNA (SEQ. ID NO:21) or any suitable fragment comprising at least 18 or more consecutive bases of SEQ. ID NO:1 or SEQ. ID NO:3 to form a stable duplex both with a polynucleotide comprising SEQ. ID NO:1 and with a polynucleotide comprising SEQ. ID NO:3, but not a polynucleotide comprising one of SEQ. ID NO:23 to SEQ. ID NO:29. Altematively, to conduct an assay that is specific due to amplification with a specific primer. DNA or RNA is prepared from the biological sample as before. Optionally, the target polynucleotide is pre-ampiified in a PCR using primers which are not species specific, such as those listed in Table 4. The target is then amplified using specific primers, such as those listed in Table 6 or Table 7. For example, if it is desired that the test be specific for RFHV, then VASGA, ILPCA, PIEAB, PEARB, or a combination thereof may be used. If it is desired that the test be specific for KSHV, then SGILA, CLNIA, IEASB, EARFB, or a combination thereof may be used. If it is desired that the test be able to detect gamma heφes vimses related to RFHV or KSHV, then degenerate or cross-reactive probes, such as those listed in Table 6, or a combination thereof may be used. In a preferred embodiment, two rounds of amplification are performed, using oligonucleotide primers in a nested fashion: vims-specific or non-specific in the first round; vims-specific in the second round. This provides an assay which is both sensitive and specific. Use of a specific primer during amplification is sufficient to provide the required specificity. A positive test may be indicated by the presence of sufficient reaction product at the end of the amplification series. Amplified polynucleotide can be detected, for example, by blotting the reaction mixture onto a medium such as nitrocellulose and staining with ethidium bromide. Alternatively, a radiolabeled substrate may be added to the mixture during a final amplification cycle; the incoφorated label may be separated from unincoφorated label (e.g., by blotting or by size separation), and the label may be detected (e.g. by counting or by autoradiography). If mn on a gel of agarose or polyacrylamide, the size of the product may help confirm the identity of the amplified fragment. Specific amplification can also be followed by specific hybridization, by using the amplification mixture obtained from the foregoing procedure as a target source for the hybridization reaction outlined earlier. Use of polynucleotides for gene therapy Embodied in this invention are pharmaceuticals comprising vims-specific polynucleotides, polypeptides, or antibodies as an active ingredient. Such compositions may decrease the pathology of the vims or infected cells on their own, or render the vims or infected cells more susceptible to treatment by non-specific pharmaceutical compounds. Polynucleotides of this invention encoding part of a heφes vims DNA polymerase may be used, for example, for administration to an infected individual for puφoses of gene therapy (see generally U.S. Patent No. 5,399,346: Anderson et al.). The general principle is to administer the polynucleotide in such a way that it interferes with the expression of the corresponding gene, such as by complexing with the gene itself or with the RNA transcribed from the gene. Entry of the polynucleotide into the cell is facilitated by suitable techniques known in the art, such as providing the polynucleotide in the form of a suitable vector, or encapsulation of the polynucleotide in a liposome. The polynucleotide may be injected systemically, or provided to the site of infection by an antigen-specific homing mechanism, or by direct injection. A preferred mode of gene therapy is to provide the polynucleotide in such a way that it will replicate inside the cell, enhancing and prolonging the interference effect. Thus, the polynucleotide is operatively linked to a suitable promoter, such as the natural promoter of the corresponding gene, a heterologous promoter that is intrinsically active in infected cells, or a heterologous promoter that can be induced by a suitable agent. Preferably, the constmct is designed so that the polynucleotide sequence operatively linked to the promoter is complementary to the sequence of the corresponding gene. Thus, once integrated into the cellular genome, the transcript of the administered polynucleotide will be complementary to the transcript of the gene, and capable of hybridizing with it. This approach is known as anti-sense therapy. RFHV/KSHV subfamily polypeptides with DNA polymerase activity and fragments thereof The RFHV and KSHV polynucleotides shown in Figure 1 each have an open reading frame. The polypeptides encoded are respectively designated SEQ. ID NO:2 and SEQ. ID NO:4. The polypeptides have a significant number of homologous residues to DNA polymerases of other sequenced heφes vimses. They are more closely identical to each other within this fragment than to the corresponding fragment of the other sequenced vimses. The fragment is believed to encompass residues that are near the nucleotide substrate binding site of the intact protein. This region may play a role in the catalytic activity of the polymerase. Polypeptides with DNA polymerase activity from other members of the RFHV/KSHV subfamily are expected to share a large proportion of identical residues over this region. In general, residues conserved between RFHV and KSHV are expected to be relatively conserved within the subfamily. Beginning at about amino acid 89 of SEQ. ID NO:2, there is a linear sequence of about 46 residues that is shared identically between the DNA polymerase of RFHV and KSHV. Beginning at about amino acid 88 of SEQ. ID NO:2, there is a linear sequence of about 31 residues shared between the DNA polymerase of RFHV and eHV2. The sequence shared with eHV2 is listed separately in SEQ. ID NO:112. Also contained in SEQ. ID NO:112 is a sequence of about 26 amino acids shared between RFHV and sHV1 , and two sequences of 12 amino acids shared between RFHV and EBV. Beginning at about amino acid 10 of SEQ. ID NO:4, there is a linear sequence of about 15 residues shared between KSHV and various other gamma heφes vimses. This shared sequence is listed separately in SEQ. ID NO:113. The longest sequence contained in SEQ. ID NOS:2 or 4 but not in SEQ. ID NOS:112 or 113 that is shared with other known heφes vims DNA polymerases is 10 amino acids in length. Hence, any fragment of the RFHV or KSHV DNA polymerase protein sequence that is 11 amino acids or longer, and not in SEQ. ID NOS:112 or 113, is believed to be specific for the RFHV/KSHV subfamily, or species and variants therein. This invention embodies both intact DNA polymerase from heφes vimses of the RFHV/KSHV subfamily, and any fragment thereof that is specific for the subfamily. Preferred DNA polymerase fragments of this invention are at least 11 amino acids in length; more preferably they are about 12 amino acids in length, more preferably they are at least about 15 amino acids in length; even more preferably they are at least about 20 amino acids in length, still more preferably they are at least about 30 amino acids in length. The amino acid sequence of the RFHV and KSHV DNA polymerase fragments can be used to identify vims-specific and cross-reactive antigenic regions. In principle, a specific antibody could recognize any amino acid difference between sequences that is not also shared by the species from which the antibody is derived. Antibody binding sites are generally big enough to encompass 5-9 amino acid residues of an antigen, and are quite capable of recognizing a single amino acid difference. Specific antibodies may be part of a polyclonal response arising spontaneously in animals infected with a vims expressing the DNA polymerase. Specific antibodies may also be induced by injecting an experimental animal with either the intact polymerase or a polymerase fragment. Thus, any peptide of 5 amino acids or more that is unique to RFHV or KSHV is a potential vims-specific antigen, and could be recognized by a RFHV- or KSHV-specific antibody. Peptides of at least 5 amino acids shared between RFHV and KSHV, but not EBV, eHV2 and sHV1 are potential RFHV/KSHV subfamily specific antigens. Some examples of preferred peptides are shown in Table 8. Practitioners in the art will immediately recognize that other peptides with similar specificities may be designed by minor alterations to the length of the peptides listed and/or moving the frame of the peptide a few residues in either direction. The Class I peptides shown in Table 8 are conserved between all known DNA polymerase polypeptide sequences of the gamma heφes vims subfamily. An antibody directed against one such DNA polymerase in this region is expected to cross-react with the others. Class II peptides are conserved between RFHV and KSHV, but not with sHV1 and EBV. An antibody directed against this region is expected to cross-react between RFHV, KSHV, and other vimses of the RFHV/KSHV subfamily. Class III peptides are different between RFHV and KSHV. An antibody binding to this region, particularly to non-identical residues, is expected to distinguish the RFHV DNA polymerase from the KSHV DNA polymerase. TABLE 8: Antigen Peptides Specificity Sequence SEQ. ID NO: Class 1: Peptides contained within RTILDKQQLAIKVTCNAVYGFTGVASGILPCL (SEQJD NO:112) Shared amongst some Peptides contained within members ofthe RFHV/KSHV subfamily and other gamma SIIQAHNLCYSTLIP heφes vimses (SEQJD NO:113) lAETVTL 73 Class 11: PDDYETF 90 Shared amongst members of KRKEIRK 91 the RFHV/KSHV subfamily 1 LAKRKEI 92 LASCTDP 93 VASGILP 2 74 GILPCLN 75 CLNIAET 76 QGRKMLE 77 SQAFVE 78 ARFKVI 79 Class III: TGSALHG (RFHV) 94 RFHV or KSHV specific 3 PGDSLHL (KSHV) 95 SALHGHP (RFHV) 96 DSLHLHP (KSHV) 97 GHPELTP (RFHV) 98 LHPHLGP (KSHV) 99 HLSGGTV (RFHV) 100 VLSGGLV (KSHV) 101 TDPTMRT (RFHV) 102 TDPALKT (KSHV) 103 LETSQAF (RFHV) 80 LERSQAF (KSHV) 81 EGISPTA (RFHV) 82 EAISPER (KSHV) 83 ADLLQRP (RFHV) 84 AGLLRRP (KSHV) 85 TABLE 8: Antigen Peptides Specificity Sequence SEQ. ID NO: QRPIEAS (RFHV) 86 RRPIDVS (KSHV) 87 IEASPEA (RFHV) 88 IDVSPDA (KSHV) 89 1 - Not shared with eHV2, sHV1 or EBV, except where indicated 2 - Also shared with eHV2 but not with sHV1 or EBV 3 - Not shared with any other sequenced heφes virus; may be present in some unsequenced RFHV/KSHV subfamily viruses Particularly preferred peptides from Classes II and III are QGRKMLE, ARFKVI, RRPIDVS, QRPIEAS, IEASPEA, and IDVSPDA. Given the complete sequence of a DNA polymerase from RFHV and/or KSHV, virus- or subfamily-specific peptides can be predicted for other regions of the molecule by a similar analysis. Preparation of polypeptides Polypeptides of this invention, including intact protein, protein fragments, and antigenic regions, can be prepared by several different methods, all of which will be known to a practitioner of ordinary skill. For example, the appropriate strand of the full-length cDNA can be operatively linked to a suitable promoter, and transfected into a suitable host cell. The host cell is then cultured under conditions that allow transcription and translation to occur, and the polypeptide is subsequently recovered. For a description of the expression and recovery of a heφes vims DNA polymerase by transfecting S. cerevisiae, see Haffey et al. and Patent Application EP 0337441. For a description of the expression of another heφes vims protein in mammalian cells, see U.S. Patent No. 5,244,792 (Burke et al.). Polypeptides may also be prepared directly from sequence data by chemical synthesis. Several methods of synthesis are known in the art. A preferred method is the solid-phase Merrifield technique. Alternatively, a polynucleotide encoding the desired polypeptide may be prepared by any of the methods described earlier, and translated using an in vitro translation system, such as the rabbit reticulocyte system. See, e.g., Dorsky et al. Use of polypeptides to assess herpes virus infection The polypeptides embodied in this invention may be used to detect or assess the status of a heφes vims infection in an individual in several different applications. In one application, a polypeptide encoding a portion of a heφes virus DNA polymerase is supplied as a reagent for an assay to detect the presence of antibodies that can specifically recognize it. Such antibodies may be present, for example, in the circulation of an individual with current or past heφes vims infection. The presence of antibodies to DNA polymerase in the circulation may provide an early indication of a pathological condition. The antibody to hepatitis B vims DNA polymerase is an eariy indication of acute hepatitis B vims infection (WO 8904964: Fietelson et al.). Antibodies to DNA polymerase are useful in diagnosis of nasopharyngeal carcinoma (Lin et al., Liu et al.). Similarly, it may be useful to monitor for the presence of antibodies to DNA polymerase of KSHV in HIV-infected humans before Kaposi's sarcoma lesions are clinically apparent. Suitable clinical samples in which to measure antibody levels include semm or plasma from an individual suspected of having a gamma heφes vims infection. The presence of the antibody is determined, for example, by an immunoassay. A number of immunoassay methods are established in the art for performing the quantitation of antibody using viral peptides (see, e.g., U.S. Patent No. 5,350,671 : Houghton et al.). For example, the test sample potentially containing the specific antibody may be mixed with a pre-determined non-limiting amount of the reagent polypeptide. The reagent may contain a directly attached label, such as an enzyme or a radioisotope. For a liquid-phase assay, unreacted reagents are removed by a separation technique, such as filtration or chromatography. Alternatively, the antibody in the sample may be first captured by a reagent on a solid phase. This may be, for example, the specific polypeptide, an anti-immunoglobulin, or protein A. The captured antibody is then detected with a second reagent, such as the specific polypeptide, anti-immunoglobulin, or protein A with an attached label. At least one of the capture reagent or the detecting reagent must be the specific polypeptide. In a third variation, cells or tissue sections containing the polypeptide may be overlaid first with the test sample containing the antibody, and then with a detecting reagent such as labeled anti-immunoglobulin. In all these examples, the amount of label captured in the complex is positively related to the amount of specific antibody present in the test sample. Similar assays can be designed in which antibody in the test sample competes with labeled antibody for binding to a limiting amount of the specific peptide. The amount of label in the complex is then negatively correlated with the amount of specific antibody in the test sample. Results obtained using any of these assays are compared between test samples, and control samples from an uninfected source. By selecting the reagent polypeptide appropriately, antibodies of a desired specificity may be detected. For example, if the intact DNA polymerase is used, or a fragment comprising regions that are conserved between heφes vims, then antibodies detected in the test samples may be vims specific, cross-reactive, or both. A reagent of this nature is preferred for a general screening assay for heφes vims infection. To render the assay specific for antibodies directed either against RFHV or against KSHV, antigen peptides comprising non-conserved regions of the appropriate viral DNA polymerase are selected, such as those listed in Class III of Table 8. Preferably, a mixture of such peptides is used. To simultaneously detect antibodies against RFHV, KSHV, and closely related vimses of the gamma heφes family, but not sHV1 and EBV, antigen peptides are selected with the properties of those listed in Class II of Table 8. Preferably, a mixture of such peptides is used. Antibodies stimulated during a heφes vims infection may subside once the infection resolves, or they may persist as part of the immunological memory of the host. In the latter instance, antibodies due to current infection may be distinguished from antibodies due to immunological memory by determining the class of the antibody. For example, an assay may be conducted in which antibody in the test sample is captured with the specific polypeptide, and then developed with labeled anti-IgM or anti-IgG. The presence of specific antibody in the test sample of the IgM class indicates ongoing infection, while the presence of IgG antibodies alone indicates that the activity is due to immunological memory of a previous infection or vaccination. In another application of the invention, heφes vims encoded DNA polymerase is isolated from a sample, and the amount present is determined by an enzymatic assay. Assays for DNA polymerase activity in a biological sample can be conducted, for example, by extracting the polymerase and performing a suitable polymerization assay. The polymerase may be solubilized by standard techniques from a solid tissue sample or tissue homogenate, for example, by using non-ionic detergents such as TRITON™ X-100 or deoxycholate. Altematively, if the polymerase is secreted by infected cells, it may be possible to perform the assay on a liquid sample, such as plasma or lymph. Methods for conducting DNA polymerase assays are known in the art. For example, a polymerization mixture is prepared that contains the putative DNA polymerase, a mixture of nucleotides containing at least one labeled nucleotide, a DNA template such as M13 phage DNA, and, if necessary, a regulatory subunit. The mixture is incubated at 37°C for a time sufficient to allow polymerization to occur. Polymerase activity, or lack thereof, is determined by measuring the amount of incoφoration of label into the polynucleotide. Optimal conditions for conducting a DNA polymerase assay are readily ascertained without undue experimentation by a practitioner of ordinary skill in the art. For example, conditions for the DNA polymerase of HSV have been published by O'Donnell et al. Optimal conditions for DNA polymerase from RFHV and KSHV are expected to be analogous. Use of polypeptides as components in active vaccines An example of how polypeptides embodied in this invention can be effectively used in treatment is through vaccination. In one embodiment of this application, the polypeptide is administered as part of an active vaccine in order to stimulate antibodies that will react against the pathogenic organism; in this case, a heφesvirus of the RFHV/KSHV subfamily. The development of active vaccines from isolated heφes vims components is known in the art: see, e.g., U.S. Patent Nos. 5,171,568 (Berke et al.). This type of vaccine is especially useful in prophylaxis, since the antibodies it stimulates may be able to neutralize subsequently encountered organisms before they have a chance to invade the host's cells and begin a replicative cycle. Methods for preparing and administering polypeptide vaccines are known in the art. Peptides may be capable of eliciting an immune response on their own, or they may be rendered more immunogenic by chemical manipulation, such as cross-linking or attaching to a protein carrier like KLH. Preferably, the vaccine also comprises an adjuvant, such as alum, muramyl dipeptides, liposomes, or DETOX™. The vaccine may optionally comprise auxiliary substances such as wetting agents, emulsifying agents, and organic or inorganic salts or acids. It also comprises a pharmaceutically acceptable excipient which is compatible with the active ingredient and appropriate for the route of administration. The desired dose for peptide vaccines is generally from 10 μg to 1 mg, with a broad effective latitude. The vaccine is preferably administered first as a priming dose, and then again as a boosting dose, usually at least four weeks later. Further boosting doses may be given to enhance the effect. The dose and its timing are usually determined by the person responsible for the treatment. In another embodiment of this application, the polypeptide is an active ingredient of a vaccine designed to stimulate specific cytotoxic T lymphocytes. This type of vaccine may be especially useful in the treatment of a heφes vims infection already present in a subject. The DNA polymerase of a heφes vims is a suitable target for a cytotoxic T cell vaccine; not only because of its relatively conserved stmcture, but also because it is an important internal component of the vims. Extemal vims components are expressed by circulating intact vims and defective viral particles, and have the potential of diverting the immune system away from infected cells. However, intemal viral components are expressed extracellularly only by virally infected cells, which display them in the context of histocompatibility class I molecules. Such cells are ideal targets for specific cytotoxic T cells, as they represent the site of viral replication and are therefore the vims's most vulnerable location within the host. Cytotoxic T cell vaccines may comprise different antigenic regions than those required to stimulate antibodies. T cell epitopes are different from antibody epitopes; they generally depend less on conformational context, and/or develop from regions of the peptide capable of folding into an amphipathic alpha-helix. Cytotoxic T cell vaccines may also comprise additional active ingredients or cytokines which may enhance the presentation of the peptide to the T cell population and/or assist in the recruitment of cells of the cytotoxic T cell lineage. In a variation of either of the preceding embodiments, the immunizing peptide is provided not as an isolated protein or protein fragment, but in the form of an expression vector. A polynucleotide encoding the peptide is operatively linked to suitable controlling elements of transcription and translation, and then transfected into a suitable vector. Suitable vectors include a vaccinia vims, or an attenuated form of a heφes vims. Use of polypeptides to design or screen anti-viral drugs Interfering with the DNA polymerase gene or gene product would modify the infection process, or the progress of this disease. It is an objective of this invention to provide a method by which useful pharmaceutical compositions and methods of employing such compounds in the treatment of gamma heφes vims infection can be developed and tested. Particularly preferred are pharmaceutical compounds useful in treating infections by RFHV and KSHV. Suitable d gs are those that interfere with transcription or translation of the DNA polymerase gene, and those that interfere with the catalytic function of the polypeptide encoded by the gene. It is not necessary that the mechanism of interference be known; only that the interference be preferential for reactions associated with the infectious process. Preferred dmgs include those that competitively interfere with the binding of the DNA polymerase to the substrate nucleotide triphosphate, the DNA template. Also preferred are nucleotide analogs that can be incoφorated into the polymerizing strand synthesized by the enzyme, but form a dead-end complex that prevents further polymerization (Reardon et al.) Some non-limiting examples of preferred dmgs which may be tested by the procedures described herein are aphidicolon, acyclovir, gancyclovir, foscamet, oosporein, BHCG, PMEA, other nucleotide analogs, isotrenes of these compounds, and other compounds that are structurally or functionally related to those listed. Also preferred are dmgs that interfere with the association of DNA polymerase with regulatory subunits that are necessary for catalytic adivity. As described eariier, the UL42 subunit is essential for the DNA polymerase adivity of HSV during the replicative process. Small peptides designed from the UL42 sequence inhibit binding between UL42 and the DNA polymerase, and are effedive inhibitors of polymerase adivity (U.S. Patent No. 5,223,391: Coen et al.). The C-terminal region of the HSV DNA polymerase is responsible for binding the UL42 subunit. It is therefore expeded that under certain conditions (such as those required for viral replication), the RFHV and KSHV DNA polymerase will require a regulatory subunit which may or may not be an analog of UL42, in order to express full polymerase adivity. Thus, peptides fundionally equivalent to those described in U.S. 5,223,391 , adapted appropriately for gamma heφes vimses, are expected to have inhibitory activity and be therapeutically useful. This invention provides methods for screening pharmaceutical candidates to determine which are suitable for clinical use. The methods may be brought to bear on antiviral compounds that are currently known, and those which may be designed in the future. The method involves combining an active DNA polymerase with the pharmaceutical candidate, and determining whether the biochemical fundion is altered by the pharmaceutical candidate. The DNA polymerase may be any fragment encoded by the DNA polymerase gene of RFHV or KSHV that has DNA polymerase adivity. Suitable fragments may be obtained by expressing a genetically engineered polypeptide encoding the active sites of the molecule, or by cleaving the DNA polymerase with proteases and purifying the active fragments. In a preferred embodiment, the entire DNA polymerase is provided. The readion mixture will also comprise a suitable DNA template, substrate deoxyribonucleotide triphosphates, and whatever regulatory subunits are necessary for the readion to proceed. One embodiment of the screening method is to perform a DNA polymerase assay in vitro. The DNA polymerase is provided in isolated form, and mixed with the other reading compounds in a suitable buffer. A DNA polymerase assay is conduded and monitored as outlined in an earlier sedion. The amount of polymerase adivity per mole or per gram of enzyme in the readion mixture is measured, for example, by the rate of incoφoration of radiolabeled nucleotide into the synthesized strand. The effed of the candidate dmg may be determined by mnning two reactions in parallel, both with the same mixture of reacting substances except that one contains the candidate. Altematively, the effed of the candidate dmg may be determined by adding it to a polymerase reaction in progress, and determining whether the readion rate is altered. A desirable effed is one that eliminates or decreases the rate of synthesis of the labeled DNA. Another embodiment of the screening method is to express a polynucleotide encoding an active region of the DNA polymerase in a host cell. Transfection with the polynucleotide may enhance the rate of replication of the host cell, in which case the activity of the polymerase can be monitored by measuring the rate of replication of the cells. Altematively, activity of the polymerase may be measured as the rate of production of a product, such as a labeled polynucleotide, inside the cell. The effect of the dmg can therefore be determined by following its effed on DNA polymerase activity. Suitable control experiments include measuring DNA polymerase activity in the absence of the dmg, and measuring the effect of the dmg on untransformed host cells. A further embodiment of the screening method is to measure binding of the pharmaceutical candidate to the isolated DNA polymerase, or a fragment thereof. Compounds that bind to the catalytic site or the binding site of a regulatory subunit are expeded to interfere with DNA polymerase adivity. Thus, the entire DNA polymerase, or a fragment comprising the catalytic site or the binding site of a regulatory subunit, is mixed with the pharmaceutical candidate. Binding of the candidate can be measured diredly, for example, by providing the candidate in a radiolabeled or stable-isotope labeled form. The presence of label bound to the polymerase can be determined, for example, by precipitating the polymerase with a suitable antibody, or by providing the polymerase attached to a solid phase, and washing the solid phase after the readion. Binding of the candidate to the polymerase may also be observed as a conformational change in the polymerase, deteded for example by difference spectroscopy, nuclear magnetic resonance, or circular dichroism. Altematively, binding may be determined in a competitive assay: for example, DNA polymerase is mixed with the candidate, and then labeled nucleotide or a fragment of a regulatory subunit is added later. Binding of the candidate to the biochemically relevant site should inhibit subsequent binding ofthe labeled compound. This invention also provides for the development of pharmaceuticals for the treatment of heφes infection by rational dmg design. See, generally, Hodgson, and Erickson et al. In this embodiment, the three-dimensional stmcture of the DNA polymerase is determined, either by predictive modeling based on the amino acid sequence, or preferably, by experimental determination. Experimental methods include antibody mapping, mutational analysis, and the formation of anti-idiotypes. Especially preferred is X-ray crystallography. Knowing the three-dimensional strudure of the protease, especially the orientation of important amino acid groups near the nucleotide and regulatory subunit binding sites, a compound is designed de novo, or an existing compound is suitably modified. The designed compound will have an appropriate charge balance, hydrophobicity, and/or shape to enable it to attach near an active site of the polymerase, and sterically interfere with the normal biochemical function of that site. Preferably, compounds designed by this method are subsequently tested in a dmg screening assay, such as those outlined above. Antibodies against DNA polymerase and their preparation The amino acid sequence of the heφes vims DNA polymerases embodied herein are foreign to the hosts they infect. The polymerases are large, and potentially comprise a large number of antigenic regions. They are sequestered within the capsid of the respedive vims, and are unlikely to be mimicking host antigens. It is therefore expeded that these polymerases will be substantially immunogenic. Antibodies may be generated against them spontaneously by a vertebrate host during the course of an infection with an intact heφes vims. It is also expeded that antibodies can be raised in experimental animals by injection of isolated DNA polymerase and suitably prepared fragments. These expectations are supported by the observations described in Example 5 and Example 10. Antibodies against a polypeptide are generally prepared by any method known in the art. To stimulate antibody production in an animal experimentally, it is often preferable to enhance the immunogenicity of a polypeptide by such techniques as polymerization with glutaraldehyde, or combining with an adjuvant, such as Freund's adjuvant. The immunogen is injected into a suitable experimental animal: preferably a rodent for the preparation of monoclonal antibodies; preferably a larger animal such as a rabbit or sheep for preparation of polyclonal antibodies. It is preferable to provide a second or booster injedion after about 4 weeks, and begin harvesting the antibody source no less than about 1 week later. Sera harvested from the immunized animals provide a source of polyclonal antibodies. Detailed procedures for purifying specific antibody adivity from a source material are known within the art. If desired, the specific antibody adivity can be further purified by such techniques as protein A chromatography, ammonium sulfate precipitation, ion exchange chromatography, high-performance liquid chromatography and immunoaffinity chromatography on a column of the immunizing polypeptide coupled to a solid support. Polyclonal antibodies raised by immunizing with an intad DNA polymerase or a fragment comprising conserved sequences may be cross-readive between heφes vimses. Antibodies that are vims or subfamily specific may be raised by immunizing with a suitably specific antigen, such as those listed above in Table 8. Altematively, polyclonal antibodies raised against a larger fragment may be rendered specific by removing unwanted activity against other vims DNA polymerases, for example, by passing the antibodies over an adsorbant made from those polymerases and colleding the unbound fradion. Altematively, immune cells such as splenocytes can be recovered from the immunized animals and used to prepare a monoclonal antibody-producing cell line. See, for example, Harrow & Lane (1988), U.S. Patent Nos. 4,472,500 (Milstein et al.), and U.S. 4,444,887 (Hoffman et al.) Briefly, an antibody-producing line can be produced inter alia by cell fusion, or by transforming antibody-producing cells with Epstein Barr Vims, or transforming with oncogenic DNA. The treated cells are cloned and cultured, and clones are seleded that produce antibody of the desired specificity. Specificity testing can be performed on culture supematants by a number of techniques, such as using the immunizing polypeptide as the deteding reagent in a standard immunoassay, or using cells expressing the polypeptide in immunohistochemistry. A supply of monoclonal antibody from the selected clones can be purified from a large volume of tissue culture supematant, or from the ascites fluid of suitably prepared host animals injeded with the clone. Effective variations of this method include those in which the immunization with the polypeptide is performed on isolated cells. Antibody fragments and other derivatives can be prepared by methods of standard protein chemistry, such as subjeding the antibody to cleavage with a proteolytic enzyme. Genetically engineered variants of the antibody can be produced by obtaining a polynucleotide encoding the antibody, and applying the general methods of molecular biology to introduce mutations and translate the variant. Monoclonal antibodies raised by injecting an intact DNA polymerase or a fragment comprising conserved sequences may be cross-reactive between heφes vimses. Antibodies that are vims or subfamily specific may be raised by immunizing with a suitably specific antigen, as may be selected from Table 8. Altematively, vims-specific clones may be selected from the cloned hybridomas by using a suitable antigen, such as one seleded from Table 8, in the screening process. Use of antibodies for detecting DNA polymerase in biological samples Antibodies can be used to detect DNA polymerase polypeptides and fragments of viral origin that may be present, for example, in solid tissue samples and cultured cells. Immunohistological techniques to carry out such determinations will be obvious to a praditioner of ordinary skill. Generally, the tissue is preserved by a combination of techniques which may include freezing, exchanging into different solvents, fixing with agents such as paraformaldehyde, drying with agents such as alcohol, or embedding in a commercially available medium such as paraffin or OCT. A sedion of the sample is suitably prepared and overlaid with a primary antibody specific for the protein. The primary antibody may be provided directly with a suitable label. More frequently, the primary antibody is detected using one of a number of developing reagents which are easily produced or available commercially. Typically, these developing reagents are anti-immunoglobulin or protein A, and they typically bear labels which include, but are not limited to: fluorescent markers such as fluorescein, enzymes such as peroxidase that are capable of precipitating a suitable chemical compound, eledron dense markers such as colloidal gold, or radioisotopes such as 125 l. The section is then visualized using an appropriate microscopic technique, and the level of labeling is compared between the suspeded virally infected and a control cell, such as cells surrounding the area of infection or taken from a remote site. Proteins encoded by a DNA polymerase gene can also be detected in a standard quantitative immunoassay. If the protein is secreted or shed from infeded cell in any appreciable amount, it may be detedable in plasma or semm samples. Altematively, the target protein may be solubilized or extracted from a solid tissue sample. Before quantitating, the protein may optionally be affixed to a solid phase, such as by a blot technique or using a capture antibody. A number of immunoassay methods are established in the art for performing the quantitation. For example, the protein may be mixed with a pre-determined non-limiting amount of the reagent antibody specific for the protein. The reagent antibody may contain a diredly attached label, such as an enzyme or a radioisotope, or a second labeled reagent may be added, such as anti-immunoglobulin or protein A. For a solid-phase assay, unreaded reagents are removed by washing. For a liquid-phase assay, unreacted reagents are removed by some other separation technique, such as filtration or chromatography. The amount of label captured in the complex is positively related to the amount of target protein present in the test sample. A variation of this technique is a competitive assay, in which the target protein competes with a labeled analog for binding sites on the specific antibody. In this case, the amount of label captured is negatively related to the amount of target protein present in a test sample. Results obtained using any such assay are compared between test samples, and control samples from an uninfected source. Specific antibodies against heφes vims DNA polymerase have a number of uses in developmental, diagnostic and therapeutic work. For example, antibodies can be used in dmg screening (see U.S. Patent No. 5,120,639), or to prepare a passive vaccine. They may also be used for deteding heφes vims in a biological sample and for dmg targeting, as described in the following sections. Use of antibodies for drug targeting An example of how antibodies can be used in therapy of heφes vims infedion is in the specific targeting of effector components. Virally infected cells generally display peptides of the vims (including intemal viral components) on their cell surface in the context of histocompatibility class I antigens. The peptide therefore provides a marker for infected cells that a specific antibody can bind to. An effector component attached to the antibody therefore becomes concentrated near the infected cells, improving the effed on those cells and decreasing the effect on uninfeded cells. Furthermore, if the antibody is able to induce endocytosis, this will enhance entry ofthe effedor into the cell interior. For the puφose of targeting, an antibody specific for the viral polypeptide (in this case, a region of a DNA polymerase) is conjugated with a suitable effector component, preferably by a covalent or high-affinity bond. Suitable effedor components in such compositions include radionuclides such as 131 l, toxic chemicals, and toxic peptides such as diphtheria toxin. Another suitable effector component is an antisense polynucleotide, optionally encapsulated in a liposome. In most applications of antibody molecules in human therapy, it is preferable to use human monoclonals, or antibodies that have been humanized by techniques known in the art. This helps prevent the antibody molecules themselves from becoming a target of the host's immune system. Diagnostic kits Diagnostic procedures using the polynucleotides, oligonucleotides, peptides, or antibodies of this invention may be performed by diagnostic laboratories, experimental laboratories, practitioners, or private individuals. This invention provides diagnostic kits which can be used in these settings. The presence of a heφes vims in the individual may be manifest in a clinical sample obtained from that individual as an alteration in the DNA, RNA, protein, or antibodies contained in the sample. An alteration in one of these components resulting from the presence of a heφes vims may take the form of an increase or decrease of the level of the component, or an alteration in the form of the component, compared with that in a sample from a healthy individual. The clinical sample is optionally pre-treated for enrichment of the target being tested for. The user then applies a reagent contained in the kit in order to deted the changed level or alteration in the diagnostic component. Each kit necessarily comprises the reagent which renders the procedure specific: a reagent polynucleotide, used for detecting target DNA or RNA; a reagent antibody, used for detecting target protein; or a reagent polypeptide, used for deteding target antibody that may be present in a sample to be analyzed. The reagent is supplied in a solid form or liquid buffer that is suitable for inventory storage, and later for exchange or addition into the readion medium when the test is performed. Suitable packaging is provided. The kit may optionally provide additional components that are useful in the procedure. These optional components include buffers, capture reagents, developing reagents, labels, reacting surfaces, means for detedion, control samples, instmctions, and inteφretive infoπnation. Other members of the RFHV/KSHV subfamily RFHV and KSHV are exemplary members of the RFHV/KSHV subfamily. This invention embodies polynucleotide sequences encoding DNA polymerase of other members of the subfamily, as defined herein. We anticipate that other members of the subfamily will be identified and characterized, including some that are capable of infecting primates, including humans. One such member is another vims infecting monkeys, designated RFHV2. A segment of the DNA polymerase encoding sequence for this vims was cloned from RF tissue obtained from a Macaca mulatta monkey, as described in Example 11. In order to identify and charaderize other members of the family, reagents and methods of this invention are applied to DNA extracted from tissue samples suspected of being infeded with such a vims. Suitable sources include biological samples obtained from a wide range of conditions occurring in humans and other vertebrates. Preferred are conditions in which the agent is suspeded of being lymphotrophic, similar to other members of the gamma heφes vims subfamily; for example, infedious mononucleosis of non-EBV origin. More preferred are conditions which resemble in at least one of their clinical or histological features the conditions with which RFHV or KSHV are associated. These include: a) conditions in which fibroproliferation is part of the pathology of the disease, especially in association with collagen deposition, and especially where the fibrous tissue is disorganized; b) conditions involving vascular dysplasia; c) conditions involving malignant transformation, especially but not limited to cells of lymphocyte lineage; d) conditions for which an underlying immunodeficiency contributes to the frequency or severity of the disease; e) conditions which arise idiopathically at multiple sites in an organ or in the body as a whole; f) conditions which epidemiological data suggests are associated with an infectious or environmental agent. Conditions which fulfill more than one of these criteria are comparably more preferred. Some examples of especially preferred conditions include retroperitoneal fibrosis, nodular fibromatosis, pseudosarcomatous fibromatosis, fibrosarcomas, sclerosing mesenteritis, acute respiratory disease syndrome, idiopathic pulmonary fibrosis, diffuse proliferative glomerulonephritis of various types, gliomas, glioblastomas, gliosis, and all types of leukemias and lymphomas. The process of identification of members of the RFHV/KSHV subfamily preferably involves the use of the methods and reagents provided in this invention, either singularly or in combination. One method involves amplifying and/or characterizing a polynucleotide encoding a DNA polymerase in the sample. This can be performed, for example, by amplifying the polynucleotide in a readion such as a PCR, using an RFHV/KSHV subfamily specific oligonucleotide, such as those listed in Table 6, as a primer in the readion. The presence of amplified reaction produd suggests polynucleotide in the sample derived from a member of the RFHV/KSHV subfamily. Members of the subfamily can also be identified by performing a hybridization assay on the polynucleotide of the sample, using a suitable probe. The polynucleotide to be tested may optionally be amplified before conducting the hybridization assay, such as by using an oligonucleotide listed in Table 4 or Table 6 in a PCR. Preferred probes for the hybridization assay include the oligonucleotides of Table 6. Other preferred probes are fragments of 16 nucleotides or more of the polynucleotide encoding DNA polymerase from either RFHV or KSHV, preferably contained in SEQ. ID NO:1 or SEQ. ID NO:3. The hybridization reaction is performed under the least stringent conditions wherein the probe will not foπn a stable duplex with a polynucleotide comprising any of SEQ. ID NOS:23 to 29, but will form a stable duplex with a polynucleotide comprising SEQ. ID NO:1 or a polynucleotide comprising SEQ. ID NO:3, and preferably either one. Formation of a stable duplex with the test polynucleotide under these conditions suggests the presence of a polynucleotide in the sample derived from a member of the RFHV/KSHV subfamily. Members of the subfamily can also be identified by using a reagent antibody of a specificity that cross-reacts between antigens produced by members of the subfamily, but not with other antigens, including those produced by heφes vimses not members of the subfamily. Methods for producing such antibodies were outlined in an earlier sedion. The test is performed, for example, by using the antibodies in an immunohistochemistry study of tissue sedions prepared from individuals with the conditions listed above. Positive staining of a tissue sedion with the antibody suggests the presence of DNA polymerase in the sample from a member of the RFHV/KSHV subfamily, probably because the tissue is infected with the vims. Similariy, if antibodies cross-readive with RFHV or KSHV antigens but not with other heφes vims antigens are found in the circulation of an individual, this suggests that the individual has been subjed to a present or past infedion with a member of the RFHV/KSHV subfamily. Once a member of the RFHV/KSHV subfamily is suspected in a biological sample, it is desirable to obtain a fragment of the DNA polymerase gene corresponding to nucleotides 330-501 of Figure 1. The fragment is sequenced according to standard techniques to determine whether the vims is a bone fide member of the RFHV/KSHV subfamily, as defined herein. A preferred method of identifying members of the RFHV/KSHV subfamily is provided below in Examples 11 and 12. Once a new member of the RFHV/KSHV subfamily has been identified, other embodiments of this invention may be brought into play for puφoses of detection, diagnosis, and pharmaceutical development. Changes to render them suitable for the new subfamily member, if required, are expeded to be minor and will be obvious based on the new sequence data, or will be a matter of routine adjustment. Altered forms of DNA polymerase from the RFHV/KSHV subfamily This invention also embodies altered forms of DNA polymerase of the RFHV/KSHV subfamily. As described eariier, work with DNA polymerase from other heφes vimses has helped pinpoint adive regions and residues of the molecule involved in substrate binding, polymerase adivity, or dmg resistance. Some of the residues described appear in conserved regions of the polymerase molecule, and are identical between RFHV, KSHV, and the vims in which they were originally described. By analogy, mutation of the same residue in the DNA polymerase of the RFHV/KSHV subfamily is expeded to have a similar effect: TABLE 9: Possible Effect of Amino Acid Substitutions in DNA Polymerase of the RFHV/KSHV Subfamily Change Position Effect Y → F 8 Redudion of DNA polymerase adivity N → Y 103 Y→ F orS 106 G → D 107 Y → F 168 G → R 169 D → G or N 170 T → K or P 171 D → A or G 172 A → V 5 Increased resistance to antiviral compounds S → N 10 P → T 85 T → M 101 R → S 130 The numbering of the residues in Table 9 begins with the first amino acid encoded by the entire DNA polymerase polynucleotide fragment of KSHV shown in Figure 1 (i.e., the first amino acid of SEQ. ID NO:4). DNA polymerase adivity is believed to be essential for replication of a heφes vims. Mutations shown in Table 9 that are expeded to impair DNA polymerase activity may therefore be useful in creating attenuated forms of the respedive vims. Other mutations may increase or decrease the resistance of the RFHV or KSHV polymerase to antiviral dmgs. Heφes vimses, particularly attenuated forms, are useful in developing viral vectors for therapeutic puφoses (Johnson et al., Ward et al.). One such use is in the development of polyvalent vaccines. It is desirable, especially in developing countries, to provide prophylactic vaccines capable of stimulating the immune system against several potential pathogens simultaneously. Vimses that are engineered to express immunogenic peptides of several different pathogens may accomplish this puφose. Heφes vimses may be especially suitable vectors, because the large genome may easily accommodate several kilobases of extra DNA encoding the peptides. Ideally, the viral vector is sufficiently intact to exhibit some biological activity and attract the attention of the host's immune system, while at the same time being sufficiently attenuated not to cause significant pathology. Thus, an attenuated vims of the RFHV/KSHV subfamily may be useful as a vaccine against like vimlent forms, and may be modified to express additional peptides and extend the range of immune protection. Another use for attenuated forms of heφes vimses is as delivery vehicles for gene therapy (Latchman et al., Glorioso et al.). In order to be effective, polynucleotides in gene therapy must be delivered to the target tissue site. In the treatment of fibrotic diseases, malignancies and related conditions, attenuated viral vedors of the RFHV/KSHV subfamily may be preferable over other targeting mechanisms, including other heφes vimses, since they have the means by which to target towards the affeded tissues. In this embodiment, the vims is first attenuated, and then modified to contain the polynucleotide that is desired for gene therapy, such as those that are outlined in a previous sedion. The foregoing description provides, inter alia, a detailed explanation of how DNA polymerase encoding regions of heφes vimses can be identified and their sequences obtained. Polynucleotide sequences for regions ofthe DNA polymerase gene of RFHV and KSHV are provided. The polynucleotide sequences provided are believed to be an accurate rendition of the sequences contained in the polynucleotides from the heφes vimses in the tissue samples used for this study. However, it is recognized that sequences obtained by amplification methods such as PCR may comprise occasional errors in the sequence as a result of amplification. The error rate is estimated to be between about 0.44% and 0.75% for single determinations; about the same rate divided by V(n-1) for the consensus of n different determinations. Nevertheless, the error rate may be as high as 2% or more. Sequences free of amplification errors can be obtained by creating a library of heφes vims polynucleotide sequences, using oligonucleotides such as those provided in Table 7 to select relevant clones, and sequencing the DNA in the selected clones. The relevant methodology is well known to a practitioner of ordinary skill in the art: see, e.g., Example 9. It is recognized that allelic variants and escape mutants of heφes vimses occur. Polynucleotides and polypeptides may be isolated or derived that incoφorate mutations, either naturally occuπing, or accidentally or deliberately induced, without departing from the spirit of this invention. The examples presented below are provided as a further guide to a praditioner of ordinary skill in the art, and are not meant to be limiting in any way. EXAMPLES Example 1: Oligonucleotide primers for Herpes Virus DNA polymerase Amino acid sequences of known heφes vims DNA polymerases were obtained from the PIR protein database, or derived from DNA sequences obtained from the GenBank database. The sequences were aligned by computer-aided alignment programs and by hand. Several conserved regions were apparent. Three of the most highly conserved regions were chosen for design of amplification primers. The regions seleded are indicated in Figure 2 as REGION 1, REGION 2, and REGION 3. Having identified suitable conserved regions from the amino acid sequences, the DNA sequences for these regions were used to design the oligonucleotide primers. The primers were designed to have a degenerate segment of 12-14 base pairs at the 3' end, and a consensus segment of 18-30 bases at the 5' end. This provides primers with optimal sensitivity and specificity. The degenerate segment extended across the most highly conserved region of heφes vims DNA polymerase sequences, encompassing the least number of altemative codons. The primers could therefore be synthesized with altemative nucleotide residues at the degenerate positions and yield a minimum number of combinations. There were no more than 256 altemative forms for each of the primers derived. The consensus segment was derived from the corresponding flanking region of the DNA polymerase sequences. Generally, the consensus segment was derived by choosing the most frequently occuπing nucleotide at each position of all the DNA polymerase sequences analyzed. However, selection was biased in favor of C or G nucleotides, to maximize the ability of the primers to form stable duplexes. Results are shown in Figures 3-5, and summarized in Table 4. Figure 3 shows DNA sequences of known heφes vims DNA polymerase genes near REGION 2. These sequences were used to design the oligonucleotides DFASA and DFQSA, as shown, in a PCR, these oligonucleotides would ad as primers by hybridizing with the strand antisense to the coding strand, and initiating polymerization in the same direction as the DNA polymerase encoding sequence. Figure 4 shows DNA sequences near REGION 3, from which the oligonucleotides VYGA, VYGCA and VYGSQA were designed for initiating polymerization in the 5' diredion. Figure 5 shows DNA sequences near REGION 3, from which the oligonucleotides GDTD1 B and GDTDSQB were designed. These oligonucleotides would hybridize with the coding strand and initiate polymerization in the diredion opposite to that of the DNA polymerase encoding sequence. Synthetic oligonucleotides according to the designed sequences were ordered and obtained from Oligos Etc, Inc. Example 2: DNA extraction Biopsy specimens were obtained from Kaposi's sarcoma lesions from human subjects diagnosed with AIDS. Specimens were also obtained from retroperitoneal fibromatosis lesions in a colony of Macaca nemestrina, Macaca fasciculahs, and Macaca fuscata at the University of Washington Regional Primate Research Center. The specimens were fixed in paraformaldehyde and embedded in paraffin, which were processed for normal histological examination. Fragments of the paraffin samples were extraded with 500 μL of xylene in a 1.5 mL EPPENDORF™ conical centrifuge tube. The samples were rocked gently for 5 min at room temperature, and the tubes were centrifuged in an EPPENDORF™ bench-top centrifuge at 14,000 φm for 5 min. After removing the xylene with a Pasteur pipette, 500 μL of 95% ethanol was added, the sample was resuspended, and then re-centrifuged. The ethanol was removed, and the wash step was repeated. Samples were then air-dried for about 1 hour. 500 μL of proteinase-K buffer (0.5% TWEEN™ 20, a detergent; 50 mM Tris buffer pH 7.5, 50 mM NaCl) and 5 μL of proteinase K (20 mg/mL) were added, and the sample was incubated for 3 h at 55°C. The proteinase K was inactivated by incubating at 95°C for 10 min. Example 3: Obtaining amplified segments of RFHV and KSHV DNA polymerase The oligonucleotides obtained in Example 1 were used to amplify DNA extracted in Example 2, according to the following protocol. A first PCR reaction was conducted using 1 μL of DNA template, 1 μL of oligonucleotide DFASA (50 pmol/μL), 1 μL of oligonucleotide GDTD1B (50 pmol/μL), 10 μL of 10 x WB4 buffer (0.67 M Tris buffer pH 8.8, 40 mM MgCI 2 , 0.16 M (NH 4 ) 2 S0 4 , 0.1 M β-mercaptoethanol, 1 mg/mL bovine semm albumin), 1 μL containing 2.5 mM of each of the deoxyribonucleotide triphosphates (dNTPs), 66 μL distilled water, and 50 μL mineral oil. The mixture was heated to 75°C in a Perkin-Elmer (model 480) PCR machine. 0.5 μL Taq polymerase (BRL, 5 U/μL) and 19.5 μL water was then added. 35 cycles of amplification were conduded in the following sequence: 1 min at 94°C, 1 min at 60"C, and 1 min at 72°C. A second PCR readion was conducted as follows: to 1 μL of the reaction mixture from the previous step was added 10 μL 9-10 x WB4 buffer, 1 μL dNTPs, 0.5 μL Taq polymerase, 86.5 μL water, and 50 μL mineral oil. The mixture was heated to 75°C, and 1 μL each of oligonucleotide VYGA (50 pmol/μL) and oligonucleotide GDTD1 B (50 pmol/μL) was added. 35 cycles of amplification were conduded as before. Example 4: Sequence of the 236 base fragment An aliquot of the final amplification mixture of each of the samples was purified by eledrophoresis on a 2% agarose gel. Of 9 M. nemestrina and 1 M. fasicularis samples used, 4 M. nemestrina samples yielded amplification product. Amplification product was also obtained from human samples. The agarose gel was stained with ethidium bromide and the DNA was visualized using UN. light. Bands of the correct size were eluted onto DEAE paper. Each extraded polynucleotide was ligated to a PGEM-T™ vedor and transformed into competent baderia (E. coli JM-109). Bacterial clones containing the amplified DΝA were picked and cultured. The baderia were lysed and the DΝA was extraded using phenol-chloroform followed by precipitation with ethanol. Sequencing was performed by the Sanger & Nicholson dideoxynucleotide method, using M13 forward and reverse primers. The length of the fragment in between the primer hybridizing regions was 172 base pairs in length. For the four M. nemestrina samples used, all yielded identical sequence data. About 70% of the residues are identical in the fragment between RFHV and KSHV. Compared with the most closely related known sequences of the heφes vims family, differences in between sequences are distributed along the entire length of this fragment. The longest stretch of consecutive nucleotides that is identical between any two sequences in this fragment is 11. The polypeptide encoded in this fragment is 81% identical between RFHV and KSHV, of which the first 24 residues are 100% identical, and the first 31 are 97% identical. The longest stretch of consecutive amino acids that is identical between RFHV or KSHV and any of the other known heφes vims DNA polymerases in this fragment is 10. Example 5: RFHV and KSHV specific amplification assays Four oligonucleotides were prepared based on the sequence of the polynucleotide fragment of the RFHV and KSHV DNA polymerase for use in nested vims-specific amplification readions. Primers VASGA, ILPCA, PIEAB and PEARB were based on the RFHV sequence; primers SGILA, CLNIA, IEASB, and EARFB were based on the KSHV sequence (Table 7). The RFHV primers were used to amplify DNA samples obtained from the PBL of macaque monkeys as follows: Uncoagulated whole blood samples were collected from 20 M. nemestrina bom in the colony at the University of Washington. 30 blood samples were obtained from wild-caught M. nemestrina. None of the animals had overt symptoms of fibromatosis. Plasma and blood cells were separated by centrifugation. Peripheral blood mononuclear cells (PBMC) were prepared by centrifuging the cells through a density gradient, according to standard blood separation techniques. DNA was extracted from the cells according to the method of Example 2. The DNA was then amplified, first using primers VASGA and PEARB, then using primers ILPCA and PIEAB. The conditions of the amplification were similar to that of Example 3. The readion produd was mn on an agarose gel, stained with ethidium bromide, and examined under UN. light. When the assay was performed in duplicate and under conditions to avoid cross-contamination of PCR reaction produds, none of the RF symptom-free monkeys were found to have detectable levels of RFHV polynucleotide encoding DΝA polymerase in their peripheral blood by this assay. PBMC may also be examined by immunohistology techniques to confirm correlation between positive PCR products and RFHV antigenemia. PBMC are coated onto microscope slides, and fixed with a mixture of 50% methanol, 20% acetone and 30% water. They are overlaid with a primary semm, washed, overlaid with FITC-(rabbit anti-monkey IgG) (Nordic Labs), washed again, and then examined by fluorescence microscopy. Antibody-containing semm may be obtained from a monkey giving a positive RFHV amplification assay result, or an animal immunized with RFHV, or an RFHV extract. Semm from a monkey with a negative result may be used as control. PBMC from animals giving a positive result in the amplification test will also give a positive immunohistology result due to antigenemia of an RFHV antigen component. To conduct an amplification assay for KSHV, DNA is extraded from tissue suspeded of harboring the vims; particulariy biopsy samples from human subjeds with Kaposi's Sarcoma lesions and body cavity B-cell lymphoma. The DNA is amplified in two stages, using primers SGILA and EARFB in the first stage, and CLNIA and IEASB in the second stage. As before, a positive result is indicated by the presence of abundant polynucleotide in the reaction produd, as deteded by ethidium bromide staining. Example 6: Upstream sequence of the RFHV and KSHV DNA polymerase DNA from Kaposi's Sarcoma tissue similar to that used in Example 3 was used in additional amplification reactions to obtain a longer fragment of the gene encoding KSHV DNA polymerase. The oligonucleotides DFASA and GDTD1B were used to prime a first-stage amplification readion, as in Example 3, and the readion product was separated on an agarose gel. The size of the fragment from DFASA to GDTD1B (now known to be 536 bases long) was estimated from the known sHV1 and EBV sequences, and a corresponding band was recovered from the gel. The extraded polynucleotide was subjected to a second round of amplification using the same primers. The product was cloned into E. coli as in Example 4. Clones containing suitable inserts were identified from three different amplifications of the DNA extraded from the tissue. The clone inserts were sequenced from both ends using vector-specific oligonucleotides (M13 forward and reverse primers). About 160 nucleotides from the 5' end (including the DFASA hybridizing region) and about 233 nucleotides from the 3' end (including the GDTD1B hybridizing region) were sequenced for all three amplifications. The centermost portion of the fragment was sequenced in one of the three amplifications. A consensus sequence for the fragment was obtained by combining results of the three determinations with the results of Example 4, as appropriate. The data are shown in Figure 1, in comparison with the sequence determined for the RFHV DNA polymerase fragment in Example 4. Numbering of both sequences begins at the first position of primer DFASA. Regions of each sequence corresponding to hybridization sites for DFASA and GDTD1 B may not be accurate refledions of the target sequence. The fragment between the primers is believed to represent the DNA from which the polynucleotide used for sequencing was amplified. However, occasional errors may have been introduced during the amplification. Assuming the consensus sequence of KSHV to be an accurate refledion of the sequence of the DNA extracted from the tissue, there was about a 0.75% error rate in the sequence of each amplified product In the nucleotides towards the 5' end, and about a 0.44% error rate in the sequence towards the 3' end, not including the region hybridizing with the primers. To obtain the corresponding RFHV polynucleotide sequence, DNA from frozen RF tissue of a macaque monkey was first amplified using the broad specificity DNA polymerase primer DFASA in conjundion with the RFHV specific primer PEARB, and then by DFASA in conjunction with the RFHV specific primer PIEAB. The procedure was as follows: 5 μL of DNA template was mixed with 1 μL of each of the primers (50 pmol/μL), 10 μL of 10 x WB4 buffer, 1 μL 2.5 mM dNTP, 59-65 μL water, and 60 μL mineral oil. The temperature was raised to 60°C, and Taq polymerase (0.5 μL diluted to 20 μL in water) was added. The DNA was amplified for 35 cycles of 94°C for 1 min, 55°C for 1 min, and 72°C for 1 min. 2 μL of the amplified produd was added to 10 μL 10 x WB4 buffer, 1 μL 2.5 mM dNTP, 66.5 μL water, 0.5 μL Taq polymerase, and 60 μL mineral oil. The temperature was raised to 60°C, and then a mixture of 1 μL PIEAB (50 pmol/μL), 2 μL DFASA (50 pmol/μL), and 18 μL of water was added. Amplification cycles were conduded as before. Finally, a third round of amplification was performed to introduce a radiolabel. Oligonucleotide PIEAB was end-labeled with gamma 32 P-ATP, and 1 μL was added to 20 μL of the readion mixture from the previous amplification step, along with 1 μL 2.5 mM dNTP and 1 μL Taq polymerase. Amplification was conducted through five cycles of 94°C, 55"C and 72°C, as before. An aliquot of the radiolabeled readion product was eledrophoresed on a 6% polyacrylamide sequencing gel. A band of the correct size (predicted by analogy with the KSHV sequence) was identified by autoradiography, and cut out of the dried gel. DNA was eluted by incubation in 50 μL water. A further amplification readion was performed using 2 μL of eluted DNA, 10 μL 10 x WB4 butter, 1 μL 2.5 mM dNTP, 1 μL PIEAB (50 pmol/μL), 1 μL DFASA (50 pmol/μL), 0.5 μL Taq polymerase, and 84.5 μL water. Amplification was conducted through 35 cycles of 95°C for 30 sec, 60°C for 30 sec, and 72°C for 65 sec. The amplified product was isolated using a QUIAEX™ gel extraction kit, and the DNA was cloned into pGEM™-t vector. JM-109 cells were transformed with the DNA, and colonies containing inserts were isolated. Colonies containing inserts of the correct size were used to obtain DNA for sequencing. Data from these experiments were combined with that from Example 4 to provide the sequence of 536 base pairs corresponding to the RFHV and KSHV DNA polymerase gene. Omitting the outermost primer-hybridizing regions, 475 base pairs of each sequence have been determined for both RFHV and KSHV. These sequences are listed in Figure 6, in comparison with the corresponding region of the DNA polymerase gene from other sequenced gamma heφes vimses. The longest region that is identical between the RFHV sequence and any of the other vimses is a first 20 base pair subfragment (SEQ. ID NO:110) and a second 20 base pair fragment (SEQ. ID NO:111) shared with eHV2. Figure 7 shows the corresponding encoded polypeptide sequences. There is a linear sequence of about 31 residues near the middle of SEQ. ID NO:2 shared between the DNA polymerase of RFHV and eHV2. This shared sequence is listed separately in SEQ. ID NO:112. A sequence of 26 amino acids is shared in the same area between RFHV and sHV1 , and two sequences of 12 amino acids shared between RFHV and EBV. These areas of homology map near conserved REGION 3 of the other heφes vims DNA polymerase sequences (Figure 2). A second shared sequence occurs near the beginning of SEQ. ID NO:4 between KSHV and other gamma heφes vimses. This sequence maps near conserved REGION 2 of other heφes vims DNA polymerase sequences. This sequence fragment shared between KSHV and other gamma heφes vimses is listed separately in SEQ. ID NO:113. Figure 8 provides a comparison of the protein sequence across the spedmm of different heφes vimses corresponding to the sequence encoded by the 475 base pair sequence obtained herein for RFHV and KSHV. The degree of identity between sequences can be used to constmct a relationship map between DNA polymerases, as shown in Figure 9. The relationship between the species may reflect the relative ancestral relationship between the polypeptides, and between the organisms that encode them. Based on this analysis, RFHV and KSHV are provisionally assigned to the gamma subfamily of heφes vimses, which also includes eHV2, sHV1 and EBV. Other vimses of the RFHV/KSHV subfamily would be assignable to the heφes vims gamma subfamily on this basis. Example 7: Oligonucleotide primers and probes for the RFHV/KSHV subfamily Based on the sequence of the 475 base pair polynucleotide fragment obtained for RFHV and KSHV, five oligonucleotides were designed that could be used either as PCR primers or as hybridization probes with members of the RFHV/KSHV subfamily. These oligonucleotides were designated LSGGA, CTDPA, PCLNA, KMLEA, and GISPA. These oligonucleotides are shown in Figure 10, alongside the sequences they were derived from. Like the oligonucleotides of Example 1, they have a consensus segment towards the 5' end, and a degenerate segment towards the 3' end. However, these oligonucleotides are based only on the RFHV and KSHV sequences, and will therefore preferentially form stable duplexes with DNA polymerase of the RFHV/KSHV subfamily. Under hybridization conditions that permit them to form stable duplexes with the RFHV or KSHV encoding polynucleotide fragment, they are expected to form stable duplexes with more members of the RFHV/KSHV subfamily than would equal-length polynucleotides of the RFHV or KSHV sequence, either alone or in combination. Both oligonucleotides are oriented in the same direction. In a PCR amplification readion, one or the other of these oligonucleotides may be used as primers in combination with a primer with the opposite orientation, such as GDTD1B. Example 8: Antigenic and immunogenic regions of RFHV and KSHV DNA polymerase Based on the 475 base pair polynucleotide sequence of the RFHV and KSHV DNA polymerase encoding region, it is possible to predict what sites on the protein unique for each vims, and therefore constitute potential sites for the binding of vims-specific antibodies. Figure 7 shows example peptides of 6 or 7 amino acids in length. Some of the peptides comprise one or more residues that are distind either for RFHV or KSHV (Class III), or for the RFHV/KSHV subfamily (Class II) compared with the corresponding gamma heφes vims peptides. These peptides were listed eariier in Table 8. The numbering of the amino acid residues in both Figure 7 and Table 8 begins with the first amino acid coded after the hybridization site of the VYGA primer (nucleotide position 331 of Figure 1). To confirm that regions contained within this 57-amino acid region of the DNA polymerase may be recognized by antibody, computer analysis was performed to generate Hopp and Woods antigenicity plots. The Hopp and Woods determination is based in part on the relative hydrophilicity and hydrophobicity of consecutive amino acid residues (Hopp et al). Results are shown in Figure 11 and Figure 12. The numbering of RFHV begins with the first amino acid coded after the VYGA primer (as in Figure 7). The numbering of the KSHV polypeptide residues in Figure 12 begins with the first amino acid coded after the hybridization site of the DFASA primer (nucleotide position 28 of Figure 1). Both RFHV and KSHV contain several regions predided to be likely antibody target sites. For example, the RFHV shows several hydrophobic and antigenic patches along the amino acid sequence. KSHV shows hydrophobic patches beginning at residues 26, 44, 52, 121 and 151; and antigenic patches beginning at residues 8, 37, 45, and 94. The peptides of Figure 7 that correspond to some of these regions may be especially antigenic. Example 9: Sequencing the complete RFHV and KSHV DNA polymerase coding region Additional sequence data for the KSHV DNA polymerase encoding region has been obtained to the 5' and 3' diredion of the segment described in Example 6. Two Kaposi's sarcoma samples, designated K-12 and K-15, were used to prepare DNA according to the method of Example 2. Additional Type 1 oligonucleotide primers were designed to hybridize with heφes vims DNA polymerase nucleic acid sequences flanking the KSHV sequence already obtained. Examples are shown in Table 10: TABLE 10: Additional Type 1 Oligonucleotides used for Detecting, Amplifying, or Characterizing Herpes Virus Polynucleotides encoding DNA Polymerase Desig¬ Sequence Length No. of Target: Orien¬ SEQ nation (5' to 3') forms tation ID: QAHNA CCAAGTATCATHCARGCNCAYA 23 48 Heφes DNA 5'→3' 105 A polymerase QAHNB GGAGTAGCACAARTTRTGNGC 24 32 Heφes DNA 3'→5' 106 YTG polymerase YGDT1B AACACAGAGTCNGTRTCNCCR 23 64 Heφes DNA 3→5' 124 TA polymerase HNLCA AGCATCATCATGGCCCAYAAYC 28 32 Heφes DNA 5'→3' 125 TNTGYT polymerase DFASLYA GAYTTYGCNAGYYTNTAYCC 20 512 Heφes DNA 5'- 3" 126 polymerase FDIEC1B CACCCATRCAYTCDATRTCRAA 22 48 Heφes DNA 3'→5' 127 polymerase DIECA TACAACGTCCTCTCCTTYGAYA 29 24 Heφes DNA 5'→3' 128 THGARTG polymerase CVN1A GTCTGCGTGAAYGTNTTYGGN 23 64 Heφes DNA 5'→3' 129 CA polymerase CVNVA GACGACCGCAGCGTGTGCGTG 35 64 Heφes DNA 5'→3' 130 AAYGTNTTYGGNCA polymerase CVNVSQA ACGACCGCAGCGTGTGCGTG 20 1 Heφes DNA 5'→3' 131 polymerase CVNVB TAAAAGTACAGCTCCTGCCCG 35 64 Heφes DNA 3'- 5' 132 AANACRTTNACRCA polymerase CVNVSQB TAAAAGTACAGCTCCTGCCCG 23 1 Heφes DNA 3'→5' 133 AA polymerase SLYP1A TTTGACTTTGCCAGCCTGTAYC 32 256 Heφes DNA 5'→3' 134 CNAGYATNAT polymerase SLYP2A TTTGACTTTGCCAGCCTGTAYC 32 128 Heφes DNA 5'→3' 135 CNTCNATNAT polymerase SLYPSQA TTTGACTTTGCCAGCCTGTA 20 1 Heφes DNA 5'→3' 136 polymerase GDTD2B CGGCATGCGACAAACACGGAG 38 48 Heφes DNA 3→5' 137 TCCGTRTCNCCRTADAT polymerase YFDKB TTAGCTACTCCGTGGAGCAGY 32 16 Heφes DNA 3'->5' 138 TTRTCRAARTA polymerase (especially gamma) PCR amplification was conducted as follows: 100 ng of DNA from each sample was first amplified in 50 μL total reaction buffer under the following conditions: 1 x PCR buffer (67 mM Tris buffer pH 8.8, 16 mM (NH4)2S04, 10 mM β-mercaptoethanol, 0.1 mg/mL bovine semm albumin), 2 mM MgCI2, 50 pmol of each oligonucleotide CVN1A and FDIEC1B, 100 μM (each) dATP, dCTP, dGTP, dTTP, 1.25 units Taq DNA polymerase (AMPLITAQ™, Perkin-Elmer Cetus). Amplification was conducted through 45 cycles of 95°C for 30 sec; 50°C for 30 sec, and 72°C for 30 sec. PCR produds were electrophoresed on a 2% agarose gel and visualized by ethidium bromide staining. PCR produds were purified using QIAQUICK SPIN™ PCR purification kit (Qiagen, Chatsworth CA). Produds were cloned into PT7BLUE® Vedors (Novagen, Madison WI). Plasmids were purified using QUIAGEN SPIN™ plasmid miniprep kit. Purified plasmids were sequenced using ABI automated sequencing methodology, using M13 forward and reverse primers. Five clones were sequenced from each of K-12 and K-15. Two body cavity lymphoma cell lines, designated BC-1 and BC-2, were used as DNA sources for determination of downstream sequence. 5 x 10 5 cells from each line were washed in PBS and pelleted separately. Proteinase-K buffer was added to each pellet and incubated at 65°C for 1 h. DNA was extracted twice with 1:1 (vo vol) phenolxhloroform, precipitated and washed in ethanol, and resuspended in 10 mM Tris buffer pH 8.0. Approximately 0.5 μg total genomic DNA from BC-1 and BC-2 cell lines was used with 25 pmol of oligonucleotide primers CVNVA and EARFB, 2.5 units Taq DNA polymerase (Boehringer-Mannheim), 250 μM dNTP, and 4 mM MgCI 2 in a total volume of 100 μL of 1 x PCR buffer. PCR amplification was conducted using a "hot start" at 70°C for 1 min prior to adding the Taςf polymerase, and conducted through 35 cycles of 94°C for 45 sec; 60 °C for 45 sec, and 72 °C for 90 sec. PCR products were eledrophoresed on a 2% agarose gel and visualized by ethidium bromide staining. PCR produds were purified and cloned into PT7BLUE® vedors as before. Purified plasmids were sequenced using ABI automated sequencing methodology using KSHV sequence specific primers RDSWA, FDCSA, YSTLB, and DYETB. DNA sequences were analyzed using the GenePro algorithm for single alignments open reading frames. The ClustalW algorithm was used for determining consensus sequences for multiple alignments. The nucleotide sequence obtained is shown in Figure 13 (SEQ. ID NO:116) along with the encoded amino acid sequence (SEQ. ID NO:117). In total, 2511 nucleotides are shown, of which the first 35 correspond to the CVNVA primer, and the last 12 correspond to the YFDKB primer. Bases 36 to 2499 of SEQ. ID NO:116, corresponding to amino acids 13 to 833 of SEQ. ID NO:117, represent the KSHV DNA polymerase sequence. Alignment of part of the KSHV DNA polymerase amino acid sequence with other heφes vimses is shown in Figure 14. Residues marked with an asterisk (*) are identical amongst all the sequences shown. Residues marked with a bullet (•) represent conservative amino acid substitutions. Residues marked with an arrow (t) are of interest, because they are conserved between other heφes vimses but are different in KSHV. One of these is a histidine in KSHV in the position of an aspartic acid in other vimses, which is a non-conservative difference. Residues marked with an arrow may be suitable targets for antibodies or dmgs that are specific for KSHV or for the RFHV/KSHV subfamily. Amongst four KSHV DNA polymerase nucleotide sequences obtained, variations were noted in four positions. These are believed to represent naturally occurring allelic variants. At about nucleotide 319, the sequence TTCTCG was altematively found as TTTTCG, which is a silent variation (not affecting the encoded protein sequence). At about nucleotide 348, the sequence AACCCG was altematively found as AATCCG, which is also a silent mutation. At about nucleotide 1795, the sequence CCAGTA was alternatively found to be CCAATA, which represents a change of the encoded peptide from -Pro-Val- to - Pro-He. At about nucleotide 1822, the sequence TTCAAG was altematively found to be TTCAGG, which represents a change of the encoded peptide from -Phe-Lys- to -Phe-Arg-. Alignment of the KSHV amino acid sequence variants with DNA polymerase sequences of other heφes vimses is shown in Figure 15. Comparison of the KSHV DNA polymerase nucleotide sequence with that of other heφes vimses led to design of additional Type 3 (vims-specific) oligonucleotides, listed in Table 11 : TABLE 11: Additional Type 3 Oligonucleotides Specific for Polynucleotides Encoding DNA Polymerase from KSHV Desig¬ Sequence Length No. of Target: Orien¬ SEQ nation S' to S * ) forms tation ID: SIIQB TTGTGCGCTTGGATGATACT 21 KSHV DNA 3'→5' 139 G polymerase HVLQB GAGGGCCTGCTGGAGGACG 21 3'→5' 140 TG SCGFB CGGTGGAGAAGCCGCAGGA 21 3'→5' 141 TG LPHLA ACCTCCCGCACCTGACCGTG 21 5"→3' 142 T QARQA AAGCTAGACAGGAGGAGCTT 21 5'→3' 143 C KIIQB ACTTGAATTATCTTGACGAAC 21 3'→5' 144 KVLMA ACGACAAGGTTCTGATGAAG 21 5'→3' 145 G RDSWA AGAGACTCTTGGACGGAACT 21 KSHV DNA 5'→3' 146 G polymerase FDCSA AGTTTGACTGCAGCTGGGAG 21 5'→3" 147 G YSTLB CGGGTATCAGTGTGGAGTAG 21 3'→5' 148 c DYETB GAGGACAAAGGTTTCGTAGT 21 3'->5" 149 c Based upon other gamma heφes vimses, the KSHV DNA polymerase sequence is predicted to comprise a total of about 3000 base pairs, with additional nucleotides in both the 5' and 3' direction of the sequence shown. The remaining sequence may be determined by conducting the approach described on samples of affected tissue, using Type 1 oligonucleotides to sequence in from genes flanking the DNA polymerase in both the upstream and downstream diredion. Altematively, complete DNA polymerase sequences may be obtained by generating DNA libraries from affected tissue. For the RFHV sequence, libraries are prepared from macaque monkey PBMC known from the amplification assay of Example 5 to contain RFHV DNA. For the KSHV sequence, libraries are prepared from Kaposi's sarcoma lesions or B cell body cavity lymphoma. The DNA lysate is digested with proteinase K, and DNA is extracted using phenol-chloroform. After extensive dialysis, the preparation is partially digested with the Sau3A I restriction endonuclease. The digest is centrifuged on a sucrose gradient, and fragments of about 10-23 kilobases are recovered. The lambda DASH-2™ vedor phage (Stratagene) is prepared by cutting with BamHI. The size-seleded fragments are then mixed with the vedor and ligated using DNA ligase. The ligated vedor is prepared with the packaging extrad from Stratagene according to manufadurer's diredions. It is used to infed XL1-BLUE™ MRA baderia. About 200,000 of the phage-infeded baderia are plated onto agar at a density of about 20,000 per plate. After culturing, the plates are overlaid with nitrocellulose, and the nitrocellulose is cut into fragments. Phage are eluted from the fragments and their DNA are subjected to an amplification readion using appropriate vims-specific primers. The readion produds are mn on an agarose gel, and stained with ethidium bromide. Phage are recovered from regions of the plate giving amplified DNA of the expected size. The recovered phage are used to infect new XL1 baderia and re-plated in fresh cultures. The process is repeated until single clones are obtained at limiting dilution. Each clone seleded by this procedure is then mapped using restridion nucleases to ascertain the size of the fragment incoφorated. Inserts sufficiently large to incoφorate the entire DNA polymerase sequence are sequenced at both ends using vector-specific primers. Sequences are compared with the known polynucleotide sequence of the entire EBV genome to deteπnine whether the fragment spans the intact DNA polymerase sequence. DNA is obtained from suitable clones, sheared, and sequenced by shot-gun cloning according to standard techniques. Example 10: Identifying immunogenic sites To identify what antibodies may be generated during the natural course of infedion with RFHV, serial semm samples are obtained from 10-20 macaque monkeys giving a positive result in an RFHV DNA polymerase amplification test with PBMC, as in Example 5. To test for antibodies against KSHV, semm samples are obtained from 10-20 AIDS subjeds with Kaposi's Sarcoma lesions, from 10-20 HIV-positive symptom-negative subjeds, and 10-20 HIV-negative controls. In initial studies, sera in each population are pooled for antibody analysis. Peptides 12 residues long are synthesized according to the RFHV or KSHV sequence, as appropriate. Sequential peptides are prepared covering the entire sequence, and overlapping by 8 residues. The peptides are prepared on a nylon membrane support by standard F-Moc chemistry, using a SPOTS™ kit from Genosys according to manufacturer's diredions. Prepared membranes are overlaid with the semm, washed, and overlaid with beta-galadose conjugated anti-monkey IgG or anti-human IgG, as appropriate. The test is developed by adding the substrate X-gal. Positive staining indicates IgG antibody reactivity in the semm against the corresponding peptide. Example 11: Obtaining other DNA polymerase sequences of the RFHV/KSHV subfamily A DNA polymerase encoding sequence from a third member of the RFHV/KSHV heφes vims subfamily was obtained as follows. DNA was extraded from two frozen tissue samples from a Macaca mulatta monkey with retroperitoneal fibromatosis. Extraction was conducted according to Example 1. The extraded DNA was precipitated with ethanol in the presence of 40 μg glycogen as carrier, washed in 70% ethanol, and resuspended in 10 mM Tris buffer, pH 8.0. A 151 base pair fragment of a DNA polymerase encoding sequence was amplified using a triple- nested PCR: 100 ng of DNA from each sample was first amplified in 100 μL total reaction buffer under the following conditions: 1 x PCR buffer (67 mM Tris buffer pH 8.8, 16 mM (NH4) 2 S0 4 , 10 mM β- mercaptoethanol, 0.1 mg/mL bovine semm albumin), 4mM MgCI 2 , 25 pmol of each oligonucleotide VYGA and VYGCA, and 50 pmol of oligonucleotide GDTD1B, 25 μM (each) dATP, dCTP, dGTP, dTTP, 2.5 units Taq DNA polymerase (Boehringer-Mannheim). Amplification was conducted using a "hot start" at 70°C for 1 min prior to adding the Taq polymerase, and conduded through 42 cycles of 94°C for 30 sec; 60 °C for 30 sec, and 72 °C for 30 sec. A second amplification used 2 μL of the primary PCR product as template in 50 μL reaction volume as before, except that 25 pmol of each oligonucleotide PCLNA and GDTDSQB and 1.25 units Taq polymerase were used. Amplification was conducted using a "hot start" and 35 cycles of the same conditions as before. A third amplification used 2 μL of the secondary PCR product as template in 50 μL reaction volume as before, except that 25 pmol of each oligonucleotide KMLEA and GDTDSQB and 1.25 units Taq polymerase were used. Amplification was conducted using a "hot start" and 35 cycles of 94°C for 30 sec; 65 °C for 30 sec, and 72 °C for 30 sec. The final PCR product was eledrophoresed on a 3% agarose gel, and visualized by ethidium bromide staining. PCR products were purified using QIAQUICK SPIN™ PCR purification kit (Qiagen, Chatsworth CA). Products were cloned into PC7BLUE® vedors (Novagen, Madison WI). Plasmids were purified using QUIAGEN SPIN™ plasmid miniprep kit. Purified plasmids were sequenced using M13 forward and reverse primers with the USB Sequenase 7-deaza-dGTP kit. Based on the sequence of the 151 base pair fragment, two sequence-specific (Type 3) oligonucleotides were designed, designated KVIYB and ASPDB. These were used in a nested PCR amplification with the Type 1 oligonucleotide QAHNA to obtain a 468 base pair fragment. The first amplification was conducted by using ~1 μg of each DNA sample in 100 μL PCR mixture as before, except that 50 pmol of each of QAHNA and KVIYB were used as primers. Amplification was conducted using a "hot start" and 35 cycles of 94°C for 30 sec; 55 °C for 60 sec, and 72 °C for 60 sec. The second amplification was conduded using 3 μL primary PCR product as template in 100 μL reaction volume and 50 pmol of QAHNA and ASPDB as primers. Amplification was conduded using a "hot start" and 40 cycles of 94°C for 30 sec; 60 °C for 60 sec, and 72 °C for 60 sec. PCR produds were then electrophoresed on a 2.5% agarose gel, and visualized by ethidium bromide staining. PCR products were cloned into PC7BLUE® vectors and sequenced as before. The nucleotide sequence obtained is shown in Figure 16, shown with the designation "RFMm" (SEQ. ID NO. 18). This corresponds to a DNA polymerase encoding sequence referred to elsewhere in this application as "RFHVMm" or "RFHV2". The encoded protein sequence is shown in Figure 17 (SEQ. ID NOJ 19). Identity analysis with DNA polymerase sequences of RFHVMm with other herpes vimses is shown in Table 12: TABLE 12: Sequence identities Between RFHV2 and other herpes viruses Viral DNA SEQ. identity to Identity to RFHV Identity to KSHV Polymerase ID NO: RFHV 2 fragment fragment fragment Sequence (SEQ. ID NO:118) (SEQ. ID NO:1) (SEQ. ID NO:3) Bases 1-454 Bases 48-501 Bases 48-501 RFHV/KSHV subfamily: RFHV2 (RFHVMm) 118 83% (90%) 71% (84%) RFHV1 (RFHVMn) 1 83% (90%) 69% (81%) KSHV 3 69% (81%) 71% (84%) gamma herpes eHV2 23 63% (66%) 68% (68%) 68% (73%) sHV1 24 60% (64%) 59% (64%) 62% (68%) EBV 25 57% (62%) 54% (63%) 62% (68%) alpha heφes HSV1 36 52% (43%) 53% (46%) 53% (46%) HSV2 37 53% (44%) 53% (46%) 53% (46%) VZV 35 42% (41%) 45% (43%) 48% (45%) beta heφes hCMV 33 45% (38%) 53% (41%) 49% (40%) hHV6 42 44% (38%) 46% (41%) 48% (41%) Percent identity shown at the polynucleotide level and the (amino acid level) Phylogenetic studies were performed using distance matrices, neighbor joining and bootstrap analysis, as implemented in the PHYLIP analysis package. Figure 18 shows the results of the bootstrap analysis, with the numbers indicated being the score out of 100 supporting the branch points shown. This analysis strongly supports a branch point that separates the RFHV/KSHV subfamily from other gamma heφes vimses. RFHVMm and RFHVMn are more closely related to each other than either are to KSHV. Sequences were also analyzed for G+C content. Results are shown in Table 13. The percentage of G+C across the region corresponding to the 454 bp of RFHVMm is shown, as calculated using GenePro software (Riverside Scientific). Values in parenthesis are G+C content calculated for the entire DNA polymerase sequence, where known. Also shown are CpG ratios, which is the ratio of observed:expected frequencies of CpG, taking into consideration the monomucleotide composition. TABLE 13: G+C mononucleotide and CpG dinucleotide frequencies in the DNA polymerase genes of different herpesviruses Heφes Virus Subfamily G + C CpG ratio RFHVMn RFHVKSHV 55.9% 0.96 RFHVMm (gamma) 51.1% 1.13 KSHV 54.4% 0.91 eHV2 other gamma 64.8% (63.6%) 0.71 (0.75) sHV1 39.9% (34.9%) 0.28 (0.33) EBV 64.4% (61.8%) 0.73 (0.70) HSV1 alpha 67.6% (65.8%) 0.99 (1.06) VZV 41.5% (42.2%) 1.37 (1.15) hCMV beta 60.2% (59.9%) 1.27 (1.23) hHV6 46.0% (40.9%) 1.00 (112) The G+C frequences of the KS and RF sequences are quite similar to each other, falling midway between the high G-C content of EBV and eHV2 and the low G+C content of sHV1. The CpG dinucleotide frequences of KS and RF are quite similar, close to the expeded value (1.00) based on their mononucleotide compositions. These values are closer to those for alpha and beta heφes vimses, than for gamma heφes vimses outside the RFHV/KSHV subfamily. The CpG data suggest that RFHVMn, RFHVMm and KSHV genomes remain latent in non-dividing cells, in contrast to sHV1 and EBV which are latent in proliferating lymphoblastoid cells. The phylogenetic analysis, the CpG analysis, and the similarity between symptoms caused by the three vimses support the use of the monkey vimses as models for KSHV, and other members of the RFHV/KSHV subfamily that may infed humans. Examples of RFHVMm-specific Type 3 oligonucleotides is shown in Table 14: TABLE 14: Type 3 Oligonucleotides Specific for Polynucleotides Encoding DNA Polymerase from RFHV2 Desig¬ Sequence Length No. of Target: Orien¬ SEQ nation (5' to 3') forms tation ID: LCYSA CTATGTTACTCTACCCTGATT 21 1 RFHVMm DNA 5'→3" 150 Polymerase KVIYB GTATATCTCTTTAAACCTGGC 21 1 3'→5' 151 ASPDB AACCTGGCGTCCGGGGAAG 21 1 3'→5' 152 CG Figure 19 is a map showing the approximate relative positions for hybridization of certain oligonucleotides of this invention along the DNA polymerase encoding sequence. Numbering of nucleotide residues is approximate, and based on a starting position in the Glycoprotein B encoding region, which flanks the DNA polymerase encoding region in the upstream direction. Following each oligonucleotide designation is an abbreviation in lower case which indicates the type of oligonucleotide: h = all heφes vimses (Type 1); sq = additional sequencing tail available; g = gamma heφes vimses (Type 1); f = RFHV/KSHV subfamily heφes vimses (Type 2); m = RFHVMm specific (Type 3); n = RFHVMn specific (Type 3); ks = KSHV specific (Type 3). The phylogenetic analysis, the CpG analysis, and the similarity between symptoms caused by the three vimses support the use of the monkey vimses as models for KSHV, and other members of the RFHV/KSHV subfamily that may infed humans. Oligonucleotide primers were used in a screening assay to deted the presence of DNA polymerase encoding sequences in various biological samples. The results are shown in Figure 20. Results of RF samples of M. nemestrina monkeys #2, #3, #4, #7, #1 and #5 are shown in lanes A-D, I, and J respectively. Results from RF samples from a M. mulatta monkey is shown in lanes G & H. Results from peripheral blood lymphocytes of unaffeded SRV2-negative M. nemestrina monkeys are shown in lanes E & F. Samples were assayed using nested PCR as follows: for the M. nemestrina samples, outer primers were VASGA and PEARB; inner primers were PEARB and PIEAB. For the M. mulatta samples, outer primers were FVEGA and KVIYB; inner primers were SPKDA and ASPDB. In this and other experiment, we found that the presence of amplification product correlates with the source of the samples in two ways: First, amplification was vims-specific (the RFHVMn specific oligonucleotides failed to amplify sequence from the M. mulatta RF lesion, but the RFHVMm specific oligonucleotides did. Second, M. nemestrina samples absent of RF-related symptoms did not yield readion product, even when other vimses were present. A variety of tissues, including thymus, bone marrow, spleen, salivary gland, liver, mesenteric lymph node, ileocecal jundion, duodenum, kidney and gonads naturally infeded with SRV-2 were negative for the presence of RFHVMn sequences. Example 12: Other human-infecting gamma herpes DNA polymerase sequences of the RFHV/KSHV subfamily Human tissue samples suspeded of containing a previously undescribed gamma heφes vims, particularly fibroproliferative conditions, lymphocyte malignancies, and conditions associated with immunodeficiency and immunosuppression, such as acute respiratory disease syndrome (ARDS), are preserved by freezing, and the DNA is extraded as in Example 2. Two rounds of PCR amplification are conduded using the three heφes vims oligonucleotide primers, DFASA, VYGA and GDTD1B, according to Example 3. Altematively, subfamily-specific (Type 2) primers may be used as described earlier in this example in the discovery of RFHV2. The amplified polynucleotide is eledrophoresed in agarose and blotted onto a nylon membrane. The blot is hybridized with a probe comprising the polynucleotide fragment obtained from the RFHV polynucleotide encoding DNA polymerase (residues 330-501 of Figure 1), labeled with 32 P. The hybridization reaction is done under conditions that will permit a stable complex forming between the probe and DNA polymerase from a heφes vims, but not between the probe and endogenous eukaryotic DNA polymerase. The conditions will require approximately 60% identity between hybridizing segments of the probe and the target for a stable complex to form. These conditions are calculated using the formula given eariier, depending on the length and sequence of the probe and the corresponding sequence of the target. The conditions are estimated to be: a) allowing the probe to hybridize with the target in 6 x SSC (0.15 M NaCl, 15 mM sodium citrate buffer) at room temperature in the absence of formamide; and b) washing newly formed duplexes for a brief period (5-10 min) in 2 x SSC at room temperature. Amplified polynucleotides that hybridize to the labeled probe under these conditions are selected for further charaderization. The expected size is 236 base pairs for the amplified inner fragment including the primer-binding regions, for a vims that has no insertions or deletions relative to RFHV or KSHV, and has been amplified using VYGA and GDTD1B as inner primers. The sequence of the fragment is determined as in Example 4. Samples containing fragments different from RFHV or KSHV are seleded for determination of the entire DNA polymerase gene sequence by a method similar to that in Example 9. REFERENCES Altschul et al. (1986). Bull. Math. Bio. 48:603-616. Ambroziuk et al. (1995). Science 268:582-583. Basco et al. (1992). J. Biol. Chem. 267:19427-19434. Basco et al. (1993). Chromosoma 102:32-38. Berel V. et al. (1990). Lancet 335:123-128. Bernard et al. (1989). Cell 59:219-228. Bernard et al. (1990). Proc. Natl. Acad. Sci. USA 87:4610-4614. Beaucage et al. (1981). Tetra. Lett. 22:1859-1862. Cesarman E. et al. (1995). New Engl. J. Med. 332:1186-1191 Chang Y. et al. (1994). Science 266:1865-1869. Derbyshire et al. (1991). EMBO J., 10:17-24. Digard P. et al. (1995). Proc. Natl. Acad. Sci. USA 92:1456-1460. Dorsky D.I. et al. (1990). J. Virol. 64:1394-1397. Dorsky D.I. et al. (1988). J. Virol. 62:3224-3232. Emery VC. et al. (1992). pp. 257-277 in Molecular and Cell Biology of Opportunistic Infections in AIDS; S. Myint & A. Cann, eds, Chapman & Hall. Erickson et al. (1990). Science 249:527-533. Fields B.N. & Knipe D.M., eds. (1991). Fundamental Virology, 2nd Edition, Raven Press. Firesmith TH. et al. (1994). Int. J. Dermatol. 33:755-762. Gibbs J.S. et al. (1988a). Proc. Natl. Acad. Sci. USA 85:6672-6676. Gibbs J.S. et al. (1988b). Proc. Natl. Acad. Sci. USA 85:7969-7973. Giddens W.E. Jr. et al. (1983). pp. 249-253 in Viral and Immunological Diseases in Nonhuman Primates; Alan R. Liss Inc. Glorioso J.C. et al. (1994). Dev. Biol. Stand 82:79-87. Haffey M.L. et al. (1988). J. Virol. 62:4493-4498. Hall J.D. et al. (1989). Nucl. Acids Res. 17:9231-9244. Henikoff et al. (1992) Proc. Natl. Acad. Sci. USA 89:10915-10919. Hirose et al. (1978). Tetra. Lett (1978) 19:2449-2452. Hodgson (1991). Bio Technology 9:19-21 Hopp T.P. et al. (1981). Proc. Natl. Acad. Sci. USA 78:3824-3828. Johnson P.A. et al. (1994). Methods Cell Biol. 43A: 191-210. Karlin S. et al. (1994). J. Virol. 68:1886-1902. Knopf CW. et al. (1988). Biochim. Biophys. Acta 951:298-314. Kumar et al. (1984). J. Org. Chem. 49:4905-4912. Larder B.A. et al. (1987). EMBO J. 6:169-175. Latchman D.S. et al. (1994). Molec. Biotechnol. 2:179-195. Lin L.S. et al. (1995). J. Med. Virol. 45:99-105. Lisitsyn N. et al. (1993). Science 259:946-. Uu M.Y. et al. (1989). J. Med Virol. 28:101-105. Marcy Al. et al. (1990). J. Virol. 64:5883-5890. Martin R.W. et al. (1993). Medicine 72:245-26. Meier J.L et al. (1993). J. Virol. 67:7573-7581 Meinkoth J. et al. (1984). Anal. Biochem. 138:267-. Miles SA (1994). Curr. Opin. Oncol. 6:497-502. Mitsuyasu RT. (1993). Curr. Opin. Oncol. 5:835-844. Moore P.S. et al. (1995). New Engl. J. Med. 332:1181-1185. Northfelt. D.W. (1994). Dmgs (New Zealand) 48:569-582. O'Donnell M.E. et al. (1987). J Biol. Chem. 262:4252-4259. Reardon J.E. et al. (1989). J. Biol. Chem. 264:7405-7411 Simon et al. (1991). EMBO J. 10:2165-2171 Soengas et al. (1992). EMBO J. 11:4227-4237. Stow N.D. (1993). Nucl. Acids Res. 21:87-92. Tsai C-C. et al. (1986). Lab. Animal Sci. 36:119-124. VanDevanter et al. (1996). J. Clin. Microbiol. 34:1666-1671 Wang T. S.-F. et al. (1989). FASEB J. 3:14-21 Ward Pl. et al. (1994). Trends Genet. 10:267-274. Yeung K.C. et al. (1991). Curr. Eye Res. 10 (Suppl.) 31-37. Patents and Patent Applications: US 4415732 Caruthers M.H. et al. (polynucleotide synthesis) US 4444887 Hoffman M.K. (mAb method) US 4472500 Milstein C. et al. (mAb cell) US 4683195 Mullis K.B. (PCR) US 4683202 Mullis K.B. et al. (PCR) US 4642333 Person S. (HSV Gb expression) US 5120639 Haffey M.L. et al. (Ab vs POL in dmg screening) US 5124246 Urdea M.S. et al. (branched DNA) US 5171568 Burke R.L. et al. (HSV Gb/Gd vaccine) US 5176995 Sninsky J.J. et al. (PCR method for vimses) US 5223391 Coen D.M. et al. (UL42 peptides as POL inhibitors) US 5244792 Burke R.L. et al. (HSV Gb expression) US 5350671 Houghton M. et al. (HCV diagnostics) US 5354653 Matsumoto T. et al. (HSV strain probe assay) US 5399346 Anderson W.F. et al. (gene therapy) EP 0337441 Haffey M.L. (expression of HSV1 POL in yeast) WO 8904964 Feitelson M. et al. (anti-HBV DNA POL in diagnosis) JP 5309000 latron Lab Inc. (PCR assay for EBV POL) SEQUENCE LISTINGS: SEQ.. Desig¬ Description Type Source ID nation 1 RFHV DNA polymerase PCR segment DNA This invention 2 RFHV DNA polymerase PCR segment Protein This invention 3 KSHV DNA polymerase PCR segment DNA This invention 4 KSHV DNA polymerase PCR segment Protein This invention 5-12 Heφes vims oligonucleotides DNA This invention 13-16 RFHV specific oligonucleotide DNA This invention 17-20 KSHV specific oligonucleotide DNA This invention 21-22 RFHV/KSHV subfamily DNA This invention oligonucleotide 23 eHV2 DNA polymerase DNA Genbank locus EHVU20824 24 SHV1 DNA polymerase DNA Genbank locus HSVSPOLGBP 25 EBV DNA polymerase DNA Genbank locus EBV 26 hCMV DNA polymerase DNA Genbank locus HS5POL 27 hHV6 DNA polymerase DNA Genbank locus HH6DNAPOL 28 hVZV DNA polymerase DNA Genbank locus HEVZVXX 29 hHSVI DNA polymerase DNA Genbank locus HEHSV1DP 30 eHV2 DNA polymerase Protein Genbank locus EHVU20824 31 sHV1 DNA polymerase Protein Genbank locus HSVSPOLGBP 32 EBV DNA polymerase Protein Genbank locus EBV 33 hCMV DNA polymerase Protein Genbank locus HS5POL 34 hHV6 DNA polymerase Protein Genbank locus HH6DNAPOL 35 hVZV DNA polymerase Protein Genbank locus HEVZVXX 36 hHSVI DNA polymerase Protein Genbank locus HEHSV1DP 37 hHSV2 DNA polymerase Protein PIR locus DJBE21 38 eHV1 DNA polymerase Protein PIR locus DJBEC3 39 mCMV DNA polymerase Protein PIR locus DJBEMC 40 gpCMV DNA polymerase Protein PIR locus L25706-B 41 iHV1 DNA polymerase Protein PIR locus DJBEI1 42 hHV6 DNA polymerase segment DNA Figure 3 43 hCMV DNA polymerase segment DNA Figure 3 44 gpCMV DNA polymerase segment DNA Figure 3 45 mCMV DNA polymerase segment DNA Figure 3 46 hHSVI DNA polymerase segment DNA Figure 3 47 hHSV2 DNA polymerase segment DNA Figure 3 48 hVZV DNA polymerase segment DNA Figure 3 49 eHV2 DNA polymerase segment DNA Figure 3 50 hEBV DNA polymerase segment DNA Figure 3 51 sHV1 DNA polymerase segment DNA Figure 3 52 iHV1 DNA polymerase segment DNA Figure 3 53 hHV6 DNA polymerase segment DNA Figure 4 54 hCMV DNA polymerase segment DNA Figure 4 55 gpCMV DNA polymerase segment DNA Figure 4 56 mCMV DNA polymerase segment DNA Figure 4 57 hHSVI DNA polymerase segment DNA Figure 4 58 hVZV DNA polymerase segment DNA Figure 4 59 eHV2 DNA polymerase segment DNA Figure 4 60 hEBV DNA polymerase segment DNA Figure 4 61 sHV1 DNA polymerase segment DNA Figure 4 62 iHV1 DNA polymerase segment DNA Figure 4 63 hHV6 DNA polymerase segment DNA Figure 5 64 hCMV DNA polymerase segment DNA Figure 5 65 gpCMV DNA polymerase segment DNA Figure 5 66 mCMV DNA polymerase segment DNA Figure 5 67 hHSVI DNA polymerase segment DNA Figure 5 68 hVZV DNA polymerase segment DNA Figure 5 69 eHV2 DNA polymerase segment DNA Figure 5 70 sHV1 DNA polymerase segment DNA Figure 5 71 hEBV DNA polymerase segment DNA Figure 5 72 iHV1 DNA polymerase segment DNA Figure 5 73 IAETVTL gamma-heφes antigen Protein This invention 74-79 RFHV/KSHV subfamily antigens Protein This invention 0-103 RFHV or KSHV specific antigens Protein This invention 104 SIIQB KSHV specific oligonucleotide DNA This invention 105 QAHNA Gamma heφesoligonucleotide DNA This invention 106 QAHNB Gamma heφesoligonucleotide DNA This invention 107- RFHV/KSHV subfamily specific DNA This invention 109 oligonucleotides 110 RFHV Shared polynucleotide sequence DNA This invention fragment 111 RFHV Shared polynucleotide sequence DNA This invention fragment 112 RFHV Shared polypeptide sequence Protein This invention fragment 113 KSHV Shared polypeptide sequence Protein This invention fragment 114 KSHV KSHV fragment DNA This invention fragment 115 KSHV KSHV fragment Protein This invention fragment 116 KSHV DNA polymerase segment DNA This invention 117 KSHV DNA polymerase segment Protein This invention 118 RFHV2 DNA polymerase PCR segment DNA This invention 119 RFHV2 DNA polymerase PCR segment Protein This invention 120 KSHV DNA polymerase variant Protein This invention 121 KSHV DNA polymerase variant Protein This invention 122 KSHV DNA polymerase variant Protein This invention 123 KSHV DNA polymerase variant Protein This invention 124- Heφes vims (Type 1) DNA This invention, Table 10 138 oligonucleotides 139 - KSHV specific oligonucleotides DNA This invention, Table 11 149 150- RFHV2 specific oligonucleotides DNA This invention, Table 14 152 SEQUENCE DESCRIPTION: SEQ ID N0:1: GTGTTCGACT TTGCTAGTCT TTACCCCAGC ATCATGCAGG CACACAACCT CTGTTATTCT 60 ACCCTGAπA CAGGAAGCGC CCTACACGGG CACCCCGAAC TGACCCCCGA CGACTACGAA 120 ACCπCCACC TGAGCGGGGG AACGGTACAC TTTGTAAAAA AGCACGTCCG CGAGTCACTA 180 CTGTCCAAAC TGCTCACAAC ATGGCTGGCC AAGAGGAAAG AGATCCGCAA AAATTTAGCC 240 TCGTGCACAG ACCCCACCAT GCGCACCATA CTGGATAAAC AACAGCTGGC CATCAAGGTC 300 ACATGTAACG CGGTGTACGG GTTCACCGGC GTCGCTTCCG GCATCCTACC GTGCCTGAAC 360 ATCGCAGAGA CGGTGACCCT CCAGGGCAGG AAAATGCTGG AAACGTCTCA GGCGTTCGTA 420 GAGGGAATCT CGCCAACGGC ACTGGCAGAC CTACTGCAGC GACCGATCGA GGCGTCTCCG 480 GAAGCCAGGT TTAAAGTGAT ATACGGCGAC ACCGACTCCG TGTTTGTCGC ATGCCG 536 SEQUENCE DESCRIPTION: SEQ ID N0:2: Val Phe Asp Phe Ala Ser Leu Tyr Pro Ser lie Met Gin Ala His Asn Leu Cys Tyr Ser Thr Leu Ile Thr Gly Ser Ala Leu His Gly His Pro Glu Leu Thr Pro Asp Asp Tyr Glu Thr Phe His Leu Ser Gly Gly Thr Val His Phe Val Lys Lys His Val Arg Glu Ser Leu Leu Ser Lys Leu Leu Thr Thr Trp Leu Ala Lys Arg Lys Glu Ile Arg Lys Asn Leu Ala Ser Cys Thr Asp Pro Thr Met Arg Thr He Leu Asp Lys Gin Gin Leu Ala Ile Lys Val Thr Cys Asn Ala Val Tyr Gly Phe Thr Gly Val Ala Ser Gly He Leu Pro Cys Leu Asn Ile Ala Glu Thr Val Thr Leu Gin Gly Arg Lys Met Leu Glu Thr Ser Gin Ala Phe Val Glu Gly He Ser Pro Thr Ala Leu Ala Asp Leu Leu Gin Arg Pro He Glu Ala Ser Pro Glu Ala Arg Phe Lys Val He Tyr Gly Asp Thr Asp Ser Val Phe Val Ala Cys SEQUENCE DESCRIPTION: SEQ ID NO:3: GTGTTCGACT TTGCTAGCCT CTACCCCAGT ATCATCCAAG CGCACAACTT GTGCTACTCC 60 ACACTGATAC CCGGCGATTC GCTCCACCTG CACCCACACC TCTCCCCGGA CGACTACGAA 120 ACCTTTGTCC TCAGCGGAGG TCCGGTCCAC TTTGTAAAAA AACACAAAAG GGAGTCCCTT 180 CTTACCAAGC TTCTGACGGT ATGGCTCGCG AAGAGAAAAG AAATAAGAAA GACCCTGGCA 240 TCATGCACGG ACCCCGCACT GAAAACTATT CTAGACAAAC AACAACTGGC CATCAAGGTT 300 ACCTGCAACG CGGTTTACGG CπCACGGGC GTTGCCTCTG GCATACTGCC TTGCCTAAAC 360 ATAGCGGAGA CCGTGACACT ACAAGGGCGA AAGATGCTGG AGAGATCTCA GGCCTTTGTA 420 GAGGCCATCT CGCCGGAACG CCTAGCGGGT CTCCTGCGGA GGCCAATAGA CGTCTCACCC 480 GACGCCCGAT TCAAGGTCAT ATACGGCGAC ACCGACTCCG TGTTTGTCGC ATGCCG 536 SEQUENCE DESCRIPTION: SEQ ID N0:4: Val Phe Asp Phe Ala Ser Leu Tyr Pro Ser He Ile Gin Ala His Asn Leu Cys Tyr Ser Thr Leu Ile Pro Gly Asp Ser Leu His Leu His Pro His Leu Ser Pro Asp Asp Tyr Glu Thr Phe Val Leu Ser Gly Gly Pro Val His Phe Val Lys Lys His Lys Arg Glu Ser Leu Leu Thr Lys Leu Leu Thr Val Trp Leu Ala Lys Arg Lys Glu Ile Arg Lys Thr Leu Ala Ser Cys Thr Asp Pro Ala Leu Lys Thr He Leu Asp Lys Gin Gin Leu Ala Ile Lys Val Thr Cys Asn Ala Val Tyr Gly Phe Thr Gly Val Al a Ser Gly He Leu Pro Cys Leu Asn Ile Ala Glu Thr Val Thr Leu Gin Gly Arg Lys Met Leu Glu Arg Ser Gin Ala Phe Val Glu Ala He Ser Pro Glu Arg Leu Ala Gly Leu Leu Arg Arg Pro He Asp Val Ser Pro Asp Ala Arg Phe Lys Val He Tyr Gly Asp Thr Asp Ser Val Phe Val Ala Cys SEQUENCE DESCRIPTION: SEQ ID NO: 5: GTGTTCGACT TYGCNAGYYT NTAYCC 26 SEQUENCE DESCRIPTION: SEQ ID N0:6: GTGTTCGACT TYCARAGYYT NTAYCC 26 SEQUENCE DESCRIPTION: SEQ ID NO:7: ACGTGCAACG CGGTGTAYGG NKTNACNGG 29 SEQUENCE DESCRIPTION: SEQ ID NO:8: ACGTGCAACG CGGTGTACGG SGTSACSGG 29 SEQUENCE DESCRIPTION: SEQ ID NO:9: ACGTGCAACG CGGTGTA 17 SEQUENCE DESCRIPTION: SEQ ID NO:10: TAYGGNGAYA CNGACTCCGT GTTTGTCGCA TGCCG 35 SEQUENCE DESCRIPTION: SEQ ID NO:11: CGGCATGCGA CAAACACGGA GTCNGTRTCN CCRTA 35 SEQUENCE DESCRIPTION: SEQ ID NO:12: CGGCATGCGA CAAACACGGA 20 SEQUENCE DESCRIPTION: SEQ ID NO:13: CGTCGCTTCC GGCATCCTAC C 21 SEQUENCE DESCRIPTION: SEQ ID NO:14: GGCATCCTAC CGTGCCTGAA C 21 SEQUENCE DESCRIPTION: SEQ ID N0:15: CCGGAGACGC CTCGATCGGT C 21 SEQUENCE DESCRIPTION: SEQ ID NO:16: AACCTGGCTT CCGGAGACGC C 21 SEQUENCE DESCRIPTION: SEQ ID NO:17: GCGTTGCCTC TGGCATACTG 20 SEQUENCE DESCRIPTION: SEQ ID NO:18: CTGCCTTGCC TAAACATAGC G 21 SEQUENCE DESCRIPTION: SEQ ID N0:19: GGTGAGACGT CTATTGGCCT 20 SEQUENCE DESCRIPTION: SEQ ID N0:20: AATCGGGCGT CGGGTGAGAC G 21 SEQUENCE DESCRIPTION: SEQ ID NO:21: GTCGCCTCTG GCATCCTNCC NTGYCTNAA 29 SEQUENCE DESCRIPTION: SEQ ID NO:22: CAGGGCCGGA AGATGCTGGA RACRTCNCAR GC 32 SEQUENCE DESCRIPTION: SEQ ID N0:23: ATGAGTTTCT ACAACCCCTA CTTGGTCAAG AGGACCTTTC TTAAAAAGGC CGCCCCCTCG 60 CGGCCGACCA AGGAATATAC CAGGATAATT CCAAAATGCT TCAAGACCCC AGGCGCCGCG 120 GGGGTGGTGC CCCACACCAG CACCCTGGAC CCGGTGTGCT TCGTGGGGGA CAAGGAGACC 180 CCCATCCTGT ACGGGGACGG GAGCAGGAGC CTGTGGAGCG CGGGTGGGCG GGGCGGGCCG 240 GGGACGGGCG CGGGCCAGGG CCACACGCCT GTGGCCCTGA CCTTCCACGT CTATGACATA 300 ATAGAGACGG TGTACGGCCA GGACAGGTGC GACCACGTGC CCTTTCAGTT TCAGACGGAC 360 ATCATCCCCA GCGGGACGGT CCTCAAGCTG CTGGGTCGCA CCTCGGACGA CCGCAGCGTG 420 TGCGTGAACG TGTTCAGGCA GGAGCTGTAC TTTTACGTGC GCGTGCCCGA GGGGCTCAAG 480 CTGGACTTTC TCATCCAGCA GTGCTCGCGG GAGAACTTTA ACTTTAGCCA GGGCCGGTAC 540 CGATATGAGA AAACAAGCAA GCGCGTGTTG CGCGAGTACT GCGTCGAGGC GCGGGAGGTG 600 TACCGGGTGT TCGCGTCGAG CCAGGGGTTC GTGGACCTCC TGGCCGGGGG GCTCACGGCC 660 GCGGGGTGCG AGGTCTTCGA GACAAACGTG GACGCGGCCA GGCGGTTCAT CATAGACAAC 720 GGGTTCTCCA CCTTCGGGTG GTACTCGTGC GCGGCGGCCG TCCCGCGCCA GGGGGGCGCG 780 GCCAGGGACT CCTGGACGGA GTTGGAGTAC GACTGCGCCG CGGGGGACCT GGAGTTTCAC 840 GCGGGGCGGG CGGACTGGCC GGGCTACAAC GTCCTCTCCT TCGATATAGA GTGCCTGGGG 900 GAGAACGGGT TCCCCAACGC GAGCAGGGAC GAGGACATGA TCCTGCAGAT CTCCTGCGTG 960 ATCTGGAAGG CGGGGTCGGG GGAGGCGCCC AGGAGCGTGC TCCTGAACCT GGGCACGTGC 1020 GAGGAGATAG AGGGGGTGGA GGTGTACCAG TGCCCCTCGG AGCTGGACCT GCTCTACCTC 1080 TTTTTCACCA TGATCAGGGA CGCGGACGTG GAGTTTGTGA CGGGCTACAA CATCTCCAAC 1140 TTTGACTTCC CCTACGTGAT AGACAGGGCC ACGCAGGTGT ACAACCTGAA CCTGAAAGAG 1200 πCACCCGGG TGCGCTCCTC GTCCATCπC GAGGTGCACA AGCCCAAGAA CAGCTCAGCG 1260 GGCπCATGC GCGCGGTGTC CAAGGTCAAG GTGGCCGGGG TGGTGCCCAT AGACATGTAC 1320 CAGGTGTGCA GGGACAAGCT GAGCCTGTCC AACTACAAGC TGGACACGGT GGCCGGGGAG 1380 TGCGTGGGCG CCAAGAAGGA GGACGTCTCC TACAAGGAGA TCCCCCACCT GTTCAGGCAG 1440 GGACCGGGGG GCAGGGCCAG GCTGGGGCTG TACTGCGTCA AGGATTCCGC CCTGGTGCTG 1500 GACCTGCTGA GGTACTTTAT GACGCACGTG GAGATCTCTG AGATAGCCAA GATAGCCAAG 1560 ATCCCCACGC GGCGGGTGCT CACGGACGGG CAGCAGATCA GGGTCπCTC CTGCCTGCTG 1620 GACGTGGCCG GGCGGGAGGG CTACATCCTG CCAGTGGACA GGCACGCGGA CGCGGAGGGC 1680 TACCAGGGGG CCACGGTCAT AGACCCCTCG CCCGGGTTCT ACAACACCCC GGTGCTGGTG 1740 GTGGACTTTG CCAGCCTGTA CCCCACCATC ATCCAGGCCC ACAACCTCTG CTACTCCACC 1800 ATGATCCCCG GAGACAGGCT GTGCCTGCAC CCGCACCTCG GGCCGGGCGA CTACGAGACC 1860 TTTGAGCTCG CGAGCGGGCC GGTGCACTTT GTCAAGAAGC ACAAGGCGGT CTCGCTGCTG 1920 GCCACGCTGC TGAACGTGTG GCTGGCCAAG AGGAAGGCCA TCAGGCGCGA GCTGGCCACG 1980 GTCTCGGACG AGGCCGTCAG GACCATCCTG GACAAGCAGC AGCTGGCCAT CAAGGTCACC 2040 TGCAACGCGG TGTACGGGTT CACGGGCGTG GCCTCGGGCA TCCTGCCCTG TCTCAAGATA 2100 GCCGAGACGG TCACCTTCCA GGGCAGGCGC ATGCTGGAGA ACTCCAAGCG CTACATAGAG 2160 GGGGTGACCC CCGAGGGGCT GGCAGACATA TTGGGCAGGC GGGTGGAGTG CGCCCCCGAT 2220 GCCAGTTTTA AGGTCATCTA CGGGGACACG GACTCCCTGT TTATCCACTG CCGGGGCTAC 2280 CGCCCAGAGC AGGTCACGGG GTTCTGCGAC GAGCTGGCCG CTCACATGAC CCGAACCCTG 2340 πCGTGGACC CCATCAAGCT GGAGGCCGAA AAGACCTTCA AGTGCCTGAT CπACTGACC 2400 AAAAAGAGGT ACATAGGCAT GATGACCACC GACAGGCTGC TCATGAAGGG GGTGGACCTG 2460 GTGCGCAAGA CGGCGTGCAG GTTCGTGCAG GAGACCACCA AGGCCATCCT GGACCTGGTG 2520 ATGGGGGACG AGGCGGTGCG GGCGGCGGCC GAGCGCCTGT GCGCCATGAG GGTGGAGGAG 2580 GTGTGCGCGC GGGGGCCCCC CGTCGGGTTC CTCAAGGTGG TGGACATCCT CAACGACAGC 2640 TACAGGAAAC TAAGGCTCAA CCGGGTGCCC GTGGGCCAGC TGTCCTTCTC CACCGAGCTG 2700 AGCAGGCCCA TCTCCTAHA CAAGACCCTG ACCCTGCCCC ACCTGGTGGT GTACCACAAG 2760 ATCATGCAGA GGAACGAGGA GCTCCCCCAG ATCCACGATA GGATAGCCTA CGTGTTTGTG 2820 CAGTCCCCCA AGGGGAAGCT GAGGTCCGAG ATGGCCGAGG ACCCCGCCTA CGCGGCCCAG 2880 CACAACATCC CCCCGGCCGT GGACCTGTAC TTTGACAAGG TCATACACGG GGCGGCCAAC 2940 ATCCTGCAGT GCCTGTTTGA GAACGACAGC GATAAGGCCG CGAGGGTGCT GTACAACTTT 3000 GCGGACCTGC CCCCCGACGA CCTGTGA 3027 SEQUENCE DESCRIPTION: SEQ ID NO:24: ATGGATTTTT ACAACCCATA TCTAAGTAAA AAGCCAACAG ATACAAAGAC ACCTAAGCTT 60 CATACAACTA GACAATCTAT ATGTAGGTTA GTCCCTAAAT GTTTTAGAAA TCCTACTGAA 120 AAAGGCGTAG TGTCTGTGTC πCTTTTGCT CTTCCAACTT ACTTTTTCAA AGGTAATGAG 180 AATAAAGTAT ATCTTGAAAA TGGTAAGTCT ATGTGGCACT TAAGAAGACC GTGTAAGAAC 240 GCGTTGCTAG AAGAACAATC TATTACGTTC CATATTTATG ACATAGTAGA AACTACTTAT 300 TCAGAAGACA GATGTAACGA TATTCCTTTT AAGTTTCAAA CAGACATAAT ACCTAATGGA 360 ACAGTGTTGA AACTACTTGG AAGAACACTA GAGGGTGCGA GCGTATGTGT TAACGTGTTT 420 GGACAAAGAA AΠATTTTTA TGHAAAGTT CCGGAAGGTG GCAACATAAC CTATCTTATA 480 AAACAAGCπ TGAATGAAAA ATTTAGCCCA TCTTGTGCAT ACCAAACTGA AGCAGTAAAG 540 AAGAAGATAC TATCTAGATA TGATCCAGAA GAACATGATG TGTTTAAGGT GACAGTGTCT 600 TCTTCCCTTT CTGTTTATAA GATATCAGAT TCTTTAGTGT CTAATGGTTG TGAAGTTTTT 660 GAAACAAATG TAGATGCTAT AAGAAGATTT GTAAπGATA ATGACTTTTC TACATTTGGT 720 TGGTACACAT GTAAGTCTGC ATGTCCTCGA ATCACAAATA GAGACTCTCA TACTGACAπ 780 GAGTπGACT GCGGGTACTA TGACTTAGAA πTCATGCTG ATAGAACAGA ATGGCCACCT 840 TACAACATAA TGTCTπTGA TATAGAATGT ATAGGAGAAA AAGGATTTCC πGTGCAAAA 900 AATGAAGGAG ATTTAATAAT TCAGATTTCA TGTGTGTTπ GGCACGCTGG GGCGCπGAT 960 ACAACTAGAA ATATGCTAπ ATCTπAGGA ACGTGCTCAG CTGπGAAAA TACTGAAGπ 1020 TATGAGπCC CTAGTGAAAT AGACATGCTG CATGGGTTTT πTCAπAAT TAGAGACTTT 1080 AATGπGAAA TAAπACTGG πATAATAπ TCTAACTTTG ACTTACOTA TCTAAπGAT 1140 AGAGCTACTC AAATπATAA TATAAAGCTA TCTGAπAπ CAAGAGπAA AACAGGGTCT 1200 ATΠTTCAAG πCATACACC AAAAGATACA GGAAATGGGT πATGAGATC TGTCTCTAAA 1260 ATAAAAATTT CAGGAAπAT AGCAAπGAC ATGTACAπG TGTGCAAAGA CAAACTCAGT 1320 CTGTCTAAπ ACAAGCπGA TACAGπGCT AATCACTGTA πGGTGCAAA AAAGGAAGAT 1380 GTGTOTACA AAGATAπAT GCCTCTTTTT ATGTCCGGAC CAGAAGGCAG AGCTAAGATA 1440 GGACTATACT GTGTAATAGA πCTGπcπ GTGATGAAAC TπTGAAAπ TTTTATGAπ 1500 CATGπGAAA πTCTGAGAT AGCAAAACTC GCTAAAATCC CCACAAGAAG AGπCπACA 1560 GATGGGCAAC AAATAAGAGT TmTOTGT CTGCπGCAG CAGCTCGTGC AGAAAACTAT 1620 ATACTGCCTG TGTCAAATGA TGTCAATGCG GATGGGTTTC AAGGAGCTAC CGπATAAAT 1680 CCAAπCCTG GATπTATAA CAATGCTGTA πAGTAGTAG ACTTTGCTAG CCTGTATCCT 1740 AGTAπATAC AAGCTCATAA TCTATGCTAC TCCACTCTTA TACCCCACCA TGCTTTACAC 1800 AACTACCCTC ACπAAAATC TAGTGACTAT GAGACTTTCA TGCTCAGπC TGGACCTATA 1860 CACTTTGTGA AAAAACACAT TCAGGCATCT CTTCTATCTA GGCTCπAAC TGTGTGGCπ 1920 TCTAAGAGAA AAGCTAπAG GCAAAAGCTT GCTGAATGTG AAGACCTAGA CACTAAAACT 1980 AπCTAGATA AACAGCAACT CGCTAπAAA GTAACTTGTA ATGCTGTGTA TGGGTTTACA 2040 GGAGπGCGT CAGGCTTGCT GCCATGCATA AGCAπGCAG AGACTGπAC TCTCCAAGGC 2100 CGGACGATGC TAGAAAAATC AAAAATAπC ATAGAAGCAA TGACACCTGA TACAOTCAA 2160 GAAAπGπC CTCATATAGT GAAGCATGAA CCTGATGCGA AGπCAGAGT CATATATGGA 2220 GACACAGACT CTCTATπGT AGAATGTGπ GGGTAπCTG TAGACACAGT TGπAAAπT 2280 GGAGAπTCT TAGCTGCTTT TAOTCTGAA AAGCTCTTTA ATGCTCCTAT AAAGπAGAG 2340 TCAGAAAAAA CATπCAGTG TTTGCTAπG CπGCTAAAA AAAGATACAT TGGAATACTG 2400 TCAAATGACA AAπGCπAT GAAAGGTGπ GAGTAGTGA GAAAAACTGC πGTAAATπ 2460 GπCAAAATA CTAGCTCAAA AAπcπAAT CπATACπA AAGACCCTGA GGTAAAAGCA 2520 GCTGCTCAGC TΗTGTCAAC AAAAGATCCA GACTATGCπ πAGAGAAGG GCπCCTGAT 2580 GGGTTTTTGA AAGTGATAGA CATTTTAAAT GAAAGCCACA AAAACCTCAG AACTGGGCAA 2640 GTGCCGGTAG AGGAAπAAC AπiTCTACA GAAπGAGTA GACCTATTTC πσTACAAA 2700 ACTGAAAACT TGCCTCATπ AACTGTTTAT AAAAAAAπA πACAAGGCA TGAAGAACCT 2760 CCACAAGπC ATGACAGAAT CCCATACGπ πTGTAGGCA AGACTACATC ATGCATATCA 2820 AACATGGCTG AAGACCCAAC ATACACGGπ CAAAATAATA πCCAAπGC AGTGGATCTA 2880 TATTTTGATA AACπAπCA CGGGGTAGCT AACATAATAC AGTGTCTCπ TAAAGACAGC 2940 AGTAAAACTG TGTCTGTTTT GTATAATTπ GTATCAACTC CTGTπTAπ πcπACGAG 3000 CπCTAACTG ATCAπCTGT AAAAGCATAA 3030 SEQUENCE DESCRIPTION: SEQ ID N0:25: ATGTCTGGGG GACTCTTCTA TAACCCTTTC CTAAGACCTA ATAAAGGCCT TCTGAAAAAG 60 CCTGACAAGG AGTACCTGCG TCTCAπCCC AAGTGTπCC AGACACCAGG CGCCGCAGGG 120 GTGGTGGATG TGCGGGGGCC TCAGCCCCCC CTGTGCTTCT ACCAAGACTC CCTGACGGTG 180 GTGGGGGGTG ACGAGGATGG AAAGGGCATG TGGTGGCGCC AGCGTGCCCA AGAGGGCACG 240 GCAAGGCCGG AGGCAGACAC CCACGGAAGC CCTCTGGACT TCCATGTCTA CGACATACTC 300 GAGACGGTGT ACACGCACGA GAAATGCGCC GTCAπCCAT CGGATAAACA GGGGTATGTG 360 GTGCCATGTG GCATCGTCAT CAAGCTACTG GGCCGGCGCA AGGCCGATGG GGCCAGCGTG 420 TGTGTGAACG TGTTTGGGCA GCAGGCCTAC πCTACGCCA GCGCGCCTCA GGGTCTGGAC 480 GTGGAGTπG CAGTCCTCAG CGCCCTCAAG GCCAGCACCT TCGACCGCAG GACCCCCTGC 540 CGGGTCTCGG TGGAGAAGGT CACGCGCCGT TCCAπATGG GCTACGGCAA CCATGCCGGC 600 GACTACCACA AGATCACCCT CTCCCATCCC AACAGTGTGT GTCACGTGGC CACGTGGCTG 660 CAAGACAAGC ACGGGTGTCG GATCTTTGAG GCCAACGTGG ATGCCACGCG CCGCTTTGTC 720 CTGGACAATG ACTTTGTCAC CTTTGGCTGG TACAGCTGCC GCCGCGCCAT CCCCCGCCTC 780 CAGCACCGGG ACTCGTACGC CGAGCTCGAG TACGACTGTG AGGTGGGCGA CCTCTCGGTC 840 CGGCGTGAAG ACAGCTCCTG GCCCTCCTAC CAGGCCCTGG CCπCGATAT CGAGTGTCTG 900 GGGGAGGAGG GCTTCCCCAC GGCCACCAAC GAGGCTGACC TGATCCTGCA GATATCCTGC 960 GTCCTCTGGT CGACAGGGGA GGAGGCCGGG CGCTATAGGC GCATCCTGCT GACGCTGGGC 1020 ACCTGCGAAG ACATAGAGGG GGπGAGGTC TACGAGπCC CATCGGAGCT GGACATGCTC 1080 TACGCCπCT TCCAGCTCAT CAGAGACCTC AGCGTGGAGA πGTGACCGG CTACAACGTG 1140 GCCAACTTTG ACTGGCCCTA CAπCTGGAC AGAGCCAGGC ACATCTACAG CATCAACCCA 1200 GCCTCTCTGG GCAAAAπAG GGCTGGGGGC GTCTGCGAGG TCAGGCGACC CCATGATGCG 1260 GGCAAGGGCT TCπGCGGGC CAACACCAAG GTCCGCATCA CCGGCCTCAT CCCCATCGAC 1320 ATGTACGCCG TGTGCCGGGA CAAGCTCAGC CTCTCAGACT ACAAGCTGGA CACAGTAGCC 1380 AGGCACCTAC TGGGGGCCAA GAAGGAGGAT GTGCAπACA AGGAGAπCC TCGCCTCTTT 1440 GCAGCGGGCC CCGAGGGGCG CAGGCGGCTC GGCATGTACT GCGTGCAGGA CTCGGCCCTG 1500 GTCATGGATC TGCTAAACCA TTTCGTGATC CACGTGGAGG TGGCAGAGAT TGCCAAGATC 1560 GCTCACATCC CCTGCAGGCG GGTGCTGGAC GATGGGCAGC AGATCCGCGT GπCTCCTGC 1620 CTCCTGGCGG CCGCCCAAAA GGAAAACTπ ATCCTGCCCA TGCCCTCGGC CTCTGACCGG 1680 GACGGCTACC AGGGGGCCAC CGTCATCCAG CCCCTGTCCG GAπCTACAA CTCCCCGGπ 1740 CTGGTGGTGG ACTTTGCCAG CCTCTACCCG AGCATCAπC AGGCTCATAA TCTCTGπAT 1800 TCTACCATGA TAACGCCGGG AGAAGAGCAC AGGCTAGCCG GCCTGCGCCC GGGAGAAGAC 1860 TATGAGTCCT TCAGGCTCAC GGGGGGCGTC TACCACTTTG TAAAGAAGCA CGTGCACGAG 1920 TCCπσiTGG CTAGTCTGπ GACCTCCTGG CTGGCCAAGC GCAAGGCCAT CAAGAAGCTG 1980 CTGGCGGCCT GCGAGGATCC GCGCCAAAGG ACCATCCTCG ACAAGCAGCA GCTGGCCATC 2040 AAGTGCACGT GCAACGCCGT CTACGGCπC ACCGGGGTGG CCAACGGCCT CTTTCCCTGC 2100 CTCTCCATCG CCGAGACGGT GACGCTGCAG GGCCGCACGA TGπGGAGCG GGCCAAGGCC 2160 πCGTGGAGG CCCTGAGCCC CGCCAACCTG CAGGCCCTGG CCCCCTCCCC GGACGCCTGG 2220 GCGCCCCTCA ACCCCGAGGG CCAGCTTCGA GTCATCTACG GGGACACGGA CTCGCTGTTT 2280 ATCGAGTGCC GGGGGTTTTC AGAGAGCGAG ACCCTGCGCT πGCCGATGC CCTGGCCGCC 2340 CACACCACCC GGAGCCTGπ TGTGGCCCCC ATCTCCCTGG AGGCCGAGAA GACCπCTCC 2400 TGCCTGATGC TGAπACAAA GAAGAGATAT GTGGGGGTGC TGACGGACGG CAAGACCCTG 2460 ATGAAGGGGG TGGAGCTCGT CCGGAAGACG GCCTGCAAGT πGTGCAGAC ACGCTGCCGG 2520 CGCGTGCTCG ACCTGGTGCT GGCGGATGCC CGGGTAAAGG AGGCGGCCAG CCTCCTCTCC 2580 CACCGGCCCT TCCAAGAGTC ATTTACACAA GGGCTACCTG TGGGCTTTTT GCCCGTCAπ 2640 GACATCCTAA ACCAGGCCTA CACAGACCTC CGTGAAGGCA GGGTCCCCAT GGGGGAGCTC 2700 TGCTΠTCAA CGGAGCTCAG CCGCAAGCTC TCAGCCTACA AGAGCACCCA GATGCCTCAC 2760 CTGGCCGTCT ACCAGAAGπ CGTCGAGCGC AACGAGGAAC TGCCCCAGAT CCACGACCGC 2820 ATCCAGTACG TCTTTGTGGA GCCCAAGGGG GGAGTGAAGG GGGCGAGAAA GACGGAGATG 2880 GCCGAGGACC CGGCCTACGC CGAGCGGCAC GGCGπCCCG TGGCCGTGGA TCAπAπTC 2940 GACAAGCTGC TCCAAGGAGC GGCCAACATC CTCCAGTGCC TCTTTGATAA CAACTCCGGG 3000 GCCGCCCTCT CCGTCCTCCA GAATTTTACA GCCCGGCCAC CAπCTAA 3048 SEQUENCE DESCRIPTION: SEQ ID NO:26: ATGTmTCA ACCCGTATCT GAGCGGCGGC GTGACCGGCG GTGCGGTCGC GGGTGGCCGG 60 CGTCAGCGπ CGCAGCCCGG CTCCGCGCAG GGCTCGGGCA AGCGGCCGCC ACAGAAACAG 120 TTTTTGCAGA TCGTGCCGCG AGGTGTCATG πCGACGGTC AGACGGGGπ GATCAAGCAT 180 AAGACGGGAC GGCTGCCTCT CATGπCTAT CGAGAGAπA AACAπTGπ GAGTCATGAC 240 ATGGTTTGGC CGTGTCCπG GCGCGAGACC CTGGTGGGTC GCGTGGTGGG ACCTAπCGT 300 TTTCACACCT ACGATCAGAC GGACGCCGTG CTCπcπCG ACTCGCCCGA AAACGTGTCG 360 CCGCGCTATC GTCAGCATCT GGTGCCTTCG GGGAACGTGT TGCGTTTCπ CGGGGCCACA 420 GAACACGGCT ACAGTATCTG CGTCAACGπ πCGGGCAGC GCAGCTACπ πACTGTGAG 480 TACAGCGACA CCGATAGGCT GCGTGAGGTC AπGCCAGCG TGGGCGAACT AGTGCCCGAA 540 CCGCGGACGC CATACGCCGT GTCTGTCACG CCGGCCACCA AGACCTCCAT CTATGGGTAC 600 GGGACGCGAC CCGTGCCCGA TTTGCAGTGT GTGTCTATCA GCAACTGGAC CATGGCCAGA 660 AAAATCGGCG AGTATCTGCT GGAGCAGGGT TTTCCCGTGT ACGAGGTCCG TGTGGATCCG 720 CTGACGCGπ TGGTCATCGA TCGGCGGATC ACCACGπCG GCTGGTGCTC CGTGAATCGT 780 TACGACTGGC GGCAGCAGGG TCGCGCGTCG ACπGTGATA TCGAGGTAGA CTGCGATGTC 840 TCTGACCTGG TGGCTGTGCC CGACGACAGC TCGTGGCCGC GCTATCGATG CCTGTCCTTC 900 GATATCGAGT GCATGAGCGG CGAGGGTGGT TTTCCCTGCG CCGAGAAGTC CGATGACAπ 960 GTCAπCAGA TCTCGTGCGT GTGCTACGAG ACGGGGGGAA ACACCGCCGT GGATCAGGGG 1020 ATCCCAAACG GGAACGATGG TCGGGGCTGC ACπCGGAGG GTGTGATCTT TGGGCACTCG 1080 GGTCπCATC TCTTTACGAT CGGCACCTGC GGGCAGGTGG GCCCAGACGT GGACGTCTAC 1140 GAGπCCCπ CCGAATACGA GCTGCTGCTG GGCTTTATGC TΠTCTTTCA ACGGTACGCG 1200 CCGGCCπTG TGACCGGπA CAACATCAAC TCTTTTGACT TGAAGTACAT CCTCACGCGT 1260 CTCGAGTACC TGTATAAGGT GGACTCGCAG CGCTTCTGCA AGπGCCTAC GGCGCAGGGC 1320 GGCCGTπCT TπTACACAG CCCCGCCGTG GGTΠTAAGC GGCAGTACGC CGCCGCTπT 1380 CCCTCGGCπ CTCACAACAA TCCGGCCAGC ACGGCCGCCA CCAAGGTGTA TAπGCGGGT 1440 TCGGTGGπA TCGACATGTA CCCTGTATGC ATGGCCAAGA CTAACTCGCC CAACTATAAG 1500 CTCAACACTA TGGCCGAGCT πACCTGCGG CAACGCAAGG ATGACCTGTC πACAAGGAC 1560 ATCCCGCGπ GπTCGTGGC TAATGCCGAG GGCCGCGCCC AGGTAGGCCG πACTGTCTG 1620 CAGGACGCCG TAπ&GTGCG CGATCTGπC AACACCAπA ATπTCACTA CGAGGCCGGG 1680 GCCATCGCGC GGCTGGCTAA AAπCCGπG CGGCGTGTCA TCTTTGACGG ACAGCAGATC 1740 CGTATCTACA CCTCGCTGCT GGACGAGTGC GCCTGCCGCG ATTπATCCT GCCCAACCAC 1800 TACAGCAAAG GTACGACGGT GCCCGAAACG AATAGCGπG CTGTGTCACC TAACGCTGCT 1860 ATCATCTCTA CCGCCGCTGT GCCCGGCGAC GCGGGπCTG TGGCGGCTAT GTTTCAGATG 1920 TCGCCGCCCT TGCAATCTGC GCCGTCCAGT CAGGACGGCG πTCACCCGG CTCCGGCAGT 1980 AACAGTAGTA GCAGCGTCGG CGTnTCAGC GTCGGCTCCG GCAGTAGTGG CGGCGTCGGC 2040 GπTCCAACG ACAATCACGG CGCCGGCGGT ACTGCGGCGG TTTCGTACCA GGGCGCCACG 2100 GTGTπGAGC CCGAGGTGGG πACTACAAC GACCCCGTGG CCGTGπCGA CπTGCCAGC 2160 CTCTACCCπ CCATCATCAT GGCCCACAAC CTCTGCTACT CCACCCTGCT GGTGCCGGGT 2220 GGCGAGTACC CTGTGGACCC CGCCGACGTA TACAGCGTCA CGCTAGAGAA CGGCGTGACC 2280 CACCGCTTTG TGCGTGOTC GGTGCGCGTC TCGGTGCTCT CGGAACTGCT CAACAAGTGG 2340 GTπCGCAGC GGCGTGCCGT GCGCGAATGC ATGCGCGAGT GTCAAGACCC TGTGCGCCGT 2400 ATGCTGCTCG ACAAGGAACA GATGGCGCTC AAAGTAACGT GCAACGCTTT CTACGGTTTT 2460 ACCGGCGTGG TCAACGGTAT GATGCCGTGT CTGCCCATCG CCGCCAGCAT CACGCGCATC 2520 GGTCGCGACA TGCTAGAGCG CACGGCGCGG πCATCAAAG ACAACTπTC AGAGCCGTGT 2580 TTTTTGCACA Al 11111 IAA TCAGGAAGAC TATGTAGTGG GAACGCGGGA GGGGGAπCG 2640 GAGGAGAGCA GCGCGπACC GGAGGGGCTC GAAACATCGT CAGGGGGCTC GAACGAACGG 2700 CGGGTGGAGG CGCGGGTCAT CTACGGGGAC ACGGACAGCG TGTTTGTCCG CTTTCGTGGC 2760 CTGACGCCGC AGGCTCTGGT GGCGCGTGGG CCCAGCCTGG CGCACTACGT GACGGCCTGT 2820 CπTTTGTGG AGCCCGTCAA GCTGGAGTTT GAAAAGGTCT TCGTCTCTCT TATGATGATC 2880 TGCAAGAAAC GπACATCGG CAAAGTGGAG GGCGCCTCGG GTCTGAGCAT GAAGGGCGTG 2940 GATCTGGTGC GCAAGACGGC CTGCGAGπC GTCAAGGGCG TCACGCGTGA CGTCCTCTCG 3000 CTGCTCTπG AGGATCGCGA GGTCTCGGAA GCAGCCGTGC GCCTGTCGCG CCTCTCACTC 3060 GATGAAGTCA AGAAGTACGG CGTGCCACGC GGTTTCTGGC GTATCπACG CCGCπGGTG 3120 CAGGCCCGCG ACGATCTGTA CCTGCACCGT GTGCGTGTCG AGGACCTGGT GCπTCGTCG 3180 GTGCTCTCTA AGGACATCTC GCTGTACCGT CAATCTAACC TGCCGCACAT TGCCGTCAπ 3240 AAGCGAπGG CGGCCCGπC TGAGGAGCTA CCCTCGGTCG GGGATCGGGT CTπTACGπ 3300 CTGACGGCGC CCGGTGTCCG GACGGCGCCG CAGGGπCCT CCGACAACGG TGAπCTGTA 3360 ACCGCCGGCG TGGπTCCCG GTCGGACGCG AπGATGGCA CGGACGACGA CGCTGACGGC 3420 GGCGGGGTAG AGGAGAGCAA CAGGAGAGGA GGAGAGCCGG CAAAGAAGAG GGCGCGGAAA 3480 CCACCGTCGG CCGTGTGCAA CTACGAGGTA GCCGAAGATC CGAGCTACGT GCGCGAGCAC 3540 GGCGTGCCCA πCACGCCGA CAAGTACTTT GAGCAGGπC TCAAGGCTGT AACTAACGTG 3600 CTGTCGCCCG TCTTTCCCGG CGGCGAAACC GCGCGCAAGG ACAAGππT GCACATGGTG 3660 CTGCCGCGGC GCTTGCACTT GGAGCCGGCT TTTCTGCCGT ACAGTGTCAA GGCGCACGAA 3720 TGCTGπGA 3729 SEQUENCE DESCRIPTION: SEQ ID NO:27: ATGGAπCGG TGTCGTTTTT TAATCCATAT πGGAAGCGA ATCGOTAAA GAAAAAAAGC 60 AGATCGAGπ ACAπCGTAT ACTTCCTCGC GGTATAATGC ATGATGGTGC GGCGGGAπA 120 ATAAAGGATG TTTGTGACTC TGAACCGCGT ATGTπTATC GAGACCGACA GTATTTACTG 180 AGCAAAGAAA TGACCTGGCC GAGTTTGGAC ATAGCTCGGT CCAAGGAπA TGATCATATG 240 AGGATGAAGT πCACATATA TGATGCTGTA GAAACGπAA TGTTTACGGA πCGATCGAG 300 AATCπCCπ πCAGTATAG ACATTπGTG AπCCπCGG GGACAGTGAT TAGAATGTTT 360 GGGAGAACTG AGGACGGTGA GAAGATCTGC GTGAACGTGT πGGACAGGA GCAATATTTC 420 TACTGCGAAT GCGTCGACGG AAGAAGCCTG AAGGCTACTA TAAACAATπ GATGπAACC 480 GGCGAGGπA AAATGTCGTG πcπiTGTC AπGAGCCGG CTGATAAGπ GTCGπGTAT 540 GGGTACAATG CCAACACTGT CGπAATCTG πTAAAGTGA GπTTGGAAA TTπTATGTA 600 TCTCAACGTA πGGAAAGAT TCTGCAGAAT GAGGGAπCG TAGTTTATGA AATCGACGTA 660 GATGTπTGA CTCGTTTCπ CGTCGATAAT GG11111IGA GπTCGGATG GTATAATGTA 720 AAAAAATATA πCCTCAAGA TATGGGAAAA GGGAGTAATC πGAGGTGGA AAπAAπGT 780 CATGTCTCTG AπTAGTπC TCTGGAAGAC GπAAπGGC CπTATATGG ATGCTGGTCT 840 πCGACATAG AGTGTTTGGG TCAAAATGGG AATTTCCCGG ATGCCGAAAA TTTAGGTGAT 900 ATAGπAπC AGATπCTGT AAπAGπTC GATACGGAAG GTGACCGTGA TGAGCGACAT 960 CTGTπACTC TGGGAACATG TGAAAAAAπ GACGGCGTGC ATATATATGA ATTTGCGTCA 1020 GAGπTGAAT TACTπTGGG TΠTTTCATA ππTAAGGA πGAGTCTCC GGAGTTTAπ 1080 ACCGGπATA ATAπAATAA TΠ GATTTA AAATATTTGT GTATAAGGAT GGATAAGAπ 1140 TACCAπATG ATAπGGπG TTΠTCGAAA CTGAAGAATG GAAAGAπGG AATCTCTGTC 1200 CCTCACGAAC AGTACAGGAA GGGGπCCπ CAGGCGCAAA CCAAGGTGπ TACπCCGGA 1260 GTGπGTATC TGGATATGTA TCCCGTCTAT TCTAGTAAGA TAACGGCGCA GAAπACAAA 1320 CTGGATACTA πGCTAAGAT CTGTCTCCAG CAAGAAAAGG AGCAGπATC GTACAAGGAA 1380 ATACCAAAGA AATTTAπAG TGGACCCAGT GGCAGGGCTG πGTCGGTAA GTAπGTCTA 1440 CAGGACTCTG TCTTAGπGT GCGTCTCTTT AAACAGAπA AπATCATTT TGAGGπGCC 1500 GAGGTCGCCA GAπGGCACA CGTCACGGCT AGATGTGTGG TGπCGAGGG TCAGCAGAAG 1560 AAGATATπC CCTGCAπCT TACGGAAGCA AAACGCCGTA ATATGAπCT TCCGAGTATG 1620 GTGTCπCGC ACAATAGACA AGGGATAGGT TACAAAGGGG CTACCGTTTT GGAGCCTAAG 1680 ACGGGπAπ ATGCTGTGCC TACCGTGGTG πTGAππC AAAGTTTGTA TCCGAGCAπ 1740 ATGATGGCGC ATAATCTGTG πATAGTACT πAGπiTGG ATGAACGACA GATAGCTGGA 1800 πGTCAGAGA GTGACATCπ AACCGTGAAG πGGGGGATG AGACTCATCG GTπGTGAAG 1860 CCπGTATCC GTGAGTCTGT GCπGGGAGT CTACTAAAGG ACTGGCTGGC CAAGAGACGA 1920 GAAGTGAAGG CGGAGATGCA GAACTGπCG GATCCGATGA TGAAAOTCT TCTGGATAAA 1980 AAGCAGCTCG CTCTGAAAAC AACATGTAAC TCGGTGTACG GTGTCACGGG AGCGGCGCAC 2040 GGGπAπGC CGTGTGπGC GAπGCTGCT TCTGTAACGT GTCTTGGAAG AGAGATGCπ 2100 TGπCCACGG TGGAπATGT TAAπCCAAG ATGCAGTCCG AGCAATTTTT πGCGAGGAA 2160 TπGGπTAA CGTCATCAGA πiTACTGGT GATπGGAAG TGGAGGTAAT πATGGTGAT 2220 ACGGATAGCA TCTTTATGTC TGTCAGAAAT ATGGπAATC AGTCTCTGCG AAGGAπGCG 2280 CCGATGATCG CCAAACATAT CACAGATCGT CTGπCAAGT CGCCTATCAA GCTCGAGTTT 2340 GAAAAGATTT TATGTCCGCT AATTTTGAπ TGTAAAAAAA GATACAπGG TAGACAGGAT 2400 GAπCGCπT TAATTΠTAA GGGGGTAGAT CTGGTGAGAA AGACπcπG CGAπiTGTG 2460 AAGGGTGTGG TGAAAGATAT CGTGGACπG πGπcπTG ATGAAGAGGT TCAGACTGCT 2520 GCTGTGGAGT TTTCTCACAT GACACAGACA CAGπGCGTG AACAAGGAGT GCCTGTGGGT 2580 AπCATAAAA TTTTGCGTCG TCTGTGCGAA GCGCGGGAGG AGCTTTTTCA GAATCGGGCA 2640 GACGTGAGAC ATTTAATGπ GTCCTCTGTG CTTTCCAAAG AAATGGCTGC ATATAAGCAA 2700 CCGAATCTGG CTCACCTTAG CGTCAπAGA AGGπGGCGC AGAGAAAGGA AGAAAπCCG 2760 AATGTAGGTG ACCGAAπAT GTACGTGπA ATAGCACCAT CTAπGGCAA TAAACAGACG 2820 CATAACTATG AAπAGCAGA AGATCCCAAC TATGTGATAG AACACAAGAT TCCTATACAT 2880 GCGGAGAAGT ATTTCGATCA GAπATCAAG GCTGTGACTA ATGCGATCTC ACCCATTπT 2940 CCGAAAACCG ATATAAAAAA AGAGAAGπA CTAπGTAπ TACπCCTAT GAAAGTGTAT 3000 πGGATGAAA CAππCTGC TAπGCAGAG GTAATGTGA 3039 SEQUENCE DESCRIPTION: SEQ ID N0:28: ATGGCGATCA GAACGGGGπ πGTAATCCC πTTTAACCC AAGCATCAGG GAπAAATAT 60 AACCCAAGAA CCGGGCGCGG TAGTAACAGA GAATπcπC ATAGπACAA AACTACCATG 120 TCATCGTTTC AATmTGGC CCCTAAATGT πAGATGAAG ATGTGCCCAT GGAAGAACGA 180 AAGGGGGπC ACGTCGGTAC ACTTAGTCGA CCGCCTAAAG TTTACTGTAA TGGAAAAGAA 240 GπccGAπc TGGATΠTCG πGπccAGc CCCTGGCCTA GACGCGTGAA TATΓTGGGGG 300 GAAATCGACT πCGTGGGGA TAAGTTTGAC CCCCGCTTTA ACACAπCCA TGTATATGAT 360 AπGTCGAAA CAACAGAAGC CGCGTCTAAT GGAGATGTAT CCCGGTTTGC AACTGCAACA 420 CGACCGCπG GTACCGπAT TACTπACπ GGCATGTCCC GATGTGGAAA AAGGGTGGCA 480 GπCATGTAT ACGGCATCTG TCAATATπT TATATAAACA AAGCCGAGGT GGATACCGCT 540 TGTGGCATAC GπCCGGTAG CGAGπATCT GTAπACπG CCGAGTGTTT ACGCAGπCT 600 ATGATAACAC AAAATGATGC AACGπAAAT GGAGACAAGA ACGCTTTTCA TGGTACCTCG 660 TTTAAAAGCG CATCTCCAGA AAGCTTTCGC GπGAGGπA πGAGCGCAC AGATGTTTAT 720 TACTACGATA CACAGCCATG TGCGTTTTAC AGGGTGTAπ CTCCCTCATC TAMTTTACA 780 AAπATCTTT GTGATAACπ TCACCCGGAG πGAAAAAGT ATGAAGGTCG GGTAGACGCT 840 ACCACTCGπ πCTAATGGA TAATCCCGGC TTTGπAGπ πGGπGGTA TCAACTAAAA 900 CCTGGAGπG ATGGGGAACG TGπCGAGπ CGACCGGCAA GTCGCCAAπ AACGπAAGC 960 GACGπGAAA πGACTGCAT GTCGGATAAT CTGCAGGCTA TACCAAACGA TGACTCATGG 1020 CCTGACTACA AGπGπATG TTTCGATAπ GAATGTAAAT CAGGAGGATC TAATGAGCTG 1080 GCGπTCCCG ATGCAACACA TCTGGAGGAT CTTGTAATCC AAATπcπG TCTAπATAT 1140 TCAATCCCTC GACAGTCTTT AGAACACAπ πACTGTTπ CCCπGGCTC πGTGACπA 1200 CCACAAAGGT ATGTACAAGA AATGAAGGAC GCGGGGπAC CGGAGCCGAC TGTGCTGGAG 1260 TTTGATAGTG AAπCGAGCT AπAAπGCA πTATGACCC TCGTAAAACA GTACGCTCCC 1320 GAGTTTGCCA CAGGπATAA CAπGπAAT πTGAπGGG CGTTTAπAT GGAGAAACπ 1380 AAπCTATAT ACAGTCTCAA GCπGATGGT TATGGCAGTA TAAACCGTGG GGGTCTGTTT 1440 AAGATATGGG ATGπGGCAA ATCCGGATTT CAGCGACGAA GCAAGGTAAA GATCAACGGT 1500 CTCATATCTC TGGATATGTA TGCAAπGCA ACTGAAAAAT TAAAACTCTC GAGπATAAA 1560 πAGAπCGG πGCACGTGA AGCTCTAAAT GAGTCCAAGA GAGAπTGCC CTACAAAGAC 1620 AπCCGGGAT AπACGCTAG TGGACCGAAT ACACGAGGAA πAπGGTGA ATAπGTATA 1680 CAAGACTCGG CTOTGTGGG GAAACTGTTT TTTAAATAπ TACCACACCT TGAGπATCC 1740 GCGGπGCAA GGCTAGCTAG AAπACπTA ACCAAGGCTA πTACGACGG ACAGCAGGπ 1800 AGGAΓTTACA ccTGπTAπ AGGACTGGCT TCGTCTCGAG GATΓTATTΓT ACCCGATGGG i860 GGATACCCAG CTACTTTTGA ATATAAGGAT GπAπCCCG ATGTCGGGGA TGπGAGGAA 1920 GAGATGGATG AAGACGAGAG CGTπCTCCC ACTGGTACGT CAAGTGGGCG AAATGTAGGA 1980 TATAAAGGAG CCAGGGTTπ TGACCCTGAT ACGGGATTπ ATATCGATCC GGTGGTCGTA 2040 πGGAππG CAAGTπATA TCCAAGTATA AπCAGGCCC ATAACπATG TπTACCACG 2100 CTAACGπAA AππGAGAC GGπAAACGT πGAATCCAT CCGAπATGC CACCπTACA 2160 GπGGAGGAA AACGTCTTπ TTTTGTGCGC TCTAACGπC GAGAAAGTCT GCTGGGTGπ 2220 CππAAAAG ACTGGπGGC TATGCGCAAG GCTAπAGAG CGCGCATACC CGGAAGπCT 2280 TCAGATGAAG CAGTGπAπ AGACAAACAA CAAGCCGCGA TAAAAGTAGT πGTAAπCC 2340 GTGTACGGπ πACTGGAGT TGCGCAGGGA πTCTGCCAT GπTATACGT AGCGGCCACT 2400 GTCACTACAA πGGCCGTCA AATGπAπA AGTACCAGAG AπATAπCA TAATAACTGG 2460 GCCGCATπG AACGTTTTAT TACAGCGTπ CCAGACAπG AAAGTAGCGT TCTCTCCCAA 2520 AAAGCGTACG AGGTAAAGGT TATATATGGA GATACGGAπ CTGTGTTTAT CCGAπCAAG 2580 GGTGπAGTG πGAGGGGAT AGCTAAAATC GGCGAGAAAA TGGCACATAT AATTTCAACG 2640 GCTCTGTTTT GTCCTCCTAT AAAGπGGAG TGTGAAAAAA CmTATAAA ACππGCπ 2700 ATAACAAAGA AAAAGTACAT TGGGGTAAπ TACGGCGGAA AGGTITTAAT GAAGGGAGTC 2760 GACTTGGπA GAAAAAACAA CTGTCAATπ AπAACGAπ ATGCCCGCAA ACπGTAGAA 2820 CTGπGπAT ATGACGACAC CGTCTCGCGT GCTGCGGCGG AGGCGTCGTG TGTTTCCAπ 2880 GCTGAATGGA ATAGACGGGC CATGCCGTCT GGGATGGCCG GGTπGGACG CATAAπGCA 2940 GATGCACATC GCCAGAπAC ATCACCCAAA πGGATAπA ATAAGTTTGT TATGACGGCC 3000 GAGCTTAGTC GTCCACCATC CGCCTACATA AACCGTCGCT TGGCTCACπ AACAGTATAT 3060 TATAAAπAG TAATGAGACA GGGTCAAATC CCAAACGπC GAGAACGCAT CCCπATGπ 3120 AπGTGGCCC CCACAGACGA AGTGGAGGCT GATGCAAAAA GTGTAGCTTT GCTACGTGGA 3180 GATCCTTTAC AGAATACCGC AGGTAAACGG TGTGGGGAAG CAAAGCGTAA GπAATAATA 3240 TCTGACπAG CGGAAGATCC CAπCACGTA ACATCACACG GGCTGTCTTT AAACATTGAC 3300 TAπAππT CTCATCTCAT TGGGACGGCG AGTGTAACπ πAAGGCGπ AπTGGAAAC 3360 GACACTAAAC TCACAGAACG GCTπTAAAA CG TTAπC CAGAGACACG AGπGπAAC 3420 GπAAAATGC TAAACCGCπ GCAGGCGGCA GGCπTGTπ GTATACACGC CCCGTGCTGG 3480 GATAATAAAA TGAACACTGA AGCTGAAATC ACCGAGGAGG AACAAAGTCA TCAAATAATG 3540 CGTAGAGTCT TTTGTAπCC AAAAGCAAπ CTCCATCAAA GπAA 3585 SEQUENCE DESCRIPTION: SEQ ID NO:29: ATGTTπCCG GTGGCGGCGG CCCGCTGTCC CCCGGAGGAA AGTCGGCGGC CAGGGCGGCG 60 TCCGGGTTπ πGCGCCCGC CGGCCCTCGC GGAGCCGGCC GGGGACCCCC GCCTTGCTTG 120 AGGCAAAACT TTTACAACCC CTACCTCGCC CCAGTCGGGA CGCAACAGAA GCCGACCGGG 180 CCAACCCAGC GCCATACGTA CTATAGCGAA TGCGATGAAT πCGAπCAT CGCCCCGCGG 240 GTGCTGGACG AGGATGCCCC CCCGGAGAAG CGCGCCGGGG TGCACGACGG TCACCTCAAG 300 CGCGCCCCCA AGGTGTACTG CGGGGGGGAC GAGCGCGACG TCCTCCGCGT CGGGTCGGGC 360 GGCπCTGGC CGCGGCGCTC GCGCCTGTGG GGCGGCGTGG ACCACGCCCC GGCGGGGπC 420 AACCCCACCG TCACCGTCTT TCACGTGTAC GACATCCTGG AGAACGTGGA GCACGCGTAC 480 GGCATGCGCG CGGCCCAGπ CCACGCGCGG πTATGGACG CCATCACACC GACGGGGACC 540 GTCATCACGC TCCTGGGCCT GACTCCGGAA GGCCACCGGG TGGCCGπCA CGTTTACGGC 600 ACGCGGCAGT ACTTTTACAT GAACAAGGAG GAGGTCGACA GGCACCTACA ATGCCGCGCC 660 CCACGAGATC TCTGCGAGCG CATGGCCGCG GCCCTGCGCG AGTCCCCGGG CGCGTCGπC 720 CGCGGCATTT CCGCGGACCA CTTCGAGGCG GAGGTGGTGG AGCGCACCGA CGTGTACTAC 780 TACGAGACGC GCCCCGCTCT GTTTTACCGC GTCTACGTCC GAAGCGGGCG CGTGCTGTCG 840 TACCTGTGCG ACAACTTCTG CCCGGCCATC AAGAAGTACG AGGGTGGGGT CGACGCCACC 900 ACCCGGπCA TCCTGGACAA CCCCGGGπC GTCACOTCG GCTGGTACCG TCTCAAACCG 960 GGCCGGAACA ACACGCTAGC CCAGCCGCGG GCCCCGATGG CCTTCGGGAC ATCCAGCGAC 1020 GTCGAGTπA ACTGTACGGC GGACAACCTG GCCATCGAGG GGGGCATGAG CGACCTACCG 1080 GCATACAAGC TCATGTGCπ CGATATCGAA TGCAAGGCGG GGGGGGAGGA CGAGCTGGCC 1140 TTCCGGTGG CCGGGCACCC GGAGGACCTG GTCATCCAGA TATCCTGTCT GCTCTACGAC 1200 CTGTCCACCA CCGCCCTGGA GCACGTCCTC CTGTπTCGC TCGGπCCTG CGACCTCCCC 1260 GAATCCCACC TGAACGAGCT GGCGGCCAGG GGCCTGCCCA CGCCCGTGGT TCTGGAAπC 1320 GACAGCGAAT TCGAGATGCT GπGGCCπC ATGACCCπG TGAAACAGTA CGGCCCCGAG 1380 πCGTGACCG GGTACAACAT CATCAACπC GACTGGCCCT TCπGCTGGC CAAGCTGACG 1440 GACATTTACA AGGTCCCCCT GGACGGGTAC GGCCGCATGA ACGGCCGGGG CGTGTTTCGC 1500 GTGTGGGACA TAGGCCAGAG CCACπCCAG AAGCGCAGCA AGATAAAGGT GAACGGCATG 1560 GTGAGCATCG ACATGTACGG GAπATAACC GACAAGATCA AGCTCTCGAG CTACAAGCTC 1620 AACGCCGTGG CCGAAGCCGT CCTGAAGGAC AAGAAGAAGG ACCTGAGCTA TCGCGACATC 1680 CCCGCCTACT ACGCCGCCGG GCCCGCGCAA CGCGGGGTGA TCGGCGAGTA CTGCATACAG 1740 GAπCCCTGC TGGTGGGCCA GCTGπmT AAGππTGC CCCATCTGGA GCTCTCGGCC 1800 GTCGCGCGCT TGGCGGGTAT TAACATCACC CGCACCATCT ACGACGGCCA GCAGATCCGC 1860 GTCTTTACGT GCCTGCTGCG CCTGGCCGAC CAGAAGGGCT πAπCTGCC GGACACCCAG 1920 GGGCGATTTA GGGGCGCCGG GGGGGAGGCG CCCAAGCGTC CGGCCGCAGC CCGGGAGGAC 1980 GAGGAGCGGC CAGAGGAGGA GGGGGAGGAC GAGGACGAAC GCGAGGAGGG CGGGGGCGAG 2040 CGGGAGCCGG ACGGCGCGCG GGAGACCGCC GGCCGGCACG TGGGGTACCA GGGGGCCAGG 2100 GTCCπGACC CCACTTCCGG GTTTCACGTG AACCCCGTGG TGGTGπCGA CπTGCCAGC 2160 CTGTACCCCA GCATCATCCA GGCCCACAAC CTGTGCπCA GCACGCTCTC CCTGAGGGCC 2220 GACGCAGTGG CGCACCTGGA GGCGGGCAAG GACTACCTGG AGATCGAGGT GGGGGGGCGA 2280 CGGCTGπCT TCGTCAAGGC TCACGTGCGA GAGAGCCTCC TCAGCATCCT CCTGCGGGAC 2340 TGGCTCGCCA TGCGAAAGCA GATCCGCTCG CGGAπCCCC AGAGCAGCCC CGAGGAGGCC 2400 GTGCTCCTGG ACAAGCAGCA GGCCGCCATC AAGGTCGTGT GTAACTCGGT GTACGGGπC 2460 ACGGGAGTGC AGCACGGACT CCTGCCGTGC CTGCACGπG CCGCGACGGT GACGACCATC 2520 GGCCGCGAGA TGCTGCTCGC GACCCGCGAG TACGTCCACG CGCGCTGGGC GGCCTTCGAA 2580 CAGCTCCTGG CCGATπCCC GGAGGCGGCC GACATGCGCG CCCCCGGGCC CTAπCCATG 2640 CGCATCATCT ACGGGGACAC GGACTCCATA πTGTGCTGT GCCGCGGCCT CACGGCCGCC 2700 GGGCTGACGG CCATGGGCGA CAAGATGGCG AGCCACATCT CGCGCGCGCT GTTTCTGCCC 2760 CCCATCAAAC TCGAGTGCGA AAAGACGπC ACCAAGCTGC TGCTGATCGC CAAGAAAAAG 2820 TACATCGGCG TCATCTACGG GGGTAAGATG CTCATCAAGG GCGTGGATCT GGTGCGCAAA 2880 AACAACTGCG CGπTATCAA CCGCACCTCC AGGGCCCTGG TCGACCTGCT GTTπACGAC 2940 GATACCGTCT CCGGAGCGGC CGCCGCGπA GCCGAGCGCC CCGCAGAGGA GTGGCTGGCG 3000 CGACCCCTGC CCGAGGGACT GCAGGCGπC GGGGCCGTCC TCGTAGACGC CCATCGGCGC 3060 ATCACCGACC CGGAGAGGGA CATCCAGGAC TTTGTCCTCA CCGCCGAACT GAGCAGACAC 3120 CCGCGCGCGT ACACCAACAA GCGCCTGGCC CACCTGACGG TGTAπACAA GCTCATGGCC 3180 CGCCGCGCGC AGGTCCCGTC CATCAAGGAC CGGATCCCGT ACGTGATCGT GGCCCAGACC 3240 CGCGAGGTAG AGGAGACGGT CGCGCGGCTG GCCGCCCTCC GCGAGCTAGA CGCCGCCGCC 3300 CCAGGGGACG AGCCCGCCCC CCCCGCGGCC CTGCCCTCCC CGGCCAAGCG CCCCCGGGAG 3360 ACGCCGTCGC CTGCCGACCC CCCGGGAGGC GCGTCCAAGC CCCGCAAGCT GCTGGTGTCC 3420 GAGCTGGCCG AGGATCCCGC ATACGCCAπ GCCCACGGCG TCGCCCTGAA CACGGACTAT 3480 TACπCTCCC ACCTGπGGG GGCGGCGTGC GTGACAπCA AGGCCCTGπ TGGGAATAAC 3540 GCCAAGATCA CCGAGAGTCT GπAAAAAGG πTAπCCCG AAGTGTGGCA CCCCCCGGAC 3600 GACGTGACCG CGCGGCTCCG GGCCGCAGGG πCGGGGCGG TGGGTGCCGG CGCTACGGCG 3660 GAGGAAACTC GTCGAATGπ GCATAGAGCC TTTGATACTC TAGCATGA 3708 SEQUENCE DESCRIPTION: SEQ ID NO:73: He Ala Glu Thr Val Thr Leu SEQUENCE DESCRIPTION: SEQ ID NO:74: Val Ala Ser Gly Ile Leu Pro SEQUENCE DESCRIPTION: SEQ ID NO:75: Gly He Leu Pro Cys Leu Asn SEQUENCE DESCRIPTION: SEQ ID NO:76: Cys Leu Asn Ile Ala Glu Thr SEQUENCE DESCRIPTION: SEQ ID NO:77: Gin Gly Arg Lys Met Leu Glu SEQUENCE DESCRIPTION: SEQ ID NO:78: Ser Gin Ala Phe Val Glu SEQUENCE DESCRIPTION: SEQ ID NO:79: Ala Arg Phe Lys Val He SEQUENCE DESCRIPTION: SEQ ID NO:80: Leu Glu Thr Ser Gin Ala Phe SEQUENCE DESCRIPTION: SEQ ID N0:81: Leu Glu Arg Ser Gin Ala Phe SEQUENCE DESCRIPTION: SEQ ID NO: 82: Glu Gly Ile Ser Pro Thr Al a SEQUENCE DESCRIPTION: SEQ ID N0:83: Glu Ala He Ser Pro Glu Arg SEQUENCE DESCRIPTION: SEQ ID N0:84: Ala Asp Leu Leu Gin Arg Pro SEQUENCE DESCRIPTION: SEQ ID NO: 85: Ala Gly Leu Leu Arg Arg Pro SEQUENCE DESCRIPTION: SEQ ID N0:86: Gin Arg Pro lie Glu Ala Ser SEQUENCE DESCRIPTION: SEQ ID N0:87: Arg Arg Pro Ile Asp Val Ser SEQUENCE DESCRIPTION: SEQ ID NO:88: Ile Glu Ala Ser Pro Glu Ala SEQUENCE DESCRIPTION: SEQ ID N0:89: lie Asp Val Ser Pro Asp Ala SEQUENCE DESCRIPTION: SEQ ID NO:90: Pro Asp Asp Tyr Glu Thr Phe SEQUENCE DESCRIPTION: SEQ ID NO:91: Lys Arg Lys Glu Ile Arg Lys SEQUENCE DESCRIPTION: SEQ ID NO:92: Leu Ala Lys Arg Lys Glu Ile SEQUENCE DESCRIPTION: SEQ ID NO:93: Leu Ala Ser Cys Thr Asp Pro SEQUENCE DESCRIPTION: SEQ ID N0:94: Thr Gly Ser Ala Leu His Gly SEQUENCE DESCRIPTION: SEQ ID N0:95: Pro Gly Asp Ser Leu His Leu SEQUENCE DESCRIPTION: SEQ ID NO:96: Ser Ala Leu His Gly His Pro SEQUENCE DESCRIPTION: SEQ ID NO:97: Asp Ser Leu His Leu His Pro SEQUENCE DESCRIPTION: SEQ ID NO:98: Gly His Pro Glu Leu Thr Pro SEQUENCE DESCRIPTION: SEQ ID NO:99: Leu His Pro His Leu Gly Pro SEQUENCE DESCRIPTION: SEQ ID NO:100: His Leu Ser Gly Gly Thr Val SEQUENCE DESCRIPTION: SEQ ID NO:101: Val Leu Ser Gly Gly Leu Val SEQUENCE DESCRIPTION: SEQ ID N0:102: Thr Asp Pro Thr Met Arg Thr SEQUENCE DESCRIPTION: SEQ ID NO:103: Thr Asp Pro Ala Leu Lys Thr SEQUENCE DESCRIPTION: SEQ ID NOJ04: CAGTATCATC CAAGCGCACA A 21 SEQUENCE DESCRIPTION: SEQ ID NO:105: CCAAGTATCA THCARGCNCA YAA 23 SEQUENCE DESCRIPTION: SEQ ID N0:106: GGAGTAGCAC AARTTRTGNG CYTG 24 SEQUENCE DESCRIPTION: SEQ ID NO:107: TACGAAACCT πGACCTNAG YGGNGG 26 SEQUENCE DESCRIPTION: SEQ ID NO:108: CGCAAGAACC TGGCCTCNTG YACNGAYCC 29 SEQUENCE DESCRIPTION: SEQ ID NO:109: TCTCAGGCGT TCGTAGARGG NATHTCNCC 29 SEQUENCE DESCRIPTION: SEQ ID NO:110: CAGCTGGCCA TCAAGGTCAC 20 SEQUENCE DESCRIPTION: SEQ ID NO:111: AACGCGGTGT ACGGGπCAC 20 SEQUENCE DESCRIPTION: SEQ ID NO:112: Arg Thr He Leu Asp Lys Gin Gin Leu Ala He Lys Val Thr Cys Asn Ala Val Tyr Gly Phe Thr Gly Val Ala Ser Gly Ile Leu Pro Cys Leu SEQUENCE DESCRIPTION: SEQ ID NO:113: Ser He He Gin Ala His Asn Leu Cys Tyr Ser Thr Leu Ile Pro SEQUENCE DESCRIPTION: SEQ ID NO:114: CGπGCCTCT GGCATACTGC CTTGCCTAAA CATAGCGGAG ACCGTGACAC TACAAGGGCG 60 AAAGATGCTG GAGAGATCTC AGGCCTTTGT AGAGGCCATC TCGCCGGAAC GCCTAGCGGG 120 TCTCCTGCGG AGGCCAATAG ACGTCTCACC CGACGCCCGA πCAAGGTCA TA 172 SEQUENCE DESCRIPTION: SEQ ID N0:115: Val Ala Ser Gly Ile Leu Pro Cys Leu Asn Ile Ala Glu Thr Val Thr Leu Gin Gly Arg Lys Met Leu Glu Arg Ser Gin Ala Phe Val Glu Ala Ile Ser Pro Glu Arg Leu Ala Gly Leu Leu Arg Arg Pro He Asp Val Ser Pro Asp Ala Arg Phe Lys Val He SEQUENCE DESCRIPTION: SEQ ID NO:116: GAC GAC CGC AGC GTG TGC GTG AAY GTN TTY GGN CAG CGC TGC TAC πc 48 Asp Asp Arg Ser Val Cys Val Asn Val Phe Gly Gin Arg Cys Tyr Phe TAC ACA CTA GCA CCC CAG GGG GTA AAC CTG ACC CAC GTC CTC CAG CAG 96 Tyr Thr Leu Ala Pro Gin Gly Val Asn Leu Thr His Val Leu Gin Gin GCC CTC CAG GCT GGC πC GGT CGC GCA TCC TGC GGC πc TCC ACC GAG 144 Ala Leu Gin Ala Gly Phe Gly Arg Ala Ser Cys Gly Phe Ser Thr Glu CCG GTC AGA AAA AAA ATC πG CGC GCG TAC GAC ACA CAA CAA TAT GCT 192 Pro Val Arg Lys Lys He Leu Arg Ala Tyr Asp Thr Gin Gin Tyr Ala GTG CAA AAA ATA ACC CTG TCA TCC AGT CCG ATG ATG CGA ACG Cπ AGC 240 Val Gin Lys Ile Thr Leu Ser Ser Ser Pro Met Met Arg Thr Leu Ser GAC CGC CTA ACA ACC TGT GGG TGC GAG GTG TTT GAG TCC AAT GTG GAC 288 Asp Arg Leu Thr Thr Cys Gly Cys Glu Val Phe Glu Ser Asn Val Asp GCC Aπ AGG CGC πC GTG CTG GAC CAC GGG πc TCG ACA πC GGG TGG 336 Ala He Arg Arg Phe Val Leu Asp His Gly Phe Ser Thr Phe Gly Trp TAC GAG TGC AGC AAC CCG GCC CCC CGC ACC CAG GCC AGA GAC TCT TGG 384 Tyr Glu Cys Ser Asn Pro Ala Pro Arg Thr Gin Ala Arg Asp Ser Trp ACG GAA CTG GAG TTT GAC TGC AGC TGG GAG GAC CTA AAG m ATC CCG 432 Thr Glu Leu Glu Phe Asp Cys Ser Trp Glu Asp Leu Lys Phe He Pro GAG AGG ACG GAG TGG CCC CCA TAC ACA ATC CTA TCC TTT GAT ATA GAA 480 Glu Arg Thr Glu Trp Pro Pro Tyr Thr Ile Leu Ser Phe Asp He Glu TGT ATG GGC GAG AAG GGT TTT CCC AAC GCG ACT CAA GAC GAG GAC ATG 528 Cys Met Gly Glu Lys Gly Phe Pro Asn Ala Thr Gin Asp Glu Asp Met Aπ ATA CAA ATC TCG TGT Gπ πA CAC ACA GTC GGC AAC GAT AAA CCG 576 He He Gin He Ser Cys Val Leu His Thr Val Gly Asn Asp Lys Pro TAC ACC CGC ATG CTA CTG GGC CTG GGG ACA TGC GAC CCC Cπ CCT GGG 624 Tyr Thr Arg Met Leu Leu Gly Leu Gly Thr Cys Asp Pro Leu Pro Gly GTG GAG GTC TTT GAG Tπ CCT TCG GAG TAC GAC ATG CTG GCC GCC πC 672 Val Glu Val Phe Glu Phe Pro Ser Glu Tyr Asp Met Leu Ala Ala Phe CTC AGC ATG CTC CGC GAT TAC AAT GTG GAG TH ATA ACG GGG TAC AAC 720 Leu Ser Met Leu Arg Asp Tyr Asn Val Glu Phe Ile Thr Gly Tyr Asn ATA GCA AAC Tπ GAC CTT CCA TAC ATC ATA GCC CGG GCA ACT CAG GTG 768 lie Ala Asn Phe Asp Leu Pro Tyr Ile He Ala Arg Ala Thr Gin Val TAC GAC πC AAG CTG CAG GAC πC ACC AAA ATA AAA ACT GGG TCC GTG 816 Tyr Asp Phe Lys Leu Gin Asp Phe Thr Lys Ile Lys Thr Gly Ser Val m GAG GTC CAC CAA CCC AGA GGC GGT TCC GAT GGG GGC AAC πC ATG 864 Phe Glu Val His Gin Pro Arg Gly Gly Ser Asp Gly Gly Asn Phe Met AGG TCC CAG TCA AAG GTC AAA ATA TCG GGG ATC GTC CCC ATA GAC ATG 912 Arg Ser Gin Ser Lys Val Lys He Ser Gly Ile Val Pro Ile Asp Met TAC CAG Gπ TGC AGG GAA AAG CTG AGT CTG TCA GAC TAC AAG CTG GAC 960 Tyr Gin Val Cys Arg Glu Lys Leu Ser Leu Ser Asp Tyr Lys Leu Asp ACA GTG GCT AAG CAA TGC CTC GGT CGA CAA AAA GAT GAC ATC TCA TAC 1008 Thr Val Ala Lys Gin Cys Leu Gly Arg Gin Lys Asp Asp He Ser Tyr AAG GAC ATA CCC CCG CTT TTT AAA TCT GGG CCT GAT GGT CGC GCA AAG 1056 Lys Asp He Pro Pro Leu Phe Lys Ser Gly Pro Asp Gly Arg Ala Lys GTG GGA AAC TAC TGT Gπ Aπ GAC TCG GTC CTG Gπ ATG GAT CTT CTG 1104 Val Gly Asn Tyr Cys Val He Asp Ser Val Leu Val Met Asp Leu Leu CTA CGG TTT CAG ACC CAT Gπ GAG ATC TCG GAA ATA GCC AAG CTG GCC 1152 Leu Arg Phe Gin Thr His Val Glu He Ser Glu Ile Ala Lys Leu Ala AAG ATC CCC ACC CGT AGG GTA CTG ACG GAC GGC CAA CAG ATC AGG GTA 1200 Lys He Pro Thr Arg Arg Val Leu Thr Asp Gly Gin Gin He Arg Val Tπ TCC TGC CTC πG GAG GCT GCT GCC ACG GAA GGT TAC Aπ CTC CCC 1248 Phe Ser Cys Leu Leu Glu Ala Ala Ala Thr Glu Gly Tyr lie Leu Pro GTC CCA AAA GGA GAC GCG Gπ AGC GGG TAT CAG GGG GCC ACT GTA ATA 1296 Val Pro Lys Gly Asp Ala Val Ser Gly Tyr Gin Gly Ala Thr Val lie AGC CCC TCT CCG GGA πC TAT GAC GAC CCC GTA CTC GTG GTG GAT TTT 1344 Ser Pro Ser Pro Gly Phe Tyr Asp Asp Pro Val Leu Val Val Asp Phe GCC AGC πG TAC CCC AGT ATC ATC CAA GCG CAC AAC πG TGC TAC TCC 1392 Ala Ser Leu Tyr Pro Ser He Ile Gin Ala His Asn Leu Cys Tyr Ser ACA CTG ATA CCC GGC GAT TCG CTC CAC CTG CAC CCA CAC CTC TCC CCG 1440 Thr Leu He Pro Gly Asp Ser Leu His Leu His Pro His Leu Ser Pro GAC GAC TAC GAA ACC Tπ GTC CTC AGC GGA GGT CCG GTC CAC TTT GTA 1488 Asp Asp Tyr Glu Thr Phe Val Leu Ser Gly Gly Pro Val His Phe Val AAA AAA CAC AAA AGG GAG TCC CTT CTT GCC AAG CTT CTG ACG GTA TGG 1536 Lys Lys His Lys Arg Glu Ser Leu Leu Ala Lys Leu Leu Thr Val Trp CTC GCG AAG AGA AAA GAA ATA AGA AAG ACC CTG GCA TCA TGC ACG GAC 1584 Leu Ala Lys Arg Lys Glu He Arg Lys Thr Leu Ala Ser Cys Thr Asp CCC GCA CTG AAA ACT Aπ CTA GAC AAA CAA CAA CTG GCC ATC AAG Gπ 1632 Pro Ala Leu Lys Thr Ile Leu Asp Lys Gin Gin Leu Ala He Lys Val ACC TGC AAC GCC Gπ TAC GGC πC ACG GGC Gπ GCC TCT GGC ATA CTG 1680 Thr Cys Asn Ala Val Tyr Gly Phe Thr Gly Val Ala Ser Gly Ile Leu CCT TGC CTA AAC ATA GCG GAG ACC GTG ACA CTA CAA GGG CGA AAG ATG 1728 Pro Cys Leu Asn Ile Ala Glu Thr Val Thr Leu Gin Gly Arg Lys Met CTG GAG AGA TCT CAG GCC Tπ GTA GAG GCC ATC TCG CCG GAA CGC CTA 1776 Leu Glu Arg Ser Gin Ala Phe Val Glu Ala Ile Ser Pro Glu Arg Leu GCG GGT CTC CTG CGG AGG CCA GTA GAC GTC TCA CCC GAC GCC CGA πC 1824 Ala Gly Leu Leu Arg Arg Pro Val Asp Val Ser Pro Asp Ala Arg Phe AAG GTC ATA TAC GGC GAC ACT GAC TCT CTT πC ATA TGC TGC ATG GGT 1872 Lys Val Ile Tyr Gly Asp Thr Asp Ser Leu Phe Ile Cys Cys Met Gly πC AAC ATG GAC AGC GTG TCA GAC πC GCG GAG GAG CTA GCG TCA ATC 1920 Phe Asn Met Asp Ser Val Ser Asp Phe Ala Glu Glu Leu Ala Ser He ACC ACC AAC ACG CTG TU CGT AGC CCC ATC AAG CTG GAG GCT GAA AAG 1968 Thr Thr Asn Thr Leu Phe Arg Ser Pro Ile Lys Leu Glu Ala Glu Lys ATC πC AAG TGC CTT CTG CTC CTG ACT AAA AAG AGA TAC GTG GGG GTA 2016 He Phe Lys Cys Leu Leu Leu Leu Thr Lys Lys Arg Tyr Val Gly Val CTC AGT GAC GAC AAG Gπ CTG ATG AAG GGC GTA GAC CTC Aπ AGG AAA 2064 Leu Ser Asp Asp Lys Val Leu Met Lys Gly Val Asp Leu He Arg Lys ACA GCC TGT CGT TTT GTC CAG GAA AAG AGC AGT CAG GTC CTG GAC CTC 2112 Thr Ala Cys Arg Phe Val Gin Glu Lys Ser Ser Gin Val Leu Asp Leu ATA CTG CGG GAG CCG AGC GTC AAG GCC GCG GCC AAG CTT Aπ TCG GGG 2160 Ile Leu Arg Glu Pro Ser Val Lys Ala Ala Ala Lys Leu He Ser Gly CAG GCG ACA GAC TGG GTG TAC AGG GAA GGG CTC CCA GAG GGG πC GTC 2208 Gin Ala Thr Asp Trp Val Tyr Arg Glu Gly Leu Pro Glu Gly Phe Val AAG ATA Aπ CAA GTG CTC AAC GCG AGC CAC CGG GAA CTG TGC GAA CGC 2256 Lys Ile He Gin Val Leu Asn Ala Ser His Arg Glu Leu Cys Glu Arg AGC GTA CCA GTA GAC AAA CTG ACG TTT ACC ACC GAG CTA AGC CGC CCG 2304 Ser Val Pro Val Asp Lys Leu Thr Phe Thr Thr Glu Leu Ser Arg Pro CTG GCG GAC TAC AAG ACG CAA AAC CTC CCG CAC CTG ACC GTG TAC CAA 2352 Leu Ala Asp Tyr Lys Thr Gin Asn Leu Pro His Leu Thr Val Tyr Gin AAG CTA CAA GCT AGA CAG GAG GAG CTT CCA CAG ATA CAC GAC AGA ATC 2400 Lys Leu Gin Ala Arg Gin Glu Glu Leu Pro Gin Ile His Asp Arg Ile CCC TAC GTG πC GTC GAC GCC CCA GGT AGC CTG CGC TCC GAG CTG GCA 2448 Pro Tyr Val Phe Val Asp Ala Pro Gly Ser Leu Arg Ser Glu Leu Ala GAG CAC CCC GAG TAC Gπ AAG CAG CAC GGA CTG CGC GTG GCG GTG GAC 2496 Glu His Pro Glu Tyr Val Lys Gin His Gly Leu Arg Val Ala Val Asp CTG TAT πC GAC AAG 2511 Leu Tyr Phe Asp Lys SEQUENCE DESCRIPTION: SEQ ID NO:117: Asp Asp Arg Ser Val Cys Val Asn Val Phe Gly Gin Arg Cys Tyr Phe Tyr Thr Leu Ala Pro Gin Gly Val Asn Leu Thr His Val Leu Gin Gin Ala Leu Gin Ala Gly Phe Gly Arg Ala Ser Cys Gly Phe Ser Thr Glu Pro Val Arg Lys Lys He Leu Arg Ala Tyr Asp Thr Gin Gin Tyr Ala Val Gin Lys Ile Thr Leu Ser Ser Ser Pro Met Met Arg Thr Leu Ser Asp Arg Leu Thr Thr Cys Gly Cys Glu Val Phe Glu Ser Asn Val Asp Ala Ile Arg Arg Phe Val Leu Asp His Gly Phe Ser Thr Phe Gly Trp Tyr Glu Cys Ser Asn Pro Ala Pro Arg Thr Gin Ala Arg Asp Ser Trp Thr Glu Leu Glu Phe Asp Cys Ser Trp Glu Asp Leu Lys Phe He Pro Glu Arg Thr Glu Trp Pro Pro Tyr Thr He Leu Ser Phe Asp Ile Glu Cys Met Gly Glu Lys Gly Phe Pro Asn Ala Thr Gin Asp Glu Asp Met Ile He Gin Ile Ser Cys Val Leu His Thr Val Gly Asn Asp Lys Pro Tyr Thr Arg Met Leu Leu Gly Leu Gly Thr Cys Asp Pro Leu Pro Gly Val Glu Val Phe Glu Phe Pro Ser Glu Tyr Asp Met Leu Ala Ala Phe Leu Ser Met Leu Arg Asp Tyr Asn Val Glu Phe Ile Thr Gly Tyr Asn He Ala Asn Phe Asp Leu Pro Tyr He He Ala Arg Ala Thr Gin Val Tyr Asp Phe Lys Leu Gin Asp Phe Thr Lys Ile Lys Thr Gly Ser Val Phe Glu Val His Gin Pro Arg Gly Gly Ser Asp Gly Gly Asn Phe Met Arg Ser Gin Ser Lys Val Lys He Ser Gly He Val Pro He Asp Met Tyr Gin Val Cys Arg Glu Lys Leu Ser Leu Ser Asp Tyr Lys Leu Asp Thr Val Ala Lys Gin Cys Leu Gly Arg Gin Lys Asp Asp He Ser Tyr Lys Asp Ile Pro Pro Leu Phe Lys Ser Gly Pro Asp Gly Arg Ala Lys Val Gly Asn Tyr Cys Val Ile Asp Ser Val Leu Val Met Asp Leu Leu Leu Arg Phe Gin Thr His Val Glu Ile Ser Glu Ile Ala Lys Leu Ala Lys Ile Pro Thr Arg Arg Val Leu Thr Asp Gly Gin Gin He Arg Val Phe Ser Cys Leu Leu Glu Ala Ala Ala Thr Glu Gly Tyr He Leu Pro Val Pro Lys Gly Asp Ala Val Ser Gly Tyr Gin Gly Ala Thr Val Ile Ser Pro Ser Pro Gly Phe Tyr Asp Asp Pro Val Leu Val Val Asp Phe Ala Ser Leu Tyr Pro Ser Ile He Gin Ala His Asn Leu Cys Tyr Ser Thr Leu He Pro Gly Asp Ser Leu His Leu His Pro His Leu Ser Pro Asp Asp Tyr Glu Thr Phe Val Leu Ser Gly Gly Pro Val His Phe Val Lys Lys His Lys Arg Glu Ser Leu Leu Ala Lys Leu Leu Thr Val Trp Leu Ala Lys Arg Lys Glu Ile Arg Lys Thr Leu Ala Ser Cys Thr Asp Pro Ala Leu Lys Thr Ile Leu Asp Lys Gin Gin Leu Ala Ile Lys Val Thr Cys Asn Ala Val Tyr Gly Phe Thr Gly Val Ala Ser Gly Ile Leu Pro Cys Leu Asn He Ala Glu Thr Val Thr Leu Gin Gly Arg Lys Met Leu Glu Arg Ser Gin Ala Phe Val Glu Ala He Ser Pro Glu Arg Leu Ala Gly Leu Leu Arg Arg Pro Val Asp Val Ser Pro Asp Ala Arg Phe Lys Val Ile Tyr Gly Asp Thr Asp Ser Leu Phe He Cys Cys Met Gly Phe Asn Met Asp Ser Val Ser Asp Phe Ala Glu Glu Leu Ala Ser Ile Thr Thr Asn Thr Leu Phe Arg Ser Pro He Lys Leu Glu Ala Glu Lys He Phe Lys Cys Leu Leu Leu Leu Thr Lys Lys Arg Tyr Val Gly Val Leu Ser Asp Asp Lys Val Leu Met Lys Gly Val Asp Leu He Arg Lys Thr Al a Cys Arg Phe Val Gin Glu Lys Ser Ser Gin Val Leu Asp Leu Ile Leu Arg Glu Pro Ser Val Lys Ala Ala Ala Lys Leu He Ser Gly Gin Al a Thr Asp Trp Val Tyr Arg Glu Gly Leu Pro Glu Gly Phe Val Lys Ile Ile Gin Val Leu Asn Ala Ser His Arg Glu Leu Cys Glu Arg Ser Val Pro Val Asp Lys Leu Thr Phe Thr Thr Glu Leu Ser Arg Pro Leu Ala Asp Tyr Lys Thr Gin Asn Leu Pro His Leu Thr Val Tyr Gin Lys Leu Gin Ala Arg Gin Glu Glu Leu Pro Gin He His Asp Arg Ile Pro Tyr Val Phe Val Asp Ala Pro Gly Ser Leu Arg Ser Glu Leu Al a Glu His Pro Glu Tyr Val Lys Gin His Gly Leu Arg Val Ala Val Asp Leu Tyr Phe Asp Lys SEQUENCE DESCRIPTION: SEQ ID NO: 118: C CTA TGT TAC TCT ACC CTG Aπ CAG GGG AAC GCC Aπ CTC TCG CAC 46 Leu Cys Tyr Ser Thr Leu He Gin Gly Asn Al a Ile Leu Ser His CCC GAG πG ACC CCG AAC GAC TAC GAA ACA πC CAC CTA AGC GGA GGA 94 Pro Glu Leu Thr Pro Asn Asp Tyr Glu Thr Phe His Leu Ser Gly Gly CCG GTG CAC πC GTA AAA AAA CAC GTA CGA GAG TCA πA CTG TCA AAA 142 Pro Val His Phe Val Lys Lys His Val Arg Glu Ser Leu Leu Ser Lys Cπ CTG ACG ACT TGG CTA ACA AAA AGA AAA GAG ATC CGC AAA AAT CTC 190 Leu Leu Thr Thr Trp Leu Thr Lys Arg Lys Glu Ile Arg Lys Asn Leu GCC TCG TGC GGA GAC CCA ACC ATG CGA ACC ATC CTT GAT AAG CAG CAG 238 Al a Ser Cys Gly Asp Pro Thr Met Arg Thr Ile Leu Asp Lys Gin Gin CTG GCC ATC AAG GTC ACA TGT AAT GCG GTG TAC GGG TTT ACC GGC GTC 286 Leu Ala Ile Lys Val Thr Cys Asn Ala Val Tyr Gly Phe Thr Gly Val GCC TCC GGT Aπ CTA CCG TGC CTG AAT Aπ GCA GAA ACA GTC ACC CTC 334 Ala Ser Gly He Leu Pro Cys Leu Asn Ile Al a Glu Thr Val Thr Leu CAG GGC AGA AAA ATG CTA GAA ACG TCC CAG GCG Tπ GTA GAG GGC ATA 382 Gin Gly Arg Lys Met Leu Glu Thr Ser Gin Ala Phe Val Glu Gly He TCG CCA AAA GAC CTG TCA GAC CTG ATA CAA CGT CCG ATC GAC GCT TCC 430 Ser Pro Lys Asp Leu Ser Asp Leu Ile Gin Arg Pro Ile Asp Ala Ser CCG GAC GCC AGG TTT AAA GTG ATA 454 Pro Asp Ala Arg Phe Lys Val He SEQUENCE DESCRIPTION: SEQ ID NO: 119: Leu Cys Tyr Ser Thr Leu Ile Gin Gly Asn Ala He Leu Ser His Pro Gl u Leu Thr Pro Asn Asp Tyr Gl u Thr Phe His Leu Ser Gly Gly Pro Val His Phe Val Lys Lys His Val Arg Glu Ser Leu Leu Ser Lys Leu Leu Thr Thr Trp Leu Thr Lys Arg Lys Glu He Arg Lys Asn Leu Ala Ser Cys Gly Asp Pro Thr Met Arg Thr He Leu Asp Lys Gin Gin Leu Al a He Lys Val Thr Cys Asn Ala Val Tyr Gly Phe Thr Gly Val Al a Ser Gly He Leu Pro Cys Leu Asn Ile Al a Gl u Thr Val Thr Leu Gin Gly Arg Lys Met Leu Glu Thr Ser Gin Ala Phe Val Glu Gly He Ser Pro Lys Asp Leu Ser Asp Leu Ile Gin Arg Pro Ile Asp Ala Ser Pro Asp Ala Arg Phe Lys Val He SEQUENCE DESCRIPTION : SEQ ID NO: 120: Val Ala Ser Gly He Leu Pro Cys Leu Asn He Al a Glu Thr Val Thr Leu Gin Gly Arg Lys Met Leu Glu Arg Ser Gin Ala Phe Val Glu Al a Ile Ser Pro Glu Arg Leu Ala Gly Leu Leu Arg Arg Pro Val Asp Val Ser Pro Asp Al a Arg Phe Arg Val Ile SEQUENCE DESCRIPTION: SEQ ID NO:121: Val Ala Ser Gly Ile Leu Pro Cys Leu Asn He Ala Glu Thr Val Thr Leu Gin Gly Arg Lys Met Leu Glu Arg Ser Gin Ala Phe Val Glu Ala Ile Ser Pro Glu Arg Leu Ala Gly Leu Leu Arg Arg Pro Ile Asp Val Ser Pro Asp Ala Arg Phe Lys Val Ile SEQUENCE DESCRIPTION: SEQ ID N0:122: Val Ala Ser Gly He Leu Pro Cys Leu Asn Ile Ala Glu Thr Val Thr Leu Gin Gly Arg Lys Met Leu Glu Arg Ser Gin Ala Phe Val Glu Al a He Ser Pro Glu Arg Leu Ala Gly Leu Leu Arg Arg Pro Val Asp Val Ser Pro Asp Ala Arg Phe Lys Val Ile SEQUENCE DESCRIPTION: SEQ ID N0J23 : Val Ala Ser Gly Ile Leu Pro Cys Leu Asn He Al a Glu Thr Val Thr Leu Gin Gly Arg Lys Met Leu Glu Arg Ser Gin Ala Phe Val Glu Al a Ile Ser Pro Glu Arg Leu Ala Gly Leu Leu Arg Arg Pro Val Asp Val Ser Pro Asp Al a Arg Phe Arg Val He SEQUENCE DESCRIPTION: SEQ ID N0:124: AACACAGAGT CNGTRTCNCC RTA 23 SEQUENCE DESCRIPTION: SEQ ID NO:125: AGCATCATCA TGGCCCAYAA YCTNTGYT 28 SEQUENCE DESCRIPTION: SEQ ID NO:126: GAYTTYGCNA GYYTNTAYCC 20 SEQUENCE DESCRIPTION: SEQ ID NO:127: CACCCATRCA YTCDATRTCR AA 22 SEQUENCE DESCRIPTION: SEQ ID NO:128: TACAACGTCC TCTCCTTYGA YATHGARTG 29 SEQUENCE DESCRIPTION: SEQ ID NO:129: GTCTGCGTGA AYGTNTTYGG NCA 23 SEQUENCE DESCRIPTION: SEQ ID NO:130: GACGACCGCA GCGTGTGCGT GAAYGTNTTY GGNCA 35 SEQUENCE DESCRIPTION: SEQ ID NO:131: ACGACCGCAG CGTGTGCGTG 20 SEQUENCE DESCRIPTION: SEQ ID NO:132: TAAAAGTACA GCTCCTGCCC GAANACRTTN ACRCA 35 SEQUENCE DESCRIPTION: SEQ ID NO:133: TAAAAGTACA GCTCCTGCCC GAA 23 SEQUENCE DESCRIPTION: SEQ ID N0:134: πTGACπTG CCAGCCTGTA YCCNAGYATN AT 32 SEQUENCE DESCRIPTION: SEQ ID NO:135: πTGACπTG CCAGCCTGTA YCCNTCNATN AT 32 SEQUENCE DESCRIPTION: SEQ ID NO:136: TTTGACTTTG CCAGCCTGTA 20 SEQUENCE DESCRIPTION: SEQ ID NO:137: CGGCATGCGA CAAACACGGA GTCCGTRTCN CCRTADAT 38 SEQUENCE DESCRIPTION: SEQ ID NO:138: πAGCTACTC CGTGGAGCAG YTTRTCRAAR TA 32 SEQUENCE DESCRIPTION: SEQ ID NO:139: πGTGCGCπ GGATGATACT G 21 SEQUENCE DESCRIPTION: SEQ ID NO:140: GAGGGCCTGC TGGAGGACGT G 21 SEQUENCE DESCRIPTION: SEQ ID NO:141: CGGTGGAGAA GCCGCAGGAT G 21 SEQUENCE DESCRIPTION: SEQ ID NO:142: ACCTCCCGCA CCTGACCGTG T 21 SEQUENCE DESCRIPTION: SEQ ID NO:143: AAGCTAGACA GGAGGAGCTT C 21 SEQUENCE DESCRIPTION: SEQ ID NO:144: ACTTGAAπA TCTTGACGAA C 21 SEQUENCE DESCRIPTION: SEQ ID NO:145: ACGACAAGGT TCTGATGAAG G 21 SEQUENCE DESCRIPTION: SEQ ID NO:146: AGAGACTCπ GGACGGAACT G 21 SEQUENCE DESCRIPTION: SEQ ID NO:147: AGTTTGACTG CAGCTGGGAG G 21 SEQUENCE DESCRIPTION: SEQ ID NO:148: CGGGTATCAG TGTGGAGTAG C 21 SEQUENCE DESCRIPTION: SEQ ID NO:149: GAGGACAAAG GTTTCGTAGT C 21 SEQUENCE DESCRIPTION: SEQ ID NO:150: CTATGπACT CTACCCTGAT T 21 SEQUENCE DESCRIPTION: SEQ ID NO:151: GTATATCTCT πAAACCTGG C 21 SEQUENCE DESCRIPTION: SEQ ID NO:152: AACCTGGCGT CCGGGGAAGC G 21

Claims: CLAIMS We claim: 1. An isolated polynucleotide with a region encoding a DNA polymerase of a heφes virus, the polynucleotide comprising a sequence of nucleotides at least 69% identical to nucleotides 27 to 501 of a sequence selected from the group consisting of SEQ. ID NO:1 and SEQ. ID NO:3. 2. An isolated polynucleotide comprising a fragment of at least 18 consecutive nucleotides of the DNA polymerase encoding region of the polynucleotide of claim 1 , wherein the sequence of said fragment is not contained in SEQ. ID NOS:110 or 111. 3. An isolated polynucleotide comprising a fragment of at least 50 consecutive nucleotides of the DNA polymerase encoding region of the polynucleotide of claim 1. 4. The isolated polynucleotide of claim 2, which encodes a polypeptide with nucleic acid binding activity, nucleotide binding activity, or DNA polymerase activity. 5. An isolated polynucleotide with a region encoding a DNA polymerase of a heφes virus, the polynucleotide comprising a sequence of 26 nucleotides at least 80% identical to oligonucleotide LSGGA (SEQ. ID NO:107), or a sequence of 29 nucleotides at least 69% identical to oligonucleotide CTDPA (SEQ. ID NO: 108) or a sequence of 32 nucleotides at least 80% identical to oligonucleotide KMLEA (SEQ. ID NO:22), or a sequence of 29 nucleotides at least 69% identical to oligonucleotide GISPA (SEQ. ID NO: 109). 6. An isolated polynucleotide comprising a fragment of at least 18 consecutive nucleotides of the DNA polymerase encoding region of the polynucleotide of claim 5, wherein the sequence of said fragment is not contained in SEQ. ID NOS:110 or 111. 7. The polynucleotide of claim 1 or claim 2, wherein said herpes virus is capable of infecting primates. 8. The polynucleotide of claim 1 or claim 2, wherein said herpes virus is RFHV, RFHV2, or KSHV. 9. An isolated polynucleotide comprising a linear sequence of at least 18 nucleotides identical to a linear sequence between nucleotides 27 to 501 inclusive of SEQ. ID NO:1 , or between nucleotides 27 to 501 inclusive of SEQ. ID NO:3, or between nucleotides 36 to 2499 inclusive of SEQ. ID NO:116, or between nucleotides 1 to 454 inclusive of SEQ. ID NO:118, but not to a linear sequence within either SEQ. ID NO:110 or SEQ. ID NO:111. 10. The isolated polynucleotide of claim 9, comprising a linear sequence essentially identical to nucleotides 27 to 501 of SEQ. ID NO:1 , or to nucleotides 27 to 501 of SEQ. ID NO:3, or to nucleotides 36 to 2499 of SEQ. ID NO:116, or to nucleotides 1 to 454 of SEQ. ID NO:118. 11. An isolated polypeptide encoded by the polynucleotide of claim 3. 12. An isolated polypeptide, comprising a linear sequence of at least 12 amino acids essentially identical to a sequence between amino acids 10 to 167 inclusive of SEQ. ID NO:2 or between amino acids 10 to 167 inclusive of SEQ. ID NO:4 or between amino acids 13 to 833 inclusive of SEQ. ID NO: 117, or in any of SEQ. ID NOS: 119-123, but which is not contained in SEQ. ID NOS:112 or in SEQ. ID NO:113. 13. The isolated polypeptide of claim 12, which has nucleic acid binding activity, nucleotide binding activity, or DNA polymerase activity. 14. A fusion polypeptide comprising the amino acid sequence of an isolated peptide of claim 12, joined to a second amino acid sequence. 15. An isolated polypeptide, comprising a linear sequence of amino acids identical to a sequence selected from the group consisting of SEQ. ID NOS:80, 82, 84, 86, 88, and 90 to 103. 16. An isolated or non-naturally occurring polynucleotide encoding the polypeptide of claim 12. 17. A polynucleotide encoding a fusion polypeptide, comprising the polynucleotide of claim 2 joined directly to a second polynucleotide encoding a polypeptide. 18. A recombinant cloning vector comprising a polynucleotide sequence encoding a polypeptide of at least 12 consecutive amino acids identical to that of a polypeptide according to claim 12. 19. A recombinant expression vector comprising a polynucleotide sequence encoding a polypeptide of at least 12 consecutive amino acids identical to that of a polypeptide according to claim 12. 20. A recombinant cloning vector comprising a linear sequence encoding a DNA polymerase of a herpes virus, the sequence being at least 18 nucleotides long and identical to a linear sequence within SEQ. ID NOS:1, 3, 116, or 118, but not in SEQ. ID NOS:110 or 111. 21. A host cell genetically altered by the polynucleotide of claim 16, or by the vector of claim 18, claim 19, or claim 20. 22. A monoclonal or isolated polyclonal antibody specific for a DNA polymerase encoded in said encoding region of the polynucleotide of claim 1. 23. A monoclonal or isolated polyclonal antibody specific for the polypeptide of claim 12. 24. The antibody of claim 22, which is a monoclonal antibody. 25. The antibody of claim 22, which is an isolated polyclonal antibody. 26. An oligonucleotide essentially identical to an oligonucleotide selected from the group consisting of SEQ. ID NOS:5 to 16, 21, 22, 104-109, and 124-152. 27. A method of obtaining an amplified copy of a polynucleotide encoding a DNA polymerase, comprising the steps of: a) contacting the polynucleotide with the oligonucleotide of claim 26; and b) elongating oligonucleotide that has fonned a duplex with the polynucleotide. 28. The method of claim 27, comprising performing a polymerase chain reaction (PCR). 29. The method of claim 28, wherein said PCR comprises repeated cycles of annealing and elongating, wherein the annealing is conducted at a temperature of at least 60°C. 30. The method of claim 28, wherein said PCR is conducted in a buffer containing 10-30 mM (NH4) 2 S0 4 and 1-10 mM MgCI 2 . 31. The method of claim 27, wherein the polynucleotide which is amplified is first obtained from a biological sample taken from an individual affected with a disease featuring fibroblast proliferation and collagen deposition. 32. A method of detecting viral DNA or RNA in a sample of primate origin, comprising the steps of: a) contacting the DNA or RNA in the sample with a probe comprising the polynucleotide of claim 2 under conditions that would permit the probe to form a stable duplex with a polynucleotide having the sequence shown in SEQ. ID NO:1, and with a polynucleotide having the sequence shown in SEQ. ID NO:3, but not with a polynucleotide having a sequence of any of SEQ. ID NOS:24 to 29; and b) detecting the presence of said stable duplex formed in step a), if any. 33. The method of claim 32 further comprising conducting an amplification reaction on the DNA or RNA of the sample prior to being contacted with the probe. 34. The method of claim 33, wherein the amplification reaction is conducted using an oligonucleotide primer comprising a sequence according to claim 26. 35. A method of detecting viral DNA or RNA in a sample of primate origin, comprising the steps of: a) contading the DNA or RNA in the sample with an oligonucleotide probe comprising a sequence shown in SEQ. ID NOS: 21, 22, 107, 108, or 109, under conditions that would permit the probe to form a stable duplex with a polynucleotide having the sequence shown in SEQ. ID NO:1, and with a polynucleotide having the sequence shown in SEQ. ID NO:3, but not with a polynucleotide having a sequence of any of SEQ. ID NOS:24 to 29; and b) detecting the presence of said stable duplex formed in step a), if any. 36. A method of detecting viral DNA or RNA in a sample, comprising the steps of: a) contacting the DNA or RNA in the sample with an oligonucleotide probe comprising a sequence shown in SEQ. ID NOS:22, 107, 108 or 109 under conditions that would permit the probe to form a stable duplex with a polynucleotide having the sequence shown in SEQ. ID NO:1, and with a polynucleotide having the sequence shown in SEQ. ID NO:3, but not with a polynucleotide having a sequence of any of SEQ. ID NOS:23 to 29; and b) detecting the presence of said stable duplex formed in step a), if any. 37. A method of detecting viral DNA or RNA in a sample, comprising the steps of: a) conducting an amplification reaction on a polynucleotide in the sample using the oligonucleotide of claim 26 as a primer in the reaction; and b) detecting the presence of amplified copies of the polynucleotide, if any. 38. An isolated polynucleotide capable of forming a stable duplex with an oligonucleotide comprising a sequence selected from the group consisting of SEQ. ID NO:107, SEQ. ID NO:108, and their respective complementary sequences, under conditions wherein the oligonucleotide is capable of forming a stable duplex with a polynucleotide having the sequence shown in SEQ. ID NO:1 , and with a polynucleotide having the sequence shown in SEQ. ID NO:3, but not with a polynucleotide having a sequence of any of SEQ. ID NOS:23 to 29. 39. An isolated polypeptide comprising a linear sequence of 12 amino acids encoded within the polynucleotide of claim 38. 40. A method for detecting infection of an individual by a herpes virus, comprising detecting viral DNA or RNA in a biological sample obtained from the individual, wherein the detecting of viral DNA or RNA is by the method of claim 32 41. A method for detecting infection of an individual by a herpes virus, comprising detecting viral DNA or RNA in a biological sample obtained from the individual, wherein the detecting of viral DNA or RNA is by the method of: a) contacting the DNA or RNA in the sample with a probe comprising the polynucleotide of claim 2 under conditions that would permit the probe to form a stable duplex with a polynucleotide having at least one sequence selected from the group consisting of SEQ. ID NOS:1, 3, 116, or 118, but not with polynucleotides having a sequence of any of SEQ. ID NOS:24 to 29; and b) detecting the presence of said stable duplex formed in step a), if any. 42. A method for detecting infection of an individual by a herpes virus, comprising detecting viral DNA or RNA in a biological sample obtained from the individual, wherein the detecting of viral DNA or RNA is by the method of: a) contacting the DNA or RNA in the sample with a probe comprising the polynucleotide of claim 2 under conditions that would permit the probe to form a stable duplex with a polynucleotide having a sequence shown in SEQ. ID NO:116, but not with polynucleotides having a sequence of any of SEQ. ID NOS:24 to 29; and b) detecting the presence of said stable duplex formed in step a), if any. 43. A diagnostic kit for detecting a heφes virus polynucleotide in a biological sample, comprising a reagent in suitable packaging, wherein the reagent comprises the polynucleotide of claim 2. 44. A diagnostic kit for detecting a herpes virus polynucleotide in a biological sample, comprising a reagent in suitable packaging, wherein the reagent comprises the oligonucleotide of claim 26. 45. A method of detecting infection of an individual by a herpes virus, comprising the steps of: a) contacting antibody from a sample obtained from the individual with the polypeptide of claim 11 or claim 12 under conditions that permit the formation of a stable antigen-antibody complex; and b) detecting said stable complexes formed in step a), if any. 46. A diagnostic kit for detecting an anti-herpesvirus antibody present in a biological sample, comprising a reagent in suitable packaging, wherein the reagent comprises the polypeptide of claim 11 or claim 12. 47. A method of detecting infection of an individual by a herpes virus, comprising the steps of: a) contacting a polypeptide from a sample obtained from the individual with the antibody of claim 22 or claim 23 under conditions that permit the formation of a stable antigen-antibody complex; and b) detecting said stable complexes formed in step a), if any. 48. A diagnostic kit for detecting a heφes virus polypeptide present in a biological sample, comprising a reagent in suitable packaging, wherein the reagent comprises the antibody of claim 22 or claim 23. 49. A composition for use in the treatment of herpes virus infection, comprising the polynucleotide of claim 2 and a compatible pharmaceutical excipient. 50. A method of determining whether a pharmaceutical candidate is useful for treating gamma heφes infection, comprising the steps of: a) contacting the polypeptide of claim 11 with the pharmaceutical candidate; and b) determining whether a biochemical function of the polypeptide is altered by the pharmaceutical candidate. 51. The method of claim 50, wherein the biochemical function of the polypeptide determined in step b) is the binding of the polypeptide to a nucleic acid. 52. The method of claim 50, wherein the biochemical function of the polypeptide determined in step b) is DNA polymerase activity. 53. A method of determining whether a pharmaceutical candidate is useful for treating gamma heφes infection, comprising the steps of: a) genetically altering a cell with the polynucleotide of claim 2; and b) determining the effect of the pharmaceutical candidate on the cell in comparison with a cell not genetically altered with the polynucleotide. 54. A method of obtaining a compound for use in treating an individual infected with herpes virus, comprising the steps of: a) creating a compound capable of binding a region of the polypeptide of claim 11 or claim 12 involved in interacting with a nucleic acid; and b) determining whether the compound interferes with a biochemical function of the polypeptide.

Inventors: BOSCH MARNIX L, ROSE TIMOTHY M, STRAND KURT, TODARO GEORGE J, BOSCH, MARNIX, L., ROSE, TIMOTHY, M., STRAND, KURT, TODARO, GEORGE, J.
Applicants: BOSCH MARNIX L, ROSE TIMOTHY M, STRAND KURT, TODARO GEORGE J, UNIV WASHINGTON, BOSCH, MARNIX, L., ROSE, TIMOTHY, M., STRAND, KURT, TODARO, GEORGE, J., UNIVERSITY OF WASHINGTON
Application year: 1996
Main classification: C12N15
IPC codes: A61K31, A61K39, A61K48, A61P31, C07K16, C12N1, C12N5, C12N9, C12N15, C12P21, C12Q1, C12R1